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Abstract 
Characterisation and therapeutic modulation of toll-like receptor signalling in response to 
the intracellular pathogen F. tularensis 
 
Richard Saint 
 
The induction of an innate immune response upon infection is dependent on the detection of the 
invading organism and the generation of a signalling cascade leading to the production of 
inflammatory mediators. Toll-like receptors are expressed on multiple cell types and induce the 
activation of a complex network of signalling pathways containing numerous branches with multiple 
interactions and cross-talk between the different branches. The TLR system is integral to the 
generation of a protective immune response and as such is an important target for pathogen-
associated modulation. Many bacterial and viral pathogens employ strategies for interrupting or 
modulating TLR signalling to evade the host immune response. The obligate intracellular bacterial 
pathogen, F. tularensis, successfully invades and replicates within immune and epithelial cells. 
However, despite significant research the exact mechanisms used by this pathogen to successfully 
evade the host immune response remain elusive. 
 
To establish the exact signalling events that occur within a host upon infection with F. tularensis, the 
activation of specific signalling proteins was characterised using in vitro and in vivo models. The 
MAPKs, ERK and p38, were identified as critical in generating the host response. Furthermore, the 
temporal regulation of these signalling proteins was found to be bi-phasic with an early transient 
activation of both ERK and p38 followed by a sustained activation of ERK and a suppression of p38 
activation at later time points. The role of ERK was investigated further using a specific inhibitor 
(PD0325901). Although there was no decrease in bacterial burdens in vitro and no increase in 
survival in mice treated with PD0325901, the inhibition of ERK activation reduced the secretion of 
TNF and IL-6 and reduced systemic bacterial proliferation in vivo.  
 
The induction of immune signalling cascades requires the activation of one or more receptors. The 
contribution of TLR2, TLR4 and TLR9 to the immune response to F. tularensis infection was examined 
using KO cell lines and specific antagonists. TLR2 was confirmed as a receptor for F. tularensis and 
was observed to play a role in the translational regulation of TNF. A role for TLR4 was also identified 
and further characterisation identified a potential priming relationship with TLR9. Sub-stimulation of 
13 
 
TLR4 by LPS enhanced the response induced by a subsequent stimulation of TLR9 by purified F. 
tularensis DNA. 
 
Overall, this study has provided evidence that, during infection, F. tularensis interacts with innate 
immune signalling pathways. By simultaneously suppressing p38 activation and prolonging ERK 
activation F. tularensis is able to regulate cytokine secretion and the induction of host-cell death 
mechanisms. Furthermore, this work has demonstrated that the activation of TLR9 by F. tularensis 
genomic DNA can be primed by a prior sub-stimulation of TLR4, although more research is required 
to fully understand the contribution of this interaction to the pathogenesis of F. tularensis. 
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Chapter 1: General Introduction 
1.1 Innate immunity 
The innate immune system has previously been considered a simple and non-specific mechanism 
whose function was to eliminate pathogens and present antigen to the cells of the adaptive immune 
response. However, with more focussed research it has been found that, far from being non-specific, 
the innate immune response exhibits a highly developed ability to discriminate between pathogens 
and respond accordingly. Unlike adaptive immunity, which has a slower response time and is 
mediated by T and B cells, innate immunity displays a rapid response relying on groups of pattern 
recognition receptors (PRRs) to initiate the response 1,2. The function of PRRs is to detect 
evolutionary conserved components of microbial pathogens called pathogen associated molecular 
patterns (PAMPs). PAMPs include a range of molecules such as lipids, proteins and nucleic acids and 
it is the detection of particular PAMPs by a broad range of PRRs which confer the innate immune 
system with much of its specificity. The PRRs involved in inducing a response can be categorised into 
three major families called retinoic acid inducible gene (RIG)-like receptors (RLRs), nod-like receptors 
(NLRs) and the toll-like receptors (TLRs) 3. In addition to the high degree of specificity and the rapid 
induction of the innate response, it has recently been shown that the innate immune response is 
actually a requirement for the induction of the adaptive immune response 1,2. It is clear, therefore, 
why innate immunity is now considered to represent the first line of defence against invading 
microbial pathogens.  
 
The three major PRR families are categorised according to the functions they perform and their 
structure. In dendritic cells, TLRs appear to be responsible for virus detection 4. However, in all other 
cell types RLRs take the lead role 5. RIG-1 was the first RLR to be identified as functioning within the 
innate immune response, initiating a response to double-stranded RNA 5,6. A second RLR called 
melanoma differentiation-associated gene (MDA-5) was subsequently identified and also detects 
double-stranded RNA. Interestingly, these two receptors do not perform redundant functions as 
observed using knock-out mice 7,8. Both RIG-1 and MDA-5 share a similarity with NLRs in that they 
contain a caspase-recruitment domain (CARD) which enables the recruitment of the CARD-
containing adaptor protein ‘interferon-β promoter stimulator-1’ (IPS-1) 3. Recruitment of IPS-1 leads 
to signalling events resulting in the activation of nuclear factor kappa B (NF-κB), mitogen-activated 
protein kinases (MAPKs) and interferon-response factors (IRFs) 9. 
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NLRs comprise the largest family of PRRs with 22 members in humans and more than 33 in mice 10. 
NLRs are intracellular receptors and detect a variety of bacterial components 3. The structure of NLRs 
is formed of three domains with a CARD domain at the N-terminus and a series of leucine-rich 
repeats (LRRs) at the N-terminus. These two domains are linked by a nucleotide-binding domain 
(NBD) 3. NLRs share homology with both TLRs and RLRs as they contain LRRs and CARD domains, 
respectively 3,11. The first two NLRs to be reported were nucleotide-binding oligomerisation domain 
(NOD)-1 and NOD2 which detect the components of peptidoglycan (PGN), D-γ-glutamyl-meso-DAP 
(mDAP) and muramyl dipeptide (MDP), respectively 12,13. Although NLRs share a CARD domain with 
RLRs, their subsequent adaptors are different. Signalling via NLRs involves the recruitment of 
receptor-interacting protein (RIP-2) 14,15 which leads to the activation of the IκB kinase complex (IKK) 
16-19. In recent years a lot of research has been done on this family of receptors leading to the 
discovery of numerous NLRs. As different groups simultaneously study these receptors numerous 
names have been used for specific proteins. Recently, a unified nomenclature was agreed on that 
allocates the majority of the NLRs into 5 subfamilies called NLRA, NLRB, NLRC, NLRP and NLRX based 
on the different effector domains 20.  
 
A major step forward in innate immune research was the discovery of the inflammasome complex 21. 
The inflammasome is a multi-protein complex which can be formed after activation of one of three 
NLRs, NLRP1, NLRP3 and NLRC4 10. Upon assembly of the inflammasome, caspase proteins are 
cleaved from their pro-forms to an active state leading to the processing of interleukin (IL)-1β and IL-
18. The most studied complex is formed of NLRP3, apoptosis-associated speck-like protein (ASC) and 
caspase-1 and is activated upon stimulation by numerous and varied microbes and associated 
ligands, in addition to some endogenous stimuli 22-26. To date, no direct binding of ligands to the 
NLRP3 inflammasome complex has been demonstrated and so the mechanism by which such a 
variety of ligands can activate this complex is still under investigation. 
 
Although the NLRP3-inflammasome is able to respond to many ligands, one group of ligands that 
appear not to directly signal through this inflammasome complex is cytoplasmic bacterial, viral, 
mammalian or synthetic DNA 27,28. In 2009, two groups successfully identified the cytoplasmic 
receptor responsible for initiating a response to these ligands as absent in melanoma 2 (AIM2) 29,30. 
AIM2 is able to directly bind to cytoplasmic DNA through its oligonucleotide/oligosaccharide binding 
domain and can interact with the NLR-associated protein, ASC, by means of its amino-terminal pyrin 
domain 31,32. Construction of the AIM2-inflammasome, similarly to NLRP3, results in the activation of 
caspase-1 and production of active IL-1β and IL-18 29,30.  
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The third major family of PRRs is the TLR family. As this family of receptors is the main focus of this 
work, TLRs are discussed in more detail below (Section 1.2). 
 
1.2 Toll and toll-like receptors 
1.2.1 Early milestones of TLR research 
Strangely, the event that initiated research on TLR signalling actually occurred long before the 
identification of the first TLR. Dr Charles Janeway, in a lecture in 1989, hypothesised the process 
whereby receptors present on immune cells detect microbes and instigate a protective immune 
response. Despite being seven years previous, this seminal lecture paved the way for the 
identification of the first Toll gene in 1996. At this time, Lemaitre et al. observed that the toll gene of 
Drosophila melangoster was important in dorso-ventral patterning and subsequently that mutations 
in toll led to the fly succumbing to overwhelming fungal infections 33. Characterisation of this gene 
identified it as a receptor now termed “Toll” whose role, in Drosophila, is in the detection of invading 
fungal pathogens 33. A search for Toll homologues led to the identification of the first human TLRs 
called TLR2 and TLR4, that are responsible for the detection of bacterial lipoproteins and 
lipopolysaccharide (LPS), respectively 33,34. Subsequently, TLRs have been identified across a wide 
range of species including the sea urchin that, with 222 TLRs (and 203 NLRs), has the most of any 
organism identified to date 35. In humans 11 TLRs have been identified which are expressed on 
numerous cell types including immune cells such as dendritic cells, neutrophils and alveolar 
macrophages as well as on non-immune cells such as endothelial cells and epithelial cells 36-41.  
 
1.2.2 Structure and ligands of TLRs 
TLRs are type I integral membrane glycoproteins and their cytoplasmic regions demonstrate 
substantial homology with another family of receptors known as IL-1 receptors (IL-1Rs). Together 
with these receptors TLRs form a large superfamily of receptors called the TLR/IL-1R superfamily 42. 
The cytoplasmic portion of all TLR/IL-1R family members is formed of a conserved chain of 200 
amino acids (αα), known as the Toll/IL-1R (TIR) domain 43. Within this domain are three regions, with 
high homology, that are key for homologous interactions with downstream signalling adaptors that 
also contain TIR domains within their structure 44-46. Despite the homology in the cytoplasmic 
regions, the extracellular regions of TLRs differ considerably from IL-1Rs. The extracellular region of 
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IL-1Rs is formed of three immunoglobulin-like domains whereas the extracellular region of TLRs 
consists of LRR motifs 47.  
 
The LRR motif was first identified from an α2-glycoprotein of human serum in 1985 and was 
characterised as having a 24-residue repeated sequence containing multiple hydrophobic residues 48. 
Subsequently, in 2003 the basic framework of the TLR ectodomain was suggested to be a horseshoe-
shaped solenoid formed of parallel β-sheets on its concave surface and α-helices on the convex 
surface 49. Typically, the β-sheets have uniform twist angles and radii throughout the entire 
structure, such as in TLR3 50. However, TLR4 has an unusual ectodomain as it contains sharp 
structural transitions that divide this protein into three domains; N-, central, and C-terminal domains 
51. The largest changes from typical ectodomains are found within the central domain where the 
radius is 35% smaller and twist angles are three times greater than those of TLR3 51. These structural 
alterations can be attributed to the lack of the usual asparagine ladder from LRR9 – 12 and breaking 
of the phenylalanine spine at the border between the central and C-terminal domains 51. Similar to 
TLR4, TLR2 can be divided into three domains with its central and C-terminal domain deviating 
considerably from the “typical” structure. Again this is due to the absence of both the asparagine 
ladder and the phenylalanine spine 52. The PAMP binding region of TLR2 is also located in an unusual 
place. Typically, PAMP-binding occurs on the concave surface of the solenoid structure where the 
structure provides a binding surface with a 10-fold greater area than the binding surface of 
antibodies 49. In contrast, the convex surface provides the ligand-binding pocket located at the 
border of the central and C-terminal domains 52. The unusual location of ligand-binding is suggested 
to enable a more efficient mechanism of binding small-molecule ligands such as lipopeptides in 
contrast to the large surface area provided by the concave surface for macro-molecule binding.  
 
In addition to structural differences specific residue insertions confer further specificity to ligand 
binding. For example, LRR12 and LRR20 of TLR3 contain large protruding loops that are unique to 
TLR3 and are highly conserved indicating a possible role in ligand binding 50,53. Furthermore, the 
crystal structure of the TLR1/TLR2 heterodimer bound to a synthetic ligand, Pam3CSK4, revealed 
multiple key regions including two acyl chains bound to a hydrophobic pocket on TLR2 and a third 
amide-bound acyl chain bound to a hydrophobic groove on TLR1 52. A key residue of TLR1, Gln-316, 
was also observed interacting via hydrogen-bond formation with a lipopeptide ligand 54. 
 
One method of subdividing TLRs is by the type of ligand that they primarily recognise. Using this 
method the human TLR1, TLR2, TLR4 and TLR6 are grouped on the basis of recognising lipids. 
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Similarly, TLR3, TLR7, TLR8 and TLR9 all recognise nucleic acids and finally TLR5 recognises protein 
ligands 55. However, this method does not reflect the full specificity of recognition that is 
characterised by each individual TLR. Alternatively, TLRs can be categorised by the cellular 
localisation where they are predominantly expressed. In this manner TLR1, TLR2, TLR4, TLR5, TLR6 
and TLR10 are classed as cell surface expressed receptors whereas TLR3, TLR7, TLR8 and TLR9 are 
intracellularly expressed receptors located on endosomes and lysosome 56-58. Interestingly, 
classification in this way displays a degree of overlap with the type of PAMP being recognised. Cell 
surface receptors mainly recognise bacterial products not produced by the host whereas 
intracellular receptors tend to recognise nucleic acids. In this case, prevention of host-derived ligand 
detection is supplied through physical separation rather than completely on the molecular structure 
of PAMPs 2. However, the classification of TLRs is made more complex by the fact that the receptors 
do not always function as a homologous dimer. For example, TLR2 is able to form dimers with both 
TLR1, TLR6 and, more recently identified, TLR10 59,60. In combination with TLR1, TLR2 is able to 
detect tri-acylated lipoproteins and in combination with TLR6 it is able to recognise di-acylated 
lipoproteins 61. The dimer formed between TLR10 and TLR2 shares some similarities with the 
TLR1/TLR2 dimer in that TLR10 preserves the TLR2 dimer interface and the lipopeptide-binding 
channel found in TLR1 60. Interestingly, although both TLR1/TLR2 and TLR10/TLR2 recruit MyD88, the 
downstream signalling cascades initiated are not the same. Where TLR1/TLR2 is able to initiate NF-
κB transcription, TLR10/TLR2 is unable to indicating distinct functions of these two different TLR2 
dimers 60. 
 
The cooperation between certain TLRs, such as TLR2, further diversifies the already broad range of 
PAMPs supported by the TLR system. The most descriptive and accurate, if not most concise, way of 
categorising TLRs is by examining each TLRs individual set of ligands. These are summarised in Table 
1-1. As mentioned previously, TLR2 is able to detect di- or tri-acylated lipoproteins when in 
combination with either TLR6 or TLR1, respectively. In addition, TLR2 recognises a wide variety of 
PAMPs including peptidoglycan, mycoplasma lipopeptides, fungal zymosan and cylindrical LPS 59,62-64. 
TLR3 recognises double stranded RNA (dsRNA) produced by many viruses during replication 65. TLR4, 
together with its accessory proteins MD-2 and CD14, recognises LPS from Gram-negative bacteria 66. 
TLR5 detects bacterial flagellin 39. TLR7, TLR8 and TLR9 all detect nucleic acids with TLR7 and TLR8 
specifically detecting single stranded RNA (ssRNA) and TLR9 detecting unmethylated CpG motifs 
present in bacterial and viral genomes 67,68. TLR10 shares the ligand repertoire of TLR1 and the 
human TLR11 is thought to be non-functional due to a stop codon present within its sequence 60,69. 
This list of PAMPs is by no means exhaustive and only mentions the primary ligands of these  
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TLR # 
Cellular 
location 
Ligand 
group 
Specific ligands Microorganism Synthetic ligands 
TLR2 
/ 
TLR1 
Plasma 
membrane 
Lipids 
Tri-acylated  
lipoproteins 70 
Bacteria 
Compounds A,B,C 
54 
TLR2 
/ 
TLR6 
Plasma 
membrane 
Lipids 
Di-acylated  
lipoproteins 61 
Bacteria 
Compounds E & F 
54 
TLR2 
Plasma 
membrane 
Lipids 
Peptidoglycan 71,72 
Gram-positive 
bacteria 
 
Zymosan 73 Saccharomyces 
Lipoteichoic acids 
72 
Gram-positive 
bacteria 
Atypical 
Lipopolysaccharide 
74,75 
Gram-negative 
bacteria 
Glycolipids 76 
Treponema 
maltophilia 
Haemaglutinin 77 Measles virus 
Structural viral 
proteins 77 
Herpes Simplex 
Virus 
Cytomegalovirus 
Porins 78 Neisseria 
TLR4 
Plasma 
membrane 
Lipids Lipolysaccharide 79 
Gram-negative 
bacteria 
 
TLR5 
Plasma 
membrane 
Protein Flagellin 55 Bacteria  
TLR3 Endosome 
Nucleic 
Acids 
ssRNA 
Viruses Poly(I:C) 80 
dsRNA 65 
TLR7 Endosome 
Nucleic 
Acids 
ssRNA 81,82 Viruses 
Imidazoquinolines 
83,84 
TLR8 Endosome 
Nucleic 
Acids 
ssRNA 85 Viruses 
Imidazoquinolines 
84,86 
TLR9 Endosome 
Nucleic 
Acids 
Unmethylated CpG 
67 
Viruses CpG  
oligonucleotides 87 Bacteria 
TLR10 
Plasma 
membrane 
Lipids 
Zymosan 60 Fungi 
 Tri-acylated 
lipoproteins 60 
Bacteria 
TLR11 
Plasma 
membrane 
Non-
functional 
N/A N/A  
 
Table 1-1: Cellular location of TLRs and their respective ligands 
The ligands of TLRs grouped into categories. TLRs that detect lipids are shown in orange. TLRs that recognise 
proteins are shown in purple. TLRs that bind to nucleic acids are shown in red and TLRs with unknown ligands 
are shown in green. Also shown are the cellular locations and further details of specific natural and synthetic 
TLR ligands.  
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receptors. It is also likely that many more ligands exist that have yet to be identified. The activation 
of TLRs is not only restricted to pathogen-associated ligands. There exists another class of ligands 
called danger-associated molecular patterns (DAMPs). The function of these host-derived ligands is 
to alert the host of damage inflicted upon its cellular structure through infection or trauma. 
Subsequent to non- infectious lung injury, fragmented hyaluronan builds up at the site of damage. 
This DAMP signals through TLR2 and TLR4 initiating the production of inflammatory mediators and 
ensuring the maintenance of epithelial cell integrity resulting in the recovery of injury 88. Another 
well studied DAMP is called high-mobility group box-1 (HMGB-1). HMGB-1 is passively released 
when tissues are damaged in the absence of an invading organism 89. In contrast to hyaluronan-
induced signalling, HMGB-1 release promotes excessive inflammation and subsequent tissue 
damage 89.  
 
1.2.3 Expression of TLRs 
In addition to certain TLRs being preferentially expressed on different cellular membranes, diverse 
cell types also preferentially express sets of receptors. Neutrophils and macrophages, two of the 
major immune cells, express all TLRs except TLR3 36. In contrast, mature dendritic cells (DCs) do 
express TLR3 in addition to TLR1, TLR2, TLR4 and TLR5 although they lack TLR7 and TLR9 36. 
Mononuclear cells, such as B-cells, have been shown to express high levels of TLR1, TLR6, TLR9 and 
TLR10 but low levels of TLR2, TLR4 and TLR7 36. However, it is not just antigen presenting cells (APCs) 
that express TLRs. Natural killer (NK) cells, a subtype of T-cell, express high levels of TLR3 and can 
become activated after direct detection of the synthetic TLR3 ligand poly(I: C) 90. More recently, it 
has been found that NK cells can respond to other ligands such as CpG DNA perhaps suggesting the 
involvement of other TLRs in addition to TLR3 91. As NK cells are major anti-viral immune cells it is 
perhaps not surprising that they express TLR3, a detector of viral components, and have the capacity 
to respond to CpG DNA.  
 
TLR expression is not restricted to immune cells and TLRs have been located on numerous epithelial 
cells isolated from the respiratory, intestinal and genitourinary tracts 36. Within the intestinal tract, 
the epithelial cells are in constant contact with commensal bacteria and the cells need to be able to 
maintain the potential to respond to pathogenic bacteria without repeatedly being activated by 
commensal bacteria. This is achieved through two mechanisms. Firstly, intestinal epithelial cells 
exhibit very low levels of expression of TLR4, keeping the cells in a hyporesponsive state to LPS 
expressed by commensal bacteria 92. The second, and possibly more tightly regulated, mechanism is 
through TLR5 exhibiting a strict polarised expression in these cells whereby TLR5 is only expressed 
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on the basolateral edge and not on the intestinal lumen (apical) side 66. This mechanism prevents 
activation by the flagella of commensal bacteria and reserves detection for pathogenic bacteria that 
make the journey across to the basolateral side. Unlike intestinal epithelium, TLR4 is widely 
expressed in pulmonary epithelial cells 36. In addition, TLR2 is highly expressed by type II alveolar 
epithelial cells 38,93. This widespread expression of TLR2 and TLR4 in the lungs could be due to the 
requirement to detect and eliminate invading pathogens rapidly before too much organ damage is 
sustained. However, the response must be strictly regulated to prevent autoimmune damage. 
 
With the range of TLRs available, human cells are able to initiate a response to a multitude of diverse 
ligands. The specificity of the response is dependent upon which TLRs are activated, the location of 
the host cell and the type of cell being activated. All of these factors contribute to the final response 
generated by the innate immune system. However, there is a requirement to link the primary 
detection event by TLRs to the generation of a specific immune response and this is provided by the 
intracellular TLR signalling cascades. 
 
1.3 TLR signalling 
The signalling cascades initiated by ligands binding to TLRs can be subdivided into two major 
pathways. These are classified as the Myeloid differentiation primary response gene-88 (MyD88) and 
TIR-domain-containing adaptor-inducing interferon-β (TRIF)-dependent pathways according to 
which of the two primary adaptor molecules (MyD88 or TRIF) are recruited to the intracellular TIR 
domain of the TLRs. Following adaptor binding there is a complex cascade of protein recruitment 
and activation involving numerous proteins and signalling branches. A schematic representation of 
the major proteins and branches is shown in Figure 1-1. The figure does not display all proteins and 
pathways known or proposed to be involved in TLR signalling but illustrates the complexity of TLR 
signalling generated by numerous signalling proteins, multiple interactions and cross-talk between 
pathways. One paper has attempted to diagrammatically describe the TLR system and nicely 
illustrates the complexity of the network even if the end result is not entirely comprehensible 94. 
1.3.1 MyD88-dependent signalling 
1.3.1.1 MyD88 and Mal 
MyD88 is the adaptor molecule responsible for the initiation of intracellular signalling upon ligand 
binding to all TLRs except TLR3. This has been demonstrated through the stimulation of MyD88-
deficient macrophages by a range of different TLR ligands 45,67,95,96. These macrophages were unable  
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Figure 1-1: MyD88-dependent and TRIF-dependent TLR signalling cascades exampled by activation of TLR4 
or TLR3 
Dimerisation of TLR4, induced by ligand binding, leads to the recruitment of both major adaptors, MyD88 and 
TRIF, through their co-adaptors Mal and TRAM, respectively. MyD88 recruits IRAK-4 (and potentially other 
members of the IRAK family) which in turn attracts TRAF-6 to the complex. Ubiquitination of TRAF-6 leads to 
the formation of a signalling complex formed of TAK-1 and its binding proteins TAB-1,-2,-3. At this point the 
MyD88-dependent pathway bifurcates into the MAPK and the NFκB branches. The MAPK branch consists of a 
cascade of phosphorylation events beginning with TAK-1 and passing through the MAP2Ks (MKK1-7) and the 
MAPKs (JNK, ERK and p38) leading to the activation of the dimeric transcription factor, AP-1. The NFκB branch 
involves the formation and activation of the IKK complex, composed of IKKα, IKKβ and IKKγ (NFκB essential 
modulator – NEMO). This complex phosphorylates the NFκB inhibitory protein, IκBα, leading to its degradation 
and the release of NFκB. NFκB then translocates to the nucleus and initiates transcription. The TRIF-dependent 
pathway is able to link into both the NFκB and the MAPK branches of the MyD88-dependent pathway through 
the signalling proteins RIP and TRAF-6 respectively. In addition, the TRIF-dependent pathway leads to the 
activation of TBK-1 and IKKi, possibly through TRAF-3. This in turn leads to the activation of the transcription 
factor, IRF-3. Figure reproduced from “TLR Signalling”, 2006, T. Kawai and S. Akira 
97
.  
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to secrete tumour necrosis factor (TNF) and IL-6 in response to LPS and macrophage-activating 
lipopeptide-2 (MALP-2), although delayed activation of NFκB was still observed in response to LPS 98. 
MyD88 is a tertiary domain protein consisting of a TIR domain at the C-terminus, which is used in the 
homologous binding to the TIR domains of TLRs, and a death-domain (DD) at the N-terminus, which 
is essential for the recruitment of downstream signalling proteins 99,100. As MyD88 is essential to the 
majority of signalling pathways induced by TLRs, the signalling cascade downstream of MyD88 is 
termed the MyD88-dependent pathway. MyD88 is the primary signalling protein recruited to the 
intracellular portion of TLRs. However, MyD88 is not the only adaptor utilised in the MyD88-
dependent pathway. Both TLR2 and TLR4 usually require a co-adaptor called MyD88-adaptor-like 
(Mal) to activate their signalling cascades 46,101. In fact, the same defective TNF and IL-6 secretion 
profile was observed in Mal-deficient macrophages stimulated with LPS and MALP-2 as was seen in 
MyD88-deficient macrophages indicating the essential requirement for Mal 101. In addition, 
activation of the downstream signalling proteins extracellular regulated kinase (ERK), p38 and c-Jun 
NH2-terminal kinase (JNK) was only observed in the presence of Mal when the cells were stimulated 
with MALP-2 101. Interestingly, more recent research demonstrates a role for Mal in TLR2 signalling 
only when low concentrations of ligand are available since the requirement for Mal can be overcome 
with high concentrations of TLR2 ligand when only MyD88 is required 95. It is possible that the 
requirement for Mal is dependent on the concentrations of ligand and acts as a sensitizer for the 
system when ligand is sparse. Work performed using the bacterial pathogen Francisella tularensis 
extends this hypothesis by showing that increasing the retention time of the bacteria within the 
phagosome also negates the requirement for Mal in TLR2 signalling 102. It appears then that Mal is 
required to enhance the sensitivity of detection only when low concentrations of ligand or a 
transient interaction with the ligand is available. Mal displays close homology with MyD88 in terms 
of having a TIR domain at its C-terminus but Mal does not have a DD and its N-terminus is 75 amino 
acids shorter than MyD88 46. The current understanding is that TLR dimerisation, in all cases except 
TLR3, induces the recruitment of MyD88 via homotypic TIR domain interactions. In the case of TLR4, 
Mal is required to bridge the connection between the TLR and MyD88 TIR domains via its own TIR 
domain. For TLR2, Mal is only a requirement if low concentrations of ligand are present. However, 
this model of Mal recruitment is not true in all cases. Infection of mice with Salmonella typhimurium 
induces early signalling events through TLR4 that aids in controlling early bacterial growth 103. 
Interestingly, this response is unaltered in mice deficient in the expression of Mal indicating that, in 
this case, Mal is not required for TLR4-induced signalling cascades 103. This observation clearly 
demonstrates the flexibility of the TLR signalling system and acts as a warning against assuming that 
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signalling proteins and interactions downstream of one stimulus will necessarily be present in the 
cascade induced by another. 
 
1.3.1.2 IRAKs 
The recruitment of MyD88 and Mal to the intracellular portion of TLRs leads to the recruitment of 
the next family of signalling proteins termed the interleukin-1 receptor-associated kinases (IRAKs). 
There are 4 members of the IRAK protein family and each has a specific role to play in TLR signalling 
104. IRAK-4 is the first family member to be recruited to the DD of MyD88 via interactions with its 
own DD 104,105. The essential role of IRAK-4 has been demonstrated in TLR2 signalling, as IκB 
degradation was prevented after stimulation with PGN in IRAK-4 deficient macrophages 106. 
Signalling downstream of TLR4 activation in IRAK-4 deficient macrophages was only delayed, as 
judged by NFκB activation, due to TLR4 having the capacity to signal through other pathways besides 
the MyD88-dependent cascade 106. The requirement for IRAK-4 is also observed in vivo as mice 
deficient in IRAK-4 are unable to secrete IL-6 and TNF in response to LPS 105,106. The function of IRAK-
4 is dependent on the kinase activity, which phosphorylates subsequent signalling proteins resulting 
in the progression of the signalling cascade. Although the role for IRAK-4 is well defined, the 
substrate which it interacts with is less certain although both IRAK-1 and IRAK-2 are potential IRAK-4 
substrates 99,107,108.  
 
IRAK-1, similarly to MyD88, has a DD at its N-terminus that is able to mediate binding to other DD-
containing proteins. Also present in its structure is a Ser/Thr kinase domain and a C-terminal domain 
that contains motifs for TNF-receptor-associated factor-6 (TRAF-6) binding 109. It has been proposed 
that in its inactive state, IRAK-1 is maintained in a folded form involving interactions between the DD 
and motifs present in the C-terminus 99. Both IRAK-4 and IRAK-1 have DDs although it has been 
observed that a homotypic binding between these domains is not required for their interaction 99. 
Despite this, a linkage between IRAK-4 activation and IRAK-1 activation and degradation has been 
seen. In macrophages stimulated with LPS, a degradation of IRAK-1 was observed within 15 min and 
this was maintained until 60 min 107. However, in the absence of IRAK-4, no degradation of IRAK-1 
was seen 107. IRAK-1 contains residues that enable it to both become autophosphorylated, at Thr-
209, and phosphorylated, at Thr-387, by other kinases 99. It is thought that a conformational change, 
induced by autophosphorylation, enables phosphorylation within its activation loop leading to full 
activation of its kinase activity 99. A subsequent conformational change might enable it to interact 
with MyD88 and recruit TRAF-6 via motifs in its C-terminus. The degradation of IRAK-1 is deemed 
essential for the release of the signalling complex from TLRs and might also function as a negative 
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feedback mechanism terminating TLR-mediated NFκB activation 107. Recent structural studies have 
provided insight into the associations between MyD88 and members of the IRAK family, known as 
the Myddosome 110,111. Alone, MyD88 forms a heterogeneous population of homo-oligomers via DD 
interactions 110. However, when IRAK-4 is present, stable complexes are formed between these two 
proteins with predictable ratios 110. Solving of the crystal structure of the Myddosome complex 
further refined knowledge of its configuration revealing the presence of six MyD88, four IRAK-4 and 
four IRAK-2 units arranged in a left-handed helix 111. Interestingly, although this structure suggests a 
sequential mechanism of protein addition, the process which interrupts the addition of MyD88 
protein to the complex and converts it to the addition of IRAK-4 followed by IRAK-2 is currently 
unknown. Assembly of the Myddosome is yet to be delineated but its composition provides valuable 
information of the proteins involved in the initiating stage of a signalling cascade. The Myddosome 
brings IRAK-4 into close proximity with IRAK-1 enabling the phosphorylation of IRAK-1 and 
progression of the signal 112. 
 
Despite evidence pointing to IRAK-1 functionality within the MyD88-dependent pathway, there are 
some unexplained inconsistencies. TRAF-6, the proposed effector of IRAK-1, requires 
autoubiquitination for its function but IRAK-1 lacks the capacity to initiate this step 113. In addition, 
recent data shows that IRAK-1 is dispensable for NFκB activation for some TLRs and might even have 
an alternative role in IRF activation 114. Another hypothesis for progression of signalling from IRAK-4 
involves another IRAK family member, IRAK-2, that can associate with both Mal and MyD88 via 
homotypic DD interactions. Two putative TRAF-6 binding motifs have also been identified and 
mutation of these motifs inhibited IRAK-2 functions suggesting TRAF-6 as a potential effector protein 
109,114. In addition, unlike IRAK-1, IRAK-2 displays the ability to initiate TRAF-6 polyubiquitination 114. 
However, like IRAK-1, IRAK-2 does not fully account for all process downstream of IRAK-4. Although 
NFκB DNA-binding activity was impaired 4 h after stimulation of IRAK-2 deficient macrophages, there 
was no impairment seen up to 40 min 108. In addition, the activation of JNK, p38 and ERK, after 
MALP-2 stimulation of IRAK-2 deficient macrophages, was not impaired suggesting that IRAK-2 is 
dispensable for this function 108. It is likely then that both IRAK-1 and IRAK-2 are required 
downstream of IRAK-4 and perform distinct functions. One model suggests that both IRAK-1 and 
IRAK-2 function redundantly in the initial stages of signalling ensuring a robust response to TLR 
stimulation. However, within 1 h of TLR stimulation IRAK-1 exhibits degradation acting as a negative 
feedback mechanism preventing the overproduction of inflammatory cytokines. Meanwhile the 
activation of IRAK-2 is sustained, up to 8 h after stimulation, ensuring a lower but maintained level of 
cytokine response 108.  
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The final IRAK family member associated with MyD88-dependent signalling is IRAK-M which is 
responsible for negative regulation 104. Along with the other IRAK proteins, IRAK-M contains a DD 
and imposes negative regulation upon IRAK-1 via homotypic DD interactions 99.  
 
1.3.1.3 TRAF-6 
TRAF-6 belongs to a family of six TRAF proteins. TRAF-6 was identified in 1996 through the use of a 
yeast two-hybrid system investigating molecules crucial for CD40 signalling 115. TRAF-6 is composed 
of a highly conserved TRAF-C domain at its C-terminus that is preceded by a coiled-coil domain and a 
really interesting gene (RING) domain and zinc-finger motifs at its N-terminus 116. It is known that, 
although TRAF-6 and TRAF-3 are both able to bind to CD40, only TRAF-6 induces the downstream 
activation of NFκB, indicating functional differences between these two TRAF proteins 115. Since the 
discovery of its role in CD40 signalling, a role for TRAF-6 has also been identified in numerous 
physiological processes including bone metabolism, cell differentiation, dendritic cell maturation and 
innate immune responses 117. Many, if not all, of these processes rely on the location of TRAF-6 
within signalling pathways, and its ability to activate downstream signalling proteins such as NFκB 
and the MAPKs 114,118,119.  
 
Each of the domains within the structure of TRAF-6 is essential to its function. The TRAF-C domain is 
the most conserved region within the TRAF proteins with 35.9% homology between TRAF-6 and 
TRAF-2 and homology between other TRAF family members ranging from 41.7% to 66.2% 120. This 
domain forms a trimeric mushroom head-like structure with three protein-binding pockets 109. The 
TRAF-C domain is important in TRAF-6 oligomerisation and in binding to upstream signalling 
proteins. Interestingly, multiple single changes of highly conserved residues within the TRAF-C 
domain do not affect the downstream activation of NFκB indicating a compact structure of this 
domain which is stabilised by multiple different residues 117. 
 
Located next to the TRAF-C domain is the coiled-coil domain that is considered essential in the 
autoubiquitination of TRAF-6 121. In studies where the coiled-coil domain is abolished from its 
structure, TRAF-6 does not induce IKK complex activation or induction of NFκB transcription 121. This 
indicates that autoubiquitination through the coiled-coil domain is crucial for the function of TRAF-6 
and the progression of signalling to downstream proteins. However, despite the role of the coiled-
coil domain in autoubiquitination of TRAF-6, it is not the actual site for attachment of ubiquitin. 
Rather it has been proposed that it is the bridge that links TRAF-6 to one of its accessory proteins, 
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ubiquitin-conjugating enzyme (Ubc)-13 121. Ubiquitination performs two functions. Lys-48-linked 
ubiquitination acts as a label targeting the protein for proteasomal degradation, as in the case of 
IRAK-1 119,122. In contrast, lys-63-linked ubiquitination acts as a scaffold leading to the formation of 
signalling complexes 119,122. The autoubiquitination of TRAF-6 is lys-63-linked and enables the 
recruitment of transforming growth factor-β (TGF-β)-activated kinase-1 (TAK-1) through its 
accessory proteins TAK-1-binding protein (TAB)-1, TAB-2 and TAB-3 123. 
 
Finally, the RING domain comprises the core of the ubiquitin ligase catalytic domain. Studies that 
altered single amino acids within this domain led to the identification of a potentially necessary but 
insufficient role for the RING domain in Lys-63-linked polyubiquitination of TRAF-6 117. The domains 
of TRAF-6 all seem to be linked to the process of ubiquitination either directly or through the 
recruitment of accessory proteins. Therefore, it seems apparent that the major function of TRAF-6 is 
in inducing the construction of Lys-63-linked ubiquitin chains that subsequently act as scaffolds for 
the recruitment of downstream proteins, in particular TAK-1 122. 
 
1.3.1.4 TAK-1 
Upon recruitment of TAK-1 to the TRAF-6 complex, TAK-1 becomes activated through dual 
phosphorylation of the Thr-178 and Thr-184 residues within the kinase activation loop 124. The initial 
phosphorylation of TAK-1 has been demonstrated to be an autophosphorylation event as a kinase-
defective TAK-1 mutant remains unphosphorylated 125. The TAK-1 accessory protein, TAB-1, is 
constitutively associated with TAK-1 through a 68 αα region located on the C-terminus of TAB-1 126. 
The association of TAK-1 with TAB-1 is required but not sufficient for activation indicating that 
another process is also required for the progression of signalling 125. However, in contrast, a more 
recent study provided evidence that TAB-1 is not required for TAK-1 activation as a result of IL-1-
induced signalling 127. Another inconsistency between studies relates to the dimerisation of TAK-1. 
One study demonstrated that TAK-1 is activated in the absence of dimerisation 125 whereas another 
study observed oligomerisation of TAK-1 127. Two key differences between these studies may explain 
the different conclusions. First, in one study oligomerisation was observed only in the presence of 
high concentrations of TAK-1. Since high concentrations of proteins often result in the formation of 
complexes, this may be an artefact of the experiment. Secondly, the differing requirements for TAB-
1 might be due to the manner by which the cells were activated as one was induced by IL-1-
stimulation and the other by TNF and IL-1 stimulation.  
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An additional function potentially attributed to TAB-1 is the negative feedback of TAK-1. TAB-1 
becomes phosphorylated by a downstream MAPK at Ser-423 and Thr-431 and this coincides with the 
down-regulation of TAK-1 128. A mechanism for this process may involve one of the other TAK-1 
accessory proteins, TAB-3 that becomes phosphorylated on residues Ser-60, Thr-404 and Ser-506 
residues as a direct or indirect result of the recruitment of p38 to the TAK-1 complex by TAB-1 129. 
The link between p38 recruitment by TAB-1 and phosphorylation of TAB-3 is demonstrated by the 
fact that in murine embryonic fibroblasts deficient in TAB-1, phosphorylation of TAB-3 is greatly 
reduced 129. It seems then that activated TAB-1 recruits p38 which leads to the phosphorylation of 
TAB-3 and the down-regulation of TAB-1 activation coinciding with negative regulation of TAK-1 
activity. TAB-2 and TAB-3 both interact with TAK-1 through a region located on TAK-1 between 
amino acids 479 and 553 123. TAB-2 and TAB-3 are able to bind to ubiquitin and may function to 
tether TAK-1 to upstream proteins such as TRAF-6 and also downstream effector proteins through 
ubiquitin scaffolding 127.  Following IL-1 stimulation, TAB-2 becomes phosphorylated at Ser-372 and 
Ser-524 and TAB-3 becomes phosphorylated at Ser-60, Thr-404 and Ser-506 129.  
 
At the point of TAK-1 recruitment and activation the MyD88-dependent pathway bifurcates into the 
MAPK pathway and the NFκB pathway, which are discussed separately in sections 1.3.3 and 1.3.4, 
respectively. 
 
1.3.2 TRIF-dependent signalling 
1.3.2.1 TRIF and TRAM 
The presence of adaptor molecules other than MyD88 and Mal were identified following the finding 
that macrophages deficient in MyD88 still display a delayed response to stimulation despite the 
immediate response being impaired 98,130. This finding led to the discovery of TRIF as the second 
major TLR adaptor protein that, at 712 amino acids long, is much larger than the 300 amino acid 
MyD88 44,131. Unlike MyD88, which is involved in signalling from all TLRs except TLR3, TRIF has been 
linked to signalling downstream of TLR4 and TLR3 only 44,132.  The unique feature of TLR4 is that it is 
able to induce both the MyD88-dependent and the TRIF-dependent signalling cascades. This means 
that MyD88-deficient macrophages stimulated by LPS retain the capacity to signal through TRIF-
dependent mechanisms and, similarly, TRIF-deficient macrophages can still signal through MyD88-
dependent processes. The major difference between the two pathways is the kinetics of the NFκB 
response. MyD88-dependent signalling leads to an early phase activation of NFκB whilst the TRIF-
dependent pathway leads to a late phase of activation 98,133. 
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Similarly to Mal bridging the connection between MyD88 and the TIR domain of TLR4, TRIF also 
utilises a co-adaptor, termed TRIF-related adaptor molecule (TRAM), for this purpose. The role for 
TRAM in TLR4 recruitment of TRIF is shown by the finding that macrophages deficient in TRAM show 
normal cytokine responses (i.e. IL-6 and TNF secretion) to stimulation via TLR2, TLR7 and TLR9 but 
defective responses to TLR4 45. In comparison, the use of TRAM as a co-adaptor has not been 
demonstrated for TLR3-induced signalling. In fact, stimulation of TRAM-deficient macrophages via 
TLR3 does not induce defective responses 45. 
 
Like MyD88, TRIF-dependent signalling can lead to NFκB and MAPK activation although, unlike 
MyD88, TRIF can also lead to activation of the IRF transcription factors, particularly IRF-3 and IRF-7. 
The link into the NFκB pathway is mediated through the interaction of TRIF with RIP-1 and the link 
into the MAPK pathway is made through TRAF-6. This occurs through the three TRAF-6 binding 
motifs located on TRIF 134. The downstream pathway from this point is the same as in the MyD88-
dependent pathway. However, the activation of IRF transcription factor occurs through an entirely 
separate pathway starting with the recruitment of TRAF-3 135. 
1.3.2.2 TRAF-3, TBK-1 and IKKi 
The requirement for TRAF-3 in signalling cascades downstream of TRIF activation was shown using 
TRAF-3 deficient macrophages that displayed elevated levels of IL-12 and IL-16 due to defective 
production of IL-10, one of the end products of TRIF-dependent signalling 135. TRAF-3 is involved in 
the recruitment of two kinases, TRAF family member-associated NFκB activator (TANK)-binding 
kinase-1 (TBK-1) and IKKi, to the signalling complex 135. Upon binding to the TRIF/TRAF-3 complex, 
TBK-1 and IKKi become activated and go on to directly phosphorylate serine residues within IRF-3 
45,136. IRF-3 resides within the cytoplasm in an inactivated state but, upon phosphorylation, dimerises 
and translocates to the nucleus 136. In the absence of TBK-1 or IKKi the majority of IRF-3 and IRF-7 is 
located within the cytoplasm. However, when TBK-1 or IKKi is activated, approximately 35% of IRF-3 
and 95% of IRF-7 translocates to the nucleus 137,138. 
 
1.3.3 MAPK-induced transcription 
Within the MAPK signalling cascade are several parallel pathways and the best characterised utilise 
the kinases known as JNK, ERK and p38 119,139,140. These kinases represent only one level of kinase 
activity within a cascade involving numerous levels. In the case of TLR signalling, one of the major 
kinases at the starting point of MAPK-induced transcription is TAK-1, discussed in 1.3.1.4. TAK-1 is a 
MAP3K protein and directly activates the group of protein kinases known as MAP2Ks. These diverse 
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proteins are situated directly upstream of JNK, ERK and p38 and demonstrate specificity to one or 
two of these proteins. JNK is situated downstream of MKK4 and MKK7, p38 is activated by MKK3 and 
MKK6 and ERK activation is preceded by MKK1 and MKK2 140.  
 
Despite being activated by specific and different kinases, the MAPKs do demonstrate substantial 
homology in terms of structure. In fact, there is an overall sequence homology of >40% 141. Through 
X-ray crystallographic analysis and amino acid mutation studies, two key domains for determining 
the specificity of interactions with both upstream MAP2Ks and downstream substrates have been 
identified. One domain, termed the common domain (CD), is universal to all MAPKs and is important 
for docking to both upstream MAP2Ks and downstream substrates 142. CDs are characterised by 
negatively charged amino acid such as aspartine and are located on the opposite side to the active 
site 142. The second region of importance is termed the ERK-docking (ED) domain and specific 
residues within this domain are key to substrate specificity 143. In fact, the exchange of two amino 
acids present in the ED domain of ERK to the corresponding ones in p38 alters the docking specificity 
of ERK to that of p38 143. The proposed model for substrate specificity currently involves the concept 
of a docking groove that comprises both the CD and ED domains. Evidence supporting this model is 
provided by the finding that when both domains are mutated in p38 an almost complete loss in 
docking to its substrate is observed 143.  
 
Further specificity for substrates is provided by the dual phosphorylation motif present in all the 
MAPKs. This is characterised by a three amino acid chain formed of Thr-Xaa-Tyr with Xaa being Glu, 
Gly and Pro for ERK, p38 and JNK, respectively 144-146. However, it is not just residues and domains 
within the MAPKs that determine their downstream specificity. Within the structure of many 
transcription factors, which are targets for the MAPKs, there is a docking domain (D-domain). Each 
individual D-domain is about 20 amino acids long and does not demonstrate a high level of sequence 
homology between separate transcription factors 147. They do, however, contain similar regions 
characterised by an area of basic amino acids followed by a Lys-X-Lys motif and a triplet of 
hydrophobic amino acids 147. Interestingly, a single variation of D-domain is able to target the 
transcription factor Elk-1 to ERK and JNK whilst also conferring serum response factor (SRF)-
accessory protein-1 (SAP-1) specificity towards ERK and p38 148,149. This might be explained by the 
fact that the D-domains are targeted by the docking groove of MAPKs which themselves contain 
specificity-determining residues within the CD and ED domains. It is likely that it is the combination 
of the CD and ED domains located on the MAPKs and the D-domains of their substrates that enables 
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the high level of specificity observed and also the ability to confer cross-talk between the parallel 
pathways of the MAPK signalling system.  
 
The duration of the signalling response also determines the final output of the MAPK signalling 
pathways. For example, sustained ERK activation causes the differentiation of pheochromocytoma 
cells whereas transient activation does not 150,151. Similarly, transient activation of JNK is considered 
a survival signal within host cells whereas sustained activation is linked with the induction of cell 
death 140,152,153. One mechanism which confers detection of signal duration has been characterised in 
ERK signalling leading to transcription by c-Fos. The half-life of c-Fos is relatively short 
(approximately 30 min) and c-Fos only accumulates to sufficient concentrations for efficient 
transcription activation when phosphorylated under sustained ERK activation 154. This means that 
only stimuli that induce a sustained ERK activation will lead to the expression of genes targeted by c-
Fos. 
 
The production of immune mediators through the MAPK signalling pathways is regulated mainly by 
the transcription factor activator protein (AP)-1. AP-1 is a collective term referring to a dimeric 
transcription factor composed of members of the Jun, Fos or AP-1-trancription factor (ATF) subunit 
families that are able to bind to the common AP-1 DNA binding site. Each MAPK has a set of 
transcription subunits that they can activate through phosphorylation. 
 
1.3.4 NFκB-induced transcription 
In mammals, there are five members of the NFκB family characterised by the presence of a 300 
amino acid Rel-homology domain (RHD). These are NFκB-1 (p105/p50), NFκB-2 (p100/p52), RelA 
(p65), RelB and c-Rel (Figure 1-2) 155. The RHD consists of a nuclear localisation sequence which is key 
to many of the proteins roles including dimerisation, DNA binding and interactions with their 
inhibitory proteins 156. The NFκB proteins are able to form multiple homo- and heterodimers which 
allows them to preferentially target precise transcription sites and act as either repressors or 
stimulators of transcription depending on the proteins involved in dimerisation. For example, the 
p50 and p52 homodimers, which lack transcriptional activation (TA) domains, function as repressors 
whereas dimers that contain RelA or c-Rel are transcriptional stimulators 157. Dimerisation also 
enables NFκB proteins that do not contain a TA domain, such as p50 and p52, to dimerise with RelA, 
RelB or c-Rel thereby acquiring a transcription stimulator function 158,159. To prevent continuous 
transcription by NFκB proteins, the majority of dimers are held in an inactive state in the cytoplasm  
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Figure 1-2: Members of the NFκB transcription factor family 
The five members of the mammalian NFκB transcription factor family are p100, p105, RelA, RelB and c-Rel. All 
members contain a Rel homology domain which itself contains a nuclear localisation sequence that is key in 
many roles including dimerisation, DNA binding and inhibitory protein interactions. RelA, RelB and c-Rel also 
contain a transcriptional activation domain that enables them to be part of a dimer stimulating transcription 
whereas p100 and p105 homodimers are suppressors of transcription due to the lack of a TA domain. The 
ankyrin repeats present only in p100 and p105 enable these transcription factors to self-inhibit dimers without 
the requirement for an IκB family member. The self-inhibition also involves the “GGG” motif that acts as a 
“hinge” region enabling the ankyrin repeats, present at the C-terminus, to bind to the RHD located at the N-
terminus. Figure adapted from “The two NF-κB activation pathways and their role in innate and adaptive 
immunity”, 2004, G. Bonizzi and M. Karin 
155
. 
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by a family of proteins called inhibitor of κB (IκBs). IκBs are able to bind to the RHD of NFκB proteins 
preventing localisation to the nucleus. This interaction occurs via a series of 5-7 ankyrin repeats 
which are found in all nine IκB family members (IκBα, IκBβ, BCL-3, IκBε, IκBy, IκBζ, IκBNS, p100 and 
p105) 160. The two NFκB family members p100 and p105 are also members of the IκB family as they 
contain ankyrin repeats within their structures and are therefore able to act as self-inhibitors of their 
own transcription dimers 161. 
 
The initiation of NFκB mediated transcription can occur via two major branches of signalling known 
as the canonical (classical) and non-canonical (alternative) pathways (Figure 1-3). 
 
1.3.4.1 Canonical pathway 
The canonical pathway begins downstream of TAK-1 activation with the formation of an IKK complex 
which is a trimeric complex composed of two kinase subunits IKKα (85 kDa), IKKβ (87 kDa) and the 
regulatory subunit IKKγ (52 kDa) (also known as NFκB essential modulator – NEMO) 162. For the IKK 
complex to become fully functional several phosphorylation events must take place. 
Autophosphorylation of the helix-loop-helix (HLH) domain of IKKβ occurs and this has been shown to 
require IKKγ 163. The regulation of this phosphorylation is dependent on the phosphorylation of the 
(NBD/γBD) in the C-terminal portion of IKKβ and so this is deemed the major regulation event of IKK 
complex activation 163. 
 
The IKK complex is able to phosphorylate both IκBα at Ser-32 and Ser-36 and IκBβ at Ser-19 and Ser-
23, located in the N-terminus of these proteins 164. Phosphorylation of these residues enables the 
recognition and polyubiquitination of IκBα and IκBβ by a protein complex called B-TrCP-SCF 164. 
Subsequently, the polyubiquitination labels the proteins for proteasomal degradation. Upon IκB 
degradation, the RHD of NFκB proteins becomes un-suppressed enabling localisation to the nucleus 
and the initiation of transcription 163. Despite the structural similarities of IKKα and IKKβ, it appears 
that IKKβ is the dominant kinase and is therefore the crucial subunit involved in canonical NFκB 
transcription 164. In fact, IKKβ demonstrates a 30-fold higher activity towards IκBα than IKKα and is 
required for the induction of most NFκB targeted genes in response to TNF 163,165. However, aside 
from NFκB activation, multiple roles have been assigned to IKKα but these mainly do not require 
IκBα degradation 166-169. In addition to the preference of IKKβ activation over IKKα activation for IκBα, 
both IKKα and IKKβ demonstrate a preference for IκBα over IκBβ 162. This might explain why IκBβ 
displays slower degradation kinetics than IκBα. Upon release from IκB-directed suppression, NFκB 
dimers localise to the nucleus where they are able to bind to numerous promoter and enhancer 
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regions containing κB sites with the sequence GGGRNNYYCC (N = any base, R = purine, Y = 
pyrimidine) 162.  
 
1.3.4.2 Non-canonical pathway 
Although IKKα does not appear to play a major role in the canonical branch of NFκB transcription, it 
performs a critical role in the non-canonical branch where IKKβ and IKKγ are not required 162. The 
only NFκB family member that is vital to the non-canonical branch is p100 160,170. Phosphorylation of 
p100 by IKKα occurs at two serine residues located at the C-terminus. Subsequently, p100 undergoes 
polyubiquitination mediated by the B-TrCP-SCF E3-ligase complex 171. Similarly to the IκB proteins, 
polyubiquitination labels p100 for degradation. However, p100 undergoes only partial proteolysis 
that is regulated by the presence of a glycine-rich region between amino acids 376 and 404 that 
serves as a stop signal 162. This ensures that the N-terminal portion of p100 containing the RHD is 
released and, combined with its usual dimerisation partner RelB, localises to the nucleus and 
initiates transcription 155. 
1.3.4.3 Regulation of NFκB 
Despite there being only 5 NFκB family members there still exists a broad range of target sites where 
NFκB transcription can occur. This indicates that there must be control mechanisms present that 
confer a degree of specificity and regulation of the sites targeted and of the duration of binding in 
response to specific stimuli. Indeed, it has been observed that in response to just TNF stimulation 
there exists two phases of NFκB activation 172. The end result of NFκB signalling appears to also be 
reliant on the oscillations of its transport from an inactivated state in the cytoplasm to an activated 
state in the nucleus 173-175. Sustained stimulation of signalling by TNF induced substantial oscillations 
in NF-κB activation 174. Alterations in oscillation frequency, amplitude and duration can be brought 
about through modulation of the mode of stimulation 175. For example, maintained expression of 
RANTES (regulated upon activation, normal T-cell expressed, and secreted) is induced by repeated 
short pulses of TNF stimulation 176. These pulses can be modulated to generate a frequency of NF-κB 
activation of 100 min and 200 min, although only the 100 min frequency is able to maintain RANTES 
expression 176. Similarly, expression of late but not early genes is brought about by high-dose TNF 
stimulation that induces NF-κB oscillations with a long duration 177. The same late gene expression is 
not induced by short duration NF-κB oscillations 177. Therefore, it is likely that the consequences of 
signalling may depend, not only on the activation state of NFκB, but on the number, duration and 
amplitude of oscillations 173. As the response depends so heavily on precise modulation of NF-κB 
activation it is clear that strict regulation of NF-κB activation must be present. 
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The IκB family members confer one mechanism of regulation upon NFκB. There are 7 IκB proteins 
and studies on these proteins have reported differing regulatory functions for each one. One 
function is the negative feedback associated with IκBα inhibition. IκBα synthesis is tightly controlled 
by a highly NFκB responsive promoter generating autoregulation of NFκB signalling 172. Simply, upon 
IκBα degradation, NFκB is released inducing transcription and the synthesis of more IκBα which then 
binds to NFκB, ceasing transcription. This results in IκBα-controlled transcription displaying a rapid 
and oscillatory profile. The function of two other IκB proteins, IκBβ and IκBε, were examined in cells 
containing only these two inhibitors. In this case, NFκB activation displayed a slower response that 
did not display any subsequent repression 172. Combining the observed profiles of all three IκB 
proteins generates a regulatory mechanism whereby the slower response of IκBβ and IκBε act to 
dampen the long-term oscillations of IκBα 172. The result is that short-term stimulation of the 
pathway induces a robust response, reliant on IκBα degradation, and prolonged stimulation 
generates a response proportional to the duration of the stimulation controlled by IκBβ and IκBε 172. 
 
IκBα, IκBβ and IκBε act in the cytoplasm of the cell by masking the NLS of NFκB proteins. However, 
the other IκB family members are located within the nucleus and interact with NFκB at this location 
to regulate transcription 160. For example, Bcl-3 functions to elongate the inhibitory role of p50 
dimers within the nucleus by blocking proteasomal degradation and stabilising the p50 complex 171.  
 
Regulation is not just provided by the IκB proteins. Within the nucleus, post-translational 
modification of RelA, through phosphorylation of Ser-376, promotes interactions with the histone 
acetyltransferases cyclic-adenosine monophosphate (cAMP)-response element-binding (CREB)-
binding protein (CBP) and p300 and aids in the displacement of histone deacetylase (HDAC) proteins, 
thereby promoting binding of RelA 178. Studies have observed that this mechanism is only important 
to a subset of NFκB-regulated genes such as those that are rapidly induced by TNF-stimulation, such 
as IL-8 179. Phosphorylation is not the only post-translational modification and acetylation of RelA has 
also been seen to provide enhancement of transcriptional activation 180.  
 
1.3.5 TLRs – Cooperation, integration and priming 
It is true that one source of specificity programmed into the innate TLR signalling response is 
generated by the range of TLRs that are expressed by cells with each one responding to a certain set 
of ligands. However, the individual pathways induced by TLR activation do not solely act in isolation. 
The range of potential responses is expanded further by the cooperation and integration of multiple 
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signalling pathways. This is possible when more than one TLR is activated by an invading pathogen, 
resulting in the initiation of at least two signalling cascades which are able to interact and produce a 
refined response.  
 
Signalling cascade cross-talk may produce a synergistic or enhanced response when compared to a 
single cascade acting in isolation. This has been observed in murine dendritic cells simultaneously 
stimulated with both a TLR4 and a TLR2 ligand 40.  Stimulation with the TLR4 ligand, LPS, or the TLR2 
ligand, Pam3CSK4, induced either low or no production of IL-10. However, when both ligands were 
used a synergistic production of the anti-inflammatory cytokine IL-10 was observed, although no 
synergy was seen in the secretion of the pro-inflammatory cytokines IL-12p40 and TNF 40. This study 
demonstrates the precise and selective nature of signalling synergy, being able to enhance one 
response whilst not affecting another. In this case, the synergistic interaction was traced to the 
MAPK pathways involving p38 and JNK that displayed a synergistic enhancement of activation upon 
simultaneous ligand stimulation. Similar cooperation has also been observed between TLR2 and 
TLR3 in dendritic cells demonstrating that signalling crosstalk can occur, not only within one type of 
major pathway but, between the MyD88-dependent and TRIF-dependent pathways 181. Interestingly, 
the cooperation between TLR2 and TLR3 consists of both synergy and cross-inhibition in that the 
production of TNF, IL-6 and IL-12p40 is enhanced but the secretion of MIG, IP-10 and IL-12p35 is 
reduced when both receptors are stimulated simultaneously 181. The function of crosstalk between 
the two major pathways may be to generate a greater response than that which can be generated 
by activation of either pathway alone whilst still retaining a level of control and integration. 
 
However, it is not just simultaneous stimulation that gives rise to synergistic or cross-inhibited 
signalling. The prior stimulation of cells with a certain ligand has been shown to result in enhanced 
or reduced responses to subsequent stimulation by the same or a different ligand. The enhancement 
of a response is known as priming and the reduction of a response is known as tolerance or cross-
tolerance, depending on whether it is due to subsequent stimulation by the same or a different 
ligand, respectively 182-184.  
 
One signalling pathway that has been the focus of much research into priming and cross-tolerance is 
the TLR9-induced pathway. In 2000, TLR9 was identified as the TLR responsible for the detection of 
bacterial DNA through unmethylated CpG motifs 67. The fact that this is such a ubiquitous ligand, 
present in bacteria and viruses, could explain why so many studies have investigated the potential 
for TLR9 to integrate with other TLR signalling pathways. One study of the effect of TLR2, TLR4 or 
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TLR9 stimulation on tolerance and cross-tolerance observed that repeated stimulation with the 
same ligand induced tolerance 184. In contrast, and unlike TLR2-directed priming that induced cross-
tolerance to subsequent TLR4 stimulation, priming of macrophages through TLR9 actually enhanced 
TNF production upon subsequent LPS stimulation 184. Of note is the fact that priming appears to be 
time dependent as 1 – 3 h pre-treatment with CpG enhanced TNF production, in response to LPS 
stimulation, whilst suppression of TNF production was seen after 6 – 9 h pre-treatment 185. An 
enhanced response was also observed in dendritic cells which secreted 5 times more IL-12p40 and 
IL-12p70 when pre-treated (primed) with CpG prior to LPS stimulation 186. This response is time-
dependent with an optimal delay after CpG priming of 4-6 h, which may be explained by the time 
taken for CpG to be taken up by the cells and to come into contact with the intracellularly expressed 
TLR9 186. Similarly to simultaneous TLR2 and TLR4 stimulation, CpG priming does not result in the up-
regulation of the whole innate immune response but just a portion, as demonstrated by another 
study that showed a suppression of IL-6 in response to LPS stimulation after CpG pre-treatment 187. 
Therefore, CpG priming appears to enhance IL-12 and TNF production while decreasing the level of 
IL-6 in response to LPS stimulation. However, it should be noted that the type of integration and 
cross-talk between TLR signalling pathways may be highly cell-type and situation dependent. For 
example, in RAW264.7 macrophages stimulation with LPS induced tolerance towards a subsequent 
LPS stimulation 184. However, in alveolar macrophages tolerance is not observed and, in fact, the 
opposite occurs. Stimulation of alveolar macrophages with LPS resulted in enhanced secretion of IL-6 
upon subsequent stimulation with LPS with an associated reduction in the secretion of cytokines 182. 
 
More recently, the inverse relationship between TLR4 and TLR9 has been studied where TLR4 is the 
priming event and TLR9 is the subsequent stimulation 188. Following LPS stimulation, TLR9 gene 
expression is up-regulated and reached a peak level of expression 3 h after stimulation 188. This was 
thought to be due to the ERK, p38 and NFκB signalling pathways 188. This could provide an 
explanation for the observation that rather than inducing tolerance, LPS pre-treatment primes TNF 
and IL-6 production by murine bone marrow-derived macrophages (BMDMs) to the TLR9 agonist, 
CpG 189. Similarly to that seen in the previous study, where TLR9 gene expression was up-regulated, 
an enhanced ERK and p38 activation correlated with the priming effect of LPS prior to CpG 
stimulation 189. A further refinement of the increased TLR9 expression mechanism proposed 
previously is suggested to involve the macrophage growth factor M-CSF (macrophage colony-
stimulating factor). When M-CSF binds to its cell surface receptor c-Fms, one of the results is the 
down regulation of TLR9 expression 190,191. It has previously been reported that LPS is able to reduce 
the surface expression of c-Fms at very low concentrations 192. It is possible then that LPS priming of 
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macrophages induces a down-regulation of c-Fms resulting in the removal of the suppression of 
TLR9 gene expression. This, in turn, leads to an increased expression of TLR9 and an enhanced 
response to subsequent CpG stimulation 189. In contrast, a previous study demonstrated a 
suppression of CpG-induced TNF production after LPS pre-treatment 184,187. However, a 24 h delay 
between LPS pre-treatment and CpG stimulation was used in the study displaying tolerance 
compared to a 2 h gap in the study showing priming. This is likely to be the reason for the 
contrasting reports of these two studies and clearly shows the sensitivity and critically time-
dependent nature of TLR signalling and integration. 
 
Further evidence for TLR4 and TLR9 cooperation was provided by a study investigating the 
interaction between these two receptors in a murine model of Gram-negative bacterial pneumonia 
caused by Klebsiella pneumoniae 193. In wild-type mice, bacterial infection resulted in the rapid 
increase in the expression of several cytokines including IL-12, TNF, IL-17 and interferon-γ (IFNγ). In 
mice lacking either TLR4 or TLR9 the secretion of IL-17 was moderately reduced but in double TLR 
mutants IL-17 secretion was almost completely abolished 193. In addition, TLR4 contributed 
significantly to the early production of IL-12 and TNF whilst later expression was more reliant on 
TLR9. It appears then that TLR4 and TLR9 have distinct time-dependent functions but also interactive 
and cooperative roles in the production of a response 193. 
 
1.3.6 Role of TLRs in innate immunity 
1.3.6.1 Chemokines 
One process that is key to combating infection is the recruitment of immune cells to the site of 
infection. The recruitment process can be split broadly into two categories. Homeostatic migration 
involves the passive movement of cells and does not require the secretion of chemotactic molecules 
194. In contrast, inducible migration requires the secretion of chemokines to attract circulating 
immune cells specifically to the site of infection 194. TLRs play an important role in the preliminary 
secretion of chemokines such as IL-8, monocyte chemotactic protein (MCP)-1, macrophage 
inflammatory protein (MIP)-1a and RANTES, thereby attracting the immune cells by inducible 
migration 195,196. However, TLR signalling is also heavily involved in the up-regulation of certain cell 
surface receptors called selectins on endothelial cells. These receptors bind to carbohydrate ligands 
on leukocytes enabling movement of these cells along the endothelial surface 197. The increase of 
receptor expression is likely to enhance the capture of immune cells moving round the system via 
homeostatic migration. In addition, the recruited leukocytes near the site of infection encounter 
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TLR-induced chemokines bound to the vascular endothelium and become activated allowing 
adhesion and translocation across the lumen wall into infected tissues 197,198. 
 
1.3.6.2 Cytokines 
Despite many of the TLRs sharing common signalling pathways they are able to induce the secretion 
of specific sets of cytokines in response to different TLR agonists. Added flexibility of the response is 
observed as the same agonists can induce differing cytokine secretion profiles depending on the 
type of cell stimulated or when signalling pathway cooperation occurs 40,130,199,200. One set of 
cytokines known as type I interferons are mainly produced after activation of TLRs which can use 
TRIF as a downstream adaptor, specifically TLR3 and TLR4, as they both have the potential of 
inducing the range of IRF transcription factors 80,98,201. Type I IFNs are implicated in the control of 
viral infections although they also have the ability to induce the production of a variety of proteins 
through binding to their own receptors 137,202,203. If type I IFNs are the characteristic cytokines 
produced in response to viral infection, IL-6 and TNF are the characteristic anti-bacterial cytokines 
implicated in the control of many bacterial pathogens, such as Legionella pneumophila and 
Mycobacterium tuberculosis 204,205. IL-6 performs many and diverse roles acting as both a pro-
inflammatory and anti-inflammatory cytokine depending upon cell-type and location 206-209. TNF, on 
the other hand, is a major pro-inflammatory agent and is an essential component of the arsenal used 
against bacterial pathogens. The secretion and full effects of TNF are tightly controlled by the innate 
immune system as, due to its highly pro-inflammatory characteristics, it has the capacity to 
negatively affect the host. In fact the dysregulation of TNF secretion is associated with several 
autoimmune diseases, rheumatoid arthritis and septic shock 210,211.  
 
1.3.6.3 Induction of adaptive immunity 
As mentioned previously, the innate immune system is responsible for the induction of the adaptive 
immune response and TLR signalling is part of this process. The adaptive response not only requires 
the presentation of antigen bound to major histocompatibility complexes (MHCs) on the surface of 
APCs but also the associated signals generated by these cells via the TLR detection system 1. A large 
proportion of APCs are formed of DCs that require a maturation stage before they are able to 
effectively activate naïve T cells. DCs deficient in MyD88 demonstrate severe defects in the up-
regulation of several cell surface markers such as MHC class II in response to mycobacteria, 
indicating a lack of maturation 1. In MyD88-deficient mice a similar defect in the induction of the 
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adaptive immune response was observed, characterised by a lack of TH1 responses although TH2 
responses were induced indicating an alternative priming mechanism for these effects 1. 
 
1.4 Francisella tularensis 
1.4.1 Strains and symptoms 
Francisella tularensis is a non-motile, gram-negative, facultative intracellular bacterium 212. The 
bacterium was initially isolated from ground squirrels in Tulare County, California, just over 100 
years ago and was originally classified as Bacterium tularense by George Walter McCoy and reported 
as a plague-like disease of rodents in 1912 213. Since then the classification of this bacterium was 
refined and it was renamed to Francisella tularensis.  
 
F. tularensis causes a spectrum of diseases, depending on the route of infection, collectively termed 
tularaemia. Tularaemia is a zoonotic disease as it survives in the environment, primarily in mammals 
such as rabbits and rodents as well as in arthropods such as ticks and flies 214,215. The usual infection 
route for humans is through an arthropod vector although F. tularensis can infect humans via a 
number of routes including inhalation of aerosolised bacteria, ingestion of contaminated food or 
water or through cuts and abrasions in skin coming into contact with contaminated animal hides 214-
216. The route of entry is important in determining the clinical presentation of the infection. 
Ulceroglandular tularaemia is characterised by an ulcer at the site of infection and swelling of the 
regional lymph node 217,218. Oropharyngeal tularaemia occurs within the mouth and lymph nodes in 
the neck display severe swelling 219-221. The inhalation of aerosolised bacteria causes pneumonic 
tularaemia which has the highest mortality rate of 30%, although this can be reduced to 2% with 
rapid administration of antibiotics 217,222,223. Independent of the route of entry, F. tularensis 
proliferates within the host and migrates from the primary site of infection to the liver and spleen, 
the major secondary sites of infection 224,225. Simultaneously with colonisation of secondary sites, the 
disease develops into typhoidal tularaemia leading to septicaemia 226,227. Symptoms of tularaemia 
include headache, fever, chills, nausea, diarrhoea, and myalgia 226,227. The ability of F. tularensis to 
rapidly and successfully colonise the host is demonstrated by the fact that the infectious dose of F. 
tularensis can be as low as 10 organisms via the inhalational route 215. 
 
There are now four subspecies of F. tularensis classified which share about 97% genome identity 
228,229. These are subspecies tularensis, holarctica, mediasiatica, and novicida. Of these four, only F. 
tularensis subsp. holarctica and F. tularensis subsp. tularensis are thought capable of causing disease 
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in humans. F. tularensis subsp. tularensis, also known as type A, is found mainly in North America 
and is the most virulent subspecies, causing the most severe forms of tularaemia. F. tularensis subsp. 
holarctica, also known as type B, is found throughout the northern hemisphere in North America, 
parts of Europe and Asia and causes a more mild form of tularaemia 230. More recently, it has been 
suggested that type A F. tularensis could be further subdivided into A1a, A1b and A2 categories 
based on differences in observed virulence 231. Type A1 infections are characterised by a high 
mortality rate whereas type A2 strains rarely lead to a fatal outcome 232,233. 
1.4.2 Bioterrorism agent 
F. tularensis is able to cause high morbidity and mortality, to infect humans via multiple routes, and 
has a very low infectious dose. These characteristics made F. tularensis a prime candidate for use as 
a biological warfare agent and in the 1950s both the USA and the USSR succeeded in weaponising F. 
tularensis 215,234. As such, the United States Centres for Disease Control have classified F. tularensis as 
a category A select agent, the same category as pathogens such as Bacillus anthracis (anthrax) and 
Yersinia pestis (plague) (http://emergency.cdc.gov/agent/agentlist.asp). This classification for 
potential use as a bioterrorism agent and the current worldwide interest in biodefence has led to a 
massive upsurge of research with this bacterium. Despite the development of F. tularensis for use as 
a biological warfare agent in the 1950s, there is no currently licensed vaccine against this pathogen. 
Previously, an attenuated F. tularensis subsp. holarctica strain, denoted the live vaccine strain (LVS), 
has been used as a vaccine. This was generated in the USSR by serial passage through mice 215,235. 
However, the causes of attenuation in this strain are not well defined as it appears to involve 
massive genomic rearrangement as opposed to specific mutations 236. As such, this strain is not 
licensed for use as a vaccine in the US or the UK and the development of a well-defined attenuated 
mutant strain or other vaccine is of interest. Despite being unsuitable for license as a vaccine, the 
use of F. tularensis LVS in a murine model of infection is a useful tool with which to study human 
infection as F. tularensis LVS retains virulence in mice when given intraperitoneally or intranasally 
and the course of infection shows similarities to that observed in humans 237. Current therapies for 
human tularaemia involve a rigorous course of antibiotics. Antibiotics used to treat tularaemia 
include streptomycin, gentamicin, doxycycline, and ciprofloxacin 
(http://www.cdc.gov/tularemia/diagnosistreatment/). However, due to the potential development 
and dissemination of antibiotic-resistant strains, and an associated mortality rate of 30% in patients 
with severe tularaemia without rapid treatment with antibiotics, further research into novel 
therapeutics is required 222. 
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Due to the severity of disease, particularly associated with inhalational tularaemia, and the lack of a 
licensed vaccine, laboratory research using the majority of F. tularensis strains, such as the highly 
virulent SchuS4 strain, is carried out under Advisory Committee on Dangerous Pathogens (ACDP) 
category III containment (http://www.hse.gov.uk/pubns/misc208.pdf). 
 
1.4.3 Infection cycle 
F. tularensis is a facultative intracellular pathogen and, as such, much of its life cycle occurs within 
host cells. This requires the bacterium to enter host cells, evade host-derived pathogen-killing 
mechanisms, replicate within the cells and then escape from the host cell in order to proliferate 
around the body 238. The processes and mechanisms by which F. tularensis accomplishes these 
different stages are discussed in the following sections and a diagram outlining the life cycle of F. 
tularensis is shown in Figure 1-4. 
 
1.4.3.1 Host cell entry 
Francisella tularensis is capable of invading numerous cell types including epithelial cells, alveolar 
macrophages, dendritic cells, and neutrophils 212,239-242. To gain entry to these cells F. tularensis has 
to cross the cell membrane without initiating an immune response or killing the cell.  
 
Two mechanisms of internalisation have been characterised in other intracellular pathogens. 
Neisseria meningitidis and Pseudomonas aeruginosa are internalised by conventional phagocytosis, a 
process where the bacterium is observed to sink into the macrophage surrounded by multiple 
pseudopodia 243. In contrast, Legionella pneumophila and Serpulina perlisicoli are internalised by 
coiling phagocytosis involving a single pseudopod which tightly coils around the bacterium 243,244. 
However, F. tularensis has been observed entering macrophages by a novel process involving 
engulfment of bacteria within asymmetric, spacious pseudopod loops 241. The pseudopod loops were 
apparent on the surface of macrophage-like THP-1 cells within 5 min of incubation with either 
virulent F. tularensis or avirulent LVS 241.  
 
The process of phagocytosis, either conventional or coiling, involves complement and complement 
receptors in studies using other intracellular pathogens such as Mycobacterium tuberculosis 245. 
Complement was therefore examined as an initiation mechanism for F. tularensis internalisation. It 
was observed that the uptake of LVS and a virulent strain increased as the percentage of serum in 
the incubation medium increased. In addition, incubation of LVS with HeLa cells demonstrated a very  
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Figure 1-4: The life-cycle of Francisella tularensis within the host cell 
F. tularensis enters the host cell through phagocytosis using a novel pseudopod looping mechanism. Upon 
phagocytosis, F. tularensis resides within a phagosome that acquires both early (EE) and late (LE) endosomal 
markers but does not fuse with lysosomes (Lys). F. tularensis rapidly escapes the phagosome through an 
unknown mechanism and replicates within the cytosol. After sufficient replication, F. tularensis causes host cell 
death by apoptosis releasing the bacteria to proliferate to neighbouring cells. In murine cells, an alternative 
pathway has been observed involving reintegration of bacteria into the endosomal pathway by the formation 
of a Francisella-containing vacuole (FCV). Whether this alternative route is host-induced or pathogen-induced 
is yet to be determined. Figure reproduced from “The Francisella intracellular life cycle: toward molecular 
mechanisms of intracellular survival and proliferation”, 2010, A. Chong and J. Celli 
238
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low level of uptake 241. HeLa cells, unlike professional phagocytes, do not express mannose, Fc or 
complement receptors 241. It was hypothesised that the lack of these receptors explained the poor 
internalisation. This hypothesis was confirmed by other studies which observed a role for both 
complement receptor 3 (CR 3) and Fcγ receptors in macrophage uptake of F. novicida 240. The use of 
complement receptors to initiate phagocytosis can be termed a stealthy method of entry into cells 
as internalisation in this way avoids triggering an oxidative burst which can be initiated through 
other entry routes and is detrimental to bacterial growth 241,246-248. Despite evidence suggesting that 
complement and complement receptors are important in the uptake of F. tularensis, the target of 
complement fixation is currently unknown. However, the fact that formalin-killed, heat-treated or 
protease-treated preparations of F. tularensis are taken up by macrophages suggests that the target 
for complement binding is a very stable molecule, possibly LPS 241. 
1.4.3.2 Escape from phagosomes 
Once internalised by a host cell, intracellular pathogens must evade host cell defence mechanisms, 
the majority of which are focussed at the phagosomal stage. Three pathways are recognised that 
enable the pathogen to do this. The extraphagosomal pathway is characterised by rapid degradation 
of the phagosome membrane releasing the pathogen into the cytoplasm, as occurs in infection with 
Listeria monocytogenes and Shigella flexneri 249. The phagolysosomal pathway requires the pathogen 
to be resistant to acidic environments as it remains within phagosomes which have fused to 
lysosomes, as occurs in infection with Coxiella burnetii 250,251. Finally, the phagosomal pathway 
involves the pathogen remaining within a phagosome that does not fuse with lysosomes, as occurs 
with Legionella pneumophila 249,251. Of these, F. tularensis follows the extraphagosomal pathway. The 
phagosomes containing F. tularensis firstly acquire the early endosome marker, effector early 
endosomal antigen 1 (EEA1), followed by late endosomal markers such as lysosomal-associated 
membrane protein 1/2 (Lamp-1/2), Cd63 and Rab7, indicating maturation of the phagosomes along 
the endocytic pathway 252-254. Although lysosome fusion does not occur, the phagosomes become 
acidified by acquiring the vacuolar ATPase. Acidification has been shown to be important for 
bacterial escape as inhibition of the ATPase results in a delay of bacterial escape from the 
phagosome 255,256. 
 
F. tularensis replicates within the cytoplasm of host cells and, as such, must leave the phagosome 
compartment. Using transmission electron microscopy, Golovliov et al. visualised LVS free in the 
cytoplasm 2 h after infection of three separate cell lines, including both human and mouse 
macrophages 257. Several other studies have also observed a similar rapid escape for LVS and a 
virulent, clinical isolate of F. tularensis 252,258. As prevention of replication represents a possible 
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therapeutic strategy, significant research has been focussed on the process of, and genes required 
for, phagosomal escape. Despite this, little is known about the exact mechanism apart from the fact 
that soon after internalisation the phagosomal membrane becomes disrupted and degraded, 
allowing F. tularensis access to the cytoplasm. 
 
Other intracellular bacteria, such as L. monocytogenes, that have to escape the phagosome before 
replicating have been shown to utilise pore-forming lysteriolysin and phospholipases, for example 
259. However, F. tularensis does not seem to use either of these mechanisms. Although the process of 
phagosomal escape of F. tularensis is not fully characterised, experiments using mutant forms of LVS 
have shed a little light on the genes that are important. The genome of F. tularensis contains a 
region known as the Francisella pathogenicity island (FPI) which includes four genes collectively 
known as the intracellular growth locus operon. The transcription of these genes is regulated by the 
global regulator MglA and one gene in particular, iglC, is up-regulated during intracellular growth 260. 
Infection of peritoneal exudate cells (PECs) with an LVS iglC mutant (ΔiglC) demonstrated the 
importance of this gene in phagosomal escape. It was observed that < 1% of the mutant bacteria 
were able to escape compared to 97% of wild-type bacteria 258. The reduction in the ability to escape 
is also seen in the J774A.1 cell line when infected with ΔiglC 254. The importance of the FPI in 
phagosome escape may lie in the suggestion that it encodes a type VI-like secretion system 261. The 
role of a type VI secretion system is to insert bacterial effector proteins directly into the surrounding 
environment, in this case, the phagosome. These bacterial proteins may be cytolysins, pore-forming 
toxins or hydrolytic enzymes, all of which are used by other intracellular pathogens. However, none 
of the genes identified within the FPI of F. tularensis display any of the characteristics of proteins 
used by other pathogens indicating that the process used by F. tularensis to enable phagosome 
escape is a previously uncharacterised one. Alternatively, the effector proteins secreted through the 
type VI-like system are encoded elsewhere in the genome and have yet to be located and 
characterised. 
 
The primary host defence mechanisms are located within the phagosome and so, upon its escape, F. 
tularensis succeeds in separating itself from the majority of the host defences. Within the relative 
safety of the cytosol, F. tularensis rapidly replicates until it induces apoptosis and proliferates 
throughout the host. Interestingly, although immune defence mechanisms are in short supply in the 
cytosol, F. tularensis is not free from detection and the subsequent activation of the host cell 
defences. 
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Further evidence demonstrating an active role for F. tularensis survival within the cytosol is provided 
by the fact that, to date, at least 268 genes have been identified that are important for intracellular 
replication 262. The surprisingly high number of genes that are required for intracellular replication 
indicates that replication within the cytosol may not be straightforward 262. 
 
1.4.3.3 Autophagy  
 
Autophagy is a process whereby cells can deliver cytoplasmic substrates for lysosomal degradation 
and can occur via three pathways known as chaperone-mediated, micro- and macro-autophagy 263-
265. Macro-autophagy is particularly important in relation to clearance of intracellular pathogens as it 
is the only mechanism by which cells can dispose of cytoplasmic substrates too large for destruction 
through proteasomal degradation 263. One major difference of macro-autophagy from chaperone- or 
micro-autophagy is the requirement to engulf the target in a double-membrane vesicle called an 
autophagosome prior to fusion with lysosomes. Engulfment of a target substrate involves the 
formation of an isolation membrane formed at membrane sites marked with phosphatidylinositol-3-
phosphate (PI3P) and the sequential activation of two ubiquitin-like systems 263,266,267. The 
subsequent targeting of autophagosomes by lysosomes is facilitated by Ras-related in brain-7 (Rab-
7) and Beclin-1 268,269. In the context of intracellular bacterial infections, macro-autophagy does not 
only lead to the lysosomal-degradation of the pathogen but also limits its proliferation and can 
reduce the possibility of pathogen-induced manipulation of cellular processes and signalling events 
263. 
 
The role of autophagy in several bacterial infections has been examined. Restriction of cytoplasmic 
colonisation has been observed in Salmonella enterica and Streptococcus pyogenes infection 270,271. 
However, bacteria have also developed mechanisms of autophagosome evasion. Recently, the 
mechanism of autophagy-activation in response to L. monocytogenes has been elucidated and was 
demonstrated to involve the activation of TLR2 and RIP2 signalling pathways and particularly ERK 
activation 272. Despite activation of autophagic pathways L. monocytogenes evades efficient macro-
autophagy by coating itself with the host protein actin nucleator A (ActA) 272. This “disguise” 
prevents ubiquitin binding to its outer surface which would usually target the bacteria for 
engulfment into an autophagosome. In contrast to evading autophagy, some bacterial species, such 
as S. aureus, use autophagy to assist their survival using the autophagosome as a replicative niche 
or, as is the case for Brucella abortus, use autophagosomes as a means of transport from cell to cell 
273-275. 
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Although F. tularensis rapidly extracts itself from the phagosome in order to replicate in the 
cytoplasm, it is becoming apparent that at later time points during infection F. tularensis is able to 
re-enter into the endocytic pathway causing the formation of a Francisella containing vacuole (FCV) 
(Figure 1-4). FCV formation was first observed by Checroun et al in 2006 as clusters of bacteria, 24 h 
post-infection, were unable to be bound by stains delivered into the cytoplasm 276. This was the case 
for both LVS and SchuS4 strains and the vacuoles were identified to be of autophagic origin due to 
monodansylcadaverine (MDC) staining 276. Unlike other bacteria that are targeted by autophagy, a 
significant delay of up to 16 h was observed before F. tularensis was seen within FCVs 270,276,277. This 
result indicates that F. tularensis may be preventing progression of the autophagic process until 
sufficient replication has taken place. Recent, re-examination of a microarray analysis of host cell 
signalling pathways affected by F. tularensis infection provided some clues for the delay in 
autophagy 278. Beclin-1, involved in the formation of an isolation membrane, and several ATG genes 
that are required for elongation of autophagosomes were down-regulated as a result of F. tularensis 
infection of human peripheral blood monocytes 278. Autophagosomes usually express high levels of 
MHC class II which could be detrimental to the progression of infection 279. However, microarray 
analysis also showed down-regulation of several MHC class II-related genes indicating that F. 
tularensis may also be modulating the efficient presentation of antigen 278. The function of re-entry 
into the endocytic pathway has not yet been elucidated. It could be that the acidic environment of 
the autophagosome provides a cue to induce genes involved with escape from the cell or re-
infection of neighbouring cells. Alternatively, as is the case for B. abortus, autophagosomes may 
enable the spread of F. tularensis from cell to cell 275. 
 
An important point to note is that, in contrast to previous studies, a recent paper failed to observe 
the re-entry of F. tularensis into the endocytic pathway at late stages of infection in human cells 
(HEK-293T) 280. This indicates that the down-regulation of Beclin-1 and ATG proteins observed by 
microarray in human monocytes may not only delay autophagy but could actually prevent its 
occurrence entirely. Furthermore, studies using F. tularensis SchuS4 observed that only replication-
deficient mutants were observed within autophagosomes in human macrophages 281. These 
contrasting reports between murine and human cells clearly demonstrate the care that must be 
taken when comparing data derived from different species. 
1.4.3.4 Regulation of apoptosis 
Cell death can occur via several routes including pyroptosis, necrosis and apoptosis. Each of these 
routes activates the surrounding cells in a different way. Pyroptosis and necrosis initiate a significant 
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inflammatory response due to total cell lysis, resulting in an uncontrolled release of inflammatory 
activators. Apoptosis, or programmed cell death, is a controlled event where the cell fragments into 
smaller bodies that contain inflammatory mediators thereby preventing the activation of 
inflammatory pathways. It is not surprising then that a number of intracellular pathogens including 
F. tularensis cause cell lysis via the apoptosis route. Hrstka et. al. found that LVS induced apoptosis 
of J774.2 cells by 12 h post-infection 282.  
 
Apoptosis is a well-characterised mechanism of cell death and is known to be initiated via two 
pathways. The extrinsic pathway involves receptor activation whereas the intrinsic pathway is 
mitochondria-mediated 283-286. Despite different origins, both pathways follow a similar, sequential 
cascade pattern in which an initiator pro-caspase is cleaved, leading to the cleaving of an 
executioner caspase 285. Apoptosis initiated by F. tularensis acts through the intrinsic, mitochondria-
mediated route 284,287,288. It is known that cytochrome-c release from mitochondria is an early step in 
the intrinsic pathway and western blots indicated a four-fold increase in cytochrome-c levels in the 
cytosol of LVS-infected macrophages 284. In addition, western blots showed the cleaved product of 
the initiator caspase, pro-caspase-9 and the executioner caspase, pro-capsase-3 from 12 h after 
infection 284. 
 
A recent study examining the p38, ERK and JNK pathways revealed another possible mechanism that 
could contribute to apoptosis 282. Hrstka et. al. found that interrupting the ERK pathway inhibited 
macrophage apoptosis 282. In contrast, inhibition of p38 activity induced apoptosis in uninfected cells 
and a reduced p38 activity was seen in LVS-infected cells 282. The conclusion drawn was that LVS-
induced apoptosis of macrophages requires activation of the ERK pathway and reduced activation of 
the p38 pathway 282. Another MAPK that has been linked to the induction of apoptosis is JNK. 
Similarly to ERK, it is the sustained activation of JNK that induces apoptosis. In contrast, the transient 
activation of JNK is thought to be linked to cell survival strategies 152. These studies together indicate 
that there are at least three routes to apoptosis as sustained activation of both the ERK and JNK 
pathways and reduction of p38 activation all lead to cell death via the apoptotic pathway. 
 
Studies using LVS deficient in iglC demonstrated a possible role for this gene in the induction of 
apoptosis. Lactate dehydrogenase (LDH) release from cells is a good indicator of cell apoptosis and 
iglC mutants caused the same amount of LDH to be released as uninfected J774A.1 cells indicating 
that the mutants could not induce apoptosis 260. This could indicate that iglC has a direct role in 
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inducing apoptosis or that an indirect role exists, for example that the escape from the phagosome is 
an action required for activation of the apoptosome. 
 
Apoptosis does not occur alone in an F. tularensis infection and cell death through pyroptosis has 
also been observed. Unlike apoptosis, pyroptosis is a pro-inflammatory method of cell death. 
Pyroptosis is a caspase-3-independent process requiring instead the activation of the caspase-1 
inflammasome 289. This results in the release of pro-inflammatory cytokines concurrent with the loss 
of plasma membrane integrity and release of highly inflammatory cytoplasmic factors 290,291. It 
appears then that pro-inflammatory and non-inflammatory mechanisms of cell death are induced in 
the course of a F. tularensis infection 284,292. 
 
Irrespective of the mechanism by which apoptosis is brought about, this process completes the 
intracellular phase of F. tularensis and allows the bacteria to escape host cells with minimal 
activation of the inflammatory response. 
1.4.4 F. tularensis and TLRs 
Many studies have examined the response of the host innate immune response to infection by F. 
tularensis species. However, many gaps in knowledge remain. The primary detection of F. tularensis 
was originally thought to be mediated by TLR4, although more recent studies show that it is likely 
that TLR2 not TLR4 confers the ability to detect F. tularensis 41,293,294. TLR4 was ruled out as a major 
receptor in the detection of F. tularensis as TLR4-defective mice were no more susceptible to an 
inhalational infection with F. tularensis than wild-type mice and the survival rates were also similar 
in both mouse strains 295. In contrast, several reports have shown a requirement for TLR2 in the 
detection of F. tularensis following infection by multiple routes and cell types 41,199,296-300. 
Furthermore, a TLR2 deficiency enhanced murine susceptibility to pulmonary infection by F. 
tularensis LVS and resulted in decreased production of proinflammatory cytokines including TNF and 
IL-6 41. In addition, TLR2 controls the hepatic lymphocyte IFN-γ response to F. tularensis by regulating 
dendritic cell IL-12 production and is involved in the mediation of the murine macrophage response 
to LVS as shown by co-localisation of TLR2 with the adaptor MyD88 and increased levels of cytokines 
and chemokines 297,298. Recently, more evidence was provided to support the role of TLR2 in F. 
tularensis detection. Two F. tularensis lipoproteins, termed TUL4 (or LpnA) and FTT1103, were found 
to be responsible for the stimulation of the TLR2/TLR1 heterodimer 300. The same study also 
indicated that F. tularensis might have proteins that could activate the TLR2/TLR6 heterodimer.  
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Further evidence against the detection of F. tularensis through TLR4 is that the ligand usually 
recognised by TLR4 is LPS 79. LPS from bacteria is typically highly stimulatory for TLR4 and atypical 
LPS generally signals through TLR2 74,75. However, LPS from F. tularensis does not seem to activate 
either TLR4 or TLR2 as suggested by the fact that F. novicida LPS did not activate signalling pathways 
in a human embryonic kidney cell line (HEK293) expressing either human or murine TLR4 or TLR2 301. 
Additional controversy surrounding the role of TLR4 and F. tularensis LPS is shown by contrasting 
reports of the susceptibility of C3H/HeJ mice which lack TLR4 and are therefore deemed 
unresponsive to LPS. Depending on route and challenge dose, different groups have observed 
increased susceptibility to subcutaneous and intravenous challenge when compared to wild-type 
mice 293,302. Conversely, decreased susceptibility of C3H/HeJ mice has been demonstrated through 
the intraperitoneal and aerosol route 294,303. More recent work has observed that the apparent un-
stimulatory character of F. tularensis LPS can be reversed in the presence of alternative pro-
inflammatory factors associated with F. tularensis 304. In combination with F. tularensis-LPS, the heat 
shock protein GroEL was used to activate human monocyte-derived macrophages resulting in a 
synergistic enhancement of IL-8 secretion 304. This suggests that the low activity of F. tularensis LPS 
may be enhanced during infection through the action of other pathogen-associated factors 304. 
Furthermore, treatment of mice with F. tularensis LPS induces an antibody response that protects 
wild-type mice against a lethal challenge with F. tularensis LVS 305. This is not due to signalling of LPS 
through TLR2 as TLR2-deficient mice still generate the antibody response but, interestingly, are no 
longer protected 305. Full protection against LVS challenge was shown to require both the LPS-
induced antibody response and macrophage activation through TLR signalling, either through TLR2 in 
wild-type mice or through activation of alternative TLRs in TLR2-deficient mice 305. It would seem 
that, despite the apparent low potency of F. tularensis LPS and the controversy surrounding its 
potential to signal through the TLR system, there is a definite role for LPS in the generation of an 
immune response to F. tularensis infection.  
 
Recently, significant progress has been made in characterising the immune response to infection 
with F. tularensis. Experiments monitoring the total immune response in terms of cytokine 
production have demonstrated that certain cytokines, such as IL-1β and TNF-α, are produced at 
similar levels in response to F. tularensis infection via all routes whereas specific cytokines (e.g. IL-6) 
are up-regulated only in response to certain routes of infection 306. A study comparing respiratory 
and intradermal routes of infection with F. tularensis strain SchuS4 in mice showed that the pro-
inflammatory cytokines IFN-γ, TNF-α, IL-6, IL-1β and IL-12p70 and the chemokines KC and MCP-1 
were up-regulated in both cases 306. However, mRNA levels of IFN-γ were higher in respiratory 
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infection whereas mRNA levels of IL-6, KC and MCP-1 secretion were higher in intradermal infection 
306. Other experiments confirmed the up-regulation of TNF-α and IFN-γ production and also 
demonstrated that IL-10 mRNA was greatly enhanced in the lungs after intra-peritoneal and intra-
dermal infection with LVS 299. Up-regulation of IL-10 in the lungs only was also seen in infections 
involving F. tularensis SchuS4 306. 
 
Macrophages are the primary replication site for F. tularensis 230,307,308. The bacteria are internalised 
by macrophages in a phagosome from which they rapidly escape and replicate within the cytoplasm 
199,241,309. Macrophages are perfectly suited to detecting and responding to infection as they are 
equipped with both membrane-bound and intracellular TLRs 36,73. The response of macrophages to F. 
tularensis requires coordination of multiple signalling pathways. Although TLR2 is able to initiate 
transcription and secretion of a number of cytokines in response to the detection of an iglC mutant, 
including TNF-α and IL-12p35, an inconsistency was observed between IL-1β mRNA transcription and 
secretion of IL-1β 199. As the iglC mutant is unable to escape from the phagosome, these results 
suggest that phagosomal escape and initiation of a separate signalling pathway is required for 
secretion of active IL-1β 199. 
 
Another group of immune cells responsible for controlling infection are mast cells, which have been 
implicated as mediators of both innate and adaptive immunity. They are able to release immune 
modulators, such as cytokines, and also have the ability to phagocytose micro-organisms 310. In one 
study, after an intranasal challenge of mice with F. tularensis LVS, numbers of all immune cells were 
raised in lymph nodes but only the frequency of mast cells were increased in the lung 311. In addition 
mast cells demonstrated the ability to affect F. tularensis uptake and growth within macrophages 311. 
Furthermore, mast cell-deficient mice exhibited greater susceptibility to pulmonary infection (20% 
survival) when compared to wild-type mice (80% survival), providing supporting evidence for the 
important role of mast cells in host defence against F. tularensis 311. However, it is not just immune 
cells that are able to respond to F. tularensis invasion. Alveolar epithelial cells have been implicated 
in host defence against LVS and SchuS4 infection. Through NF-κB activation, alveolar epithelial cells 
have been shown to raise levels of IL-8 and MCP-1 present in the lungs 312. These products are 
potent chemoattractants for immune cells such as neutrophils so alveolar epithelial cells may play a 
key role in clearing the lungs of bacteria via neutrophil invasion. 
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1.4.5 F. tularensis-induced modulation 
The TLR signalling system is designed to detect and initiate a response to invading pathogens 
resulting in the generation of an appropriate defence strategy. However, as a first line of defence, 
the TLR system is also a perfect target for pathogens to inhibit or modify, thereby altering the 
response to a more favourable end result for the pathogen. Many studies have identified pathogens 
that use the TLR system to their own advantage either by altering the expression of certain factors 
on their cell surface, evading detection by TLRs, or by actually secreting proteins that are able to 
inhibit or modify host proteins within the signalling pathways themselves 313-315. Viruses are 
particularly efficient at altering TLR signalling pathways. For example, Vaccinia virus secretes two 
proteins called A52R and A46R that are able to inhibit TLR signalling 314,315. A52R binds to both TRAF6 
and IRAK-2, resulting in the prevention of NFκB activation and cytokine production 315,316.  A46R acts 
upstream of A52R and binds to all four major TLR adaptors as well as TLR4 to inhibit signalling 314. 
However, TLR inhibition is not restricted to viruses. Salmonella enterica secretes protein A, a TIR-like 
domain-containing protein, which is able to impair TLR and MyD88-associated activation of NFκB, 
improving the ability of this bacterium to replicate within host cells 313.  
 
Unlike the examples discussed above, F. tularensis is not known to secrete any proteins that are able 
to inhibit or modify TLR signalling pathways. However, at each stage of its life cycle, from initial 
binding and entry through to escape and proliferation throughout the host, F. tularensis is 
modulating host signalling pathways and processes to facilitate its survival. A list of currently 
reported mechanisms of immune modulation is shown in Table 1-2.  
 
F. tularensis has been described as a stealthy pathogen and this is certainly true of its method of 
entry into host cells whether immune or epithelial 317. As described in section 1.4.3.1, F. tularensis 
enters cells through a novel looping phagocytosis 241. Prior to this, the bacteria are exposed to one of 
the first antimicrobial mechanism deployed by the host in the form of complement. Complement 
consists of the formation of a protein called C3b that is able to enhance phagocytosis and also 
generates C5b, a component of the membrane attack complex (MAC) that functions to lyse bacteria 
318. However, F. tularensis is able to prevent lysis through this mechanism through binding to 
another complement protein, Factor H 319. Factor H cleaves the active C3b into the inactive iC3b 
which disables the formation of the MAC 320. Additionally, and key to the stealthy entry of F. 
tularensis into host cells, iC3b is a ligand for the complement receptor CR3 321. As discussed in 
section 1.4.3.1, phagocytosis induced through CR3 does not induce an oxidative burst and so F. 
tularensis, by producing iC3b, not only disables the generation of MAC, preventing lysis, but also 
enables entry into host cells without initiating an immune response.  
60 
 
 
 
 
 
 
Stage of life 
cycle 
Modulation Details 
Cell entry 
Complement factor H binding 240,319-
321 
Cleaves C3b into inactive iC3b preventing 
formation of MAC 
Production of iC3b enables host cell entry 
via CR3 which does not induce an oxidative 
burst 
Tetra-acylated LPS 322 
Much lower stimulation of TLR4 than hexa-
acylated LPS preventing activation of 
innate immune signalling cascade 
Residence 
within 
phagosome 
Catalase and superoxide dismutase 
production 323 
These enzymes neutralise the products of 
oxidative burst 
Preventing the phosphorylation of 
p47subunit of NADPH oxidase 324 
Prevents the correct assembly of the 
complexes required for oxidative species 
production 
Rapid disruption of phagosome 
membrane 252,257,258 
Rapid escape from the phagosome 
prevents sustained exposure to killing 
mechanisms and endosomal TLRs such as 
TLR2 and TLR9 
Replication 
within 
cytosol 
Production of immune signalling 
modulators: MviN and protein 
products of FTT_0584 and 
FTT_0748 325,326 
Mutations of these genes indicate they 
may function as down-regulators of ASC 
mediated cytokine production in wild type 
bacteria reducing the inflammatory 
response 
Proliferation Induction of host cell death 284,287,288 
Induction of apoptosis via the release of 
mitochondrial cytochrome-c ensures cell 
death and proliferation with a very low 
release of pro-inflammatory mediators  
 
Table 1-2: Modulation of the immune response by F. tularensis 
  
61 
 
In addition to the expression of complement receptors on the surface of cells, TLRs are also present 
which pathogens must try and evade in order to prevent the initiation of an immune response. F. 
tularensis is able to bypass detection, particularly by TLR4, through expressing low stimulatory LPS. 
Unlike other Gram-negative bacteria that express hexa-acylated LPS, the LPS of F. tularensis is tetra-
acylated which is thought to reduce its immunogenicity measured by its ability to stimulate human 
or murine TLR4 322. Several alternative TLR ligands have been identified on the surface of F. 
tularensis, such as the TLR2 ligand Tul4 300. However, it appears that the major target cells of F. 
tularensis, such as alveolar macrophages,  are unable to respond to this ligand despite expressing 
TLR2 318. One hypothesis accounting for this defect is the inability of these cells to express high levels 
of CD14, a co-receptor that aids TLR2-ligand detection 318. When dendritic cells were supplemented 
with CD14 they were able to respond to infection by F. tularensis through the secretion of pro-
inflammatory cytokines, a response they were unable to generate previously 327. In the case of 
alveolar macrophages and dendritic cells this could be due to the failure of these cells to express the 
co-receptor, CD14, possibly required for activation of TLR2 318. 
 
Once inside the cell, F. tularensis is not free from cell defence mechanisms. Indeed, within the 
phagosome bacteria are faced with reactive oxygen and reactive nitrogen killing mechanisms. Once 
again though, F. tularensis is able to interfere with this process in several ways. Firstly, F. tularensis 
produces enzymes, such as catalase and superoxide dismutase, which are able to neutralise products 
of the oxidative burst 323. However, a mechanism by which F. tularensis prevents the correct 
assembly of complexes responsible for generating oxidative species has also been observed 324. It is 
thought that this occurs by preventing the phosphorylation of the p47 subunit of NADPH oxidase. As 
mentioned previously, F. tularensis is able to rapidly escape the phagosome representing a further 
mechanism for evasion of oxidative death 257. Rapid escape from the phagosome also prevents 
prolonged exposure to TLR2 and TLR9 that can be found on the surface of phagosomes. This was 
confirmed using mutants of F. tularensis that are incapable of phagosome escape 199. These mutant 
strains demonstrate increased secretion of pro-inflammatory cytokines linked to TLR activation 199. 
Despite a brief interaction with TLRs within the phagosome, secretion of TNF in a TLR2-dependent 
manner can still be detected. Interestingly, upon phagosome escape, a down-regulation of NFκB 
activity is observed and a reduction in TNF, IL-6, and IL-12 secretion is seen 296,328. 
 
Although residence within the cytosol removes the potential of detection through the TLRs, another 
family of PRRs are present in the cytosol, the NLRs. In murine macrophages, the receptor responsible 
for cytosolic detection of F. tularensis has been identified as AIM2 329. Upon detection, AIM2 forms a 
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complex with ASC and activates the caspase-1 associated inflammasome 29,30. This results in the 
processing of the proinflammatory cytokines IL-1β and IL-18 into their active forms 329. Once again, F. 
tularensis has mechanisms to suppress the inflammatory response. Particularly, several F. tularensis 
proteins are able to suppress AIM2-dependent IL-1β secretion. Mutations in a F. tularensis protein 
called MviN and two genes, FTT_0584 and FTT_0748 all show an increase in ASC-mediated IL-1β 
production, indicating that they may function as immune modulators in wild type bacteria 325,326.  
 
The final stage of the F. tularensis life cycle is the induction of cell death of the host cell and 
proliferation throughout the host. Cells within the tissues of mice infected with type A F. tularensis 
exhibited activation of the caspase-3 associated process of cell death between 6 – 12 h post-
infection 288. This involves the release of mitochondrial cytochrome-c into the cytosol with 
subsequent activation of caspase-3 and caspase-9. However, this appears to be just one method of 
inducing apoptosis by F. tularensis as it has been shown that F. tularensis is also able to induce cell 
death through the down regulation of the MAPK p38 282. Interestingly, although capase-3 activation 
is observed at 6 – 12 h post-infection, it is not until 18 h post-infection that apoptosis occurs in 
human monocyte-derived macrophages 284,330. One explanation for this could be the induction of 
anti-apoptotic processes which prevent premature cell death until sufficient bacterial replication has 
taken place 330. 
 
In addition to the innate immune response, F. tularensis is able to modulate alternative immune 
mechanisms. It appears that, during infection, F. tularensis is able to induce the degradation of MHC 
class II proteins whose role is in the presentation of antigen to cells of the adaptive immune 
response 331. This occurs through an ubiquitin-dependent mechanism potentially involving two 
ubiquitin proteins, the ubiquitin hydrolase USP22 and the ubiquitin ligase CDC27 280. Degradation of 
MHC class II receptors will prevent efficient presentation of antigen therefore disrupting the 
induction of the adaptive immune response. 
 
Finally, F. tularensis modulates host cytokine secretion, although the mechanism by which this 
occurs remains elusive. Both Mycobacterium tuberculosis and Mycobacterium avium inhibit IFN-γ 
responses and this is partly dependent on TLR2 engagement 332,333. F. tularensis also suppresses IFN-
γ induced responses and so it is possible that TLR2 is also involved in this response 334. Another study 
identified an inhibition of TNF-α and IL-1β secretion by macrophages infected with LVS and this 
inhibition was prevented in an iglC mutant strain 328. This suggests that escape from the phagosome 
is required for the inhibition to take place although the exact mechanism is unknown. Specific to TLR 
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signalling proteins, an initial up-regulation of three signalling proteins (p38, IκB and c-Jun) was 
observed, following infection of murine macrophages with F. tularensis LVS, but then their 
production was down-regulated. Interestingly, the down-regulation corresponded with 
internalisation of the bacteria and was not observed in iglC mutant bacteria 296. The modulation of 
cytokine production is particularly clear in the murine model of F. tularensis infection. Mice 
challenged with F. tularensis SchuS4 via the inhalational route display active suppression of the 
inflammatory response associated with decreased cytokine production 335. No cytokine secretion is 
observed at the primary site of infection, the lungs, until 72 h post-infection. By this time, the 
bacteria have successfully colonised the lungs and have begun to disseminate to the secondary sites 
of infection, the liver and spleen. It is at this point that an efficient immune response is generated. 
However, even this is subject to modulation by F. tularensis and inflammation is exacerbated to the 
point where the immune response is detrimental to the host rather than beneficial 200. This bi-phasic 
response is characteristic of F. tularensis infection and suggests that therapeutic strategies focussed 
at re-balancing the inflammatory response may be beneficial to the outcome of infection. 
 
It is clear that F. tularensis is able to modulate the host immune system at numerous points from the 
initial detection by TLRs all the way through to disrupting the efficient induction of the adaptive 
immune response. The modulatory effects of F. tularensis seem to involve both the up-regulation of 
certain signalling pathways with the down-regulation of others therefore producing a finely balanced 
and tuned response that is beneficial for replication and proliferation of the bacteria within the host. 
F. tularensis influences the immune response in many ways and interacts with signalling pathways at 
multiple points during its intracellular life-cycle. This makes therapeutic modulation of signalling 
pathways, aimed at optimising the host response to F. tularensis infection, a significant challenge. 
1.4.6 Therapeutic modulation 
Potentially the simplest method of therapeutic modulation of TLR signalling is through the direct 
binding of TLRs themselves using synthetic or naturally occurring ligands. Bacterial DNA containing 
unmethylated CpG motifs has previously been used to stimulate TLR9 and induce protection against 
subsequent challenge with the intracellular pathogens F. tularensis LVS and Listeria monocytogenes 
336. This was brought about through the induction of a TH1 cytokine response and IFN-y, TNF and IL-
12 production 336. However, in some circumstances, co-stimulation with bacterial DNA appears to 
increase the likelihood of septic shock, probably through the synergistic production of TNF 337,338. In 
addition, further work using CpG oligonucleotides (ODNs) to protect mice challenged with the highly 
virulent SchuS4 strain of F. tularensis failed to show any protection regardless of challenge dose or 
route of infection 339. In fact, it appeared that the treatment actually adversely affected the survival 
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of infected mice which all exhibited dramatically elevated cytokine levels in the lungs, livers and 
spleens 6 days after challenge 339. Alternatively, stimulation of TLR3 using the synthetic dsRNA 
analogue poly(I:C) has been evaluated for the treatment of F. tularensis LVS or SchuS4 infection of 
Balb/c mice 340. Treatment 1 h prior to or 1 h after intranasal infection led to significant 
improvement in the survival of mice, correlating to increased influx of neutrophils to the lungs and 
earlier up-regulation of IL-6, MCP-1 and TNF 340. However, for full recovery, subsequent treatment 
with the antibiotic levofloxacin was still required.  
  
To try to prevent the wide-ranging effects of direct TLR stimulation, treatments targeting specific 
proteins within the signalling cascades are now being developed.  One of these targets is located 
downstream of TLR2 and is a Ser/Thr protein kinase called glycogen synthase kinase-3B (GSK3B) 341. 
GSK3B has been implicated in the regulation of the inflammatory response as it is active in resting 
cells but becomes inactive upon phosphorylation of its N-terminus, affecting the activation status of 
both NFκB and CREB 342. Inhibition of GSK3B with lithium chloride (LiCl) significantly reduced the 
production of pro-inflammatory cytokines, such as IFN-y, IL-12p40 and TNF, and increased survival 
from 60% in untreated mice to 90% in F. tularensis LVS-infected mice 209.  
 
The diversity of treatments does raise a question about the optimal treatment protocol for F. 
tularensis infection. In some instances, the treatment is trying to promote cytokine production 
whereas, in other cases, the treatment is aiming to reduce the levels of cytokines induced. Which of 
these treatment strategies is appropriate? This question highlights an interesting characteristic of F. 
tularensis infection. Early in infection it appears that this bacterium suppresses the inflammatory 
response whilst at later time points there is an excessive stimulation of the immune system resulting 
in an overwhelming inflammatory response. Perhaps the ideal therapeutic strategy would be to 
enhance the early response followed by a suppression of the later inflammation. 
1.4.7 Aims of this research 
 In order to defend against invading pathogens, a host must be able to detect and respond 
appropriately to the invading organism. The TLR signalling system, consisting of cell surface and 
intracellular receptors linked to the manufacture and secretion of cytokines by a complex signalling 
protein network, is perfectly placed to fulfil this role. However, due to the role of the TLR system in 
generating an immune response numerous pathogens express mechanisms of evading and even 
modulating this system for their own benefit. The intracellular bacterial pathogen F. tularensis 
demonstrates the characteristics of an immune-modulating pathogen. Upon infection of a host there 
is a suppression of the inflammatory response that is subsequently followed by an up-regulation of 
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immune signalling leading to overwhelming inflammation and associated organ damage. Despite the 
exact mechanisms behind its ability to modify the immune response not being fully understood, it is 
likely that F. tularensis interacts with the TLRs and downstream signalling pathways in order to 
achieve the observed bi-phasic inflammatory response. 
 
This project aims to determine the signalling proteins that are activated upon infection by F. 
tularensis and begin to elucidate the role that the TLR signalling system plays in determining the host 
response to infection by this pathogen. As F. tularensis displays the characteristics of an immune-
modulatory pathogen there is a possibility that the immune response induced is not optimal for host 
survival. Therefore, the potential for therapeutic immune modulation to optimise the host immune 
response will also be investigated.  
 
This specific aims of this study are: 
 
 Characterise the activation of signalling cascades in response to F. tularensis infection. 
 Identify the contribution of specific TLRs in initiating an immune response to infection by F. 
tularensis. 
 Investigate the potential interaction between separate signalling pathways. 
 Investigate the potential for specific inhibition of a TLR signalling protein to optimise the 
immune response to F. tularensis. 
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Chapter 2: Materials and methods 
2.1 Microbiological techniques 
2.1.1 Bacterial techniques 
2.1.1.1 Growth and maintenance of Francisella tularensis 
Francisella tularensis strains were maintained in 30% glycerol at -70oC for long-term storage. LVS or 
the SchuS4 strain of Francisella tularensis was routinely cultured for use in infection assays. F. 
tularensis was grown on blood cysteine glucose agar (BCGA) plates and incubated overnight at 37oC. 
 
2.1.1.2 Preparation of F. tularensis inoculum 
One loop from a glycerol stock of F. tularensis was streaked onto BCGA plates for growth (2.1.1.1). 
Subsequently, bacteria were harvested from the plates into the appropriate cell culture growth 
medium. Bacterial concentrations were calculated by taking optical density (OD) readings, using a 
spectrophotometer at a wavelength of 600 nm, and concentrations were adjusted accordingly by the 
addition of phosphate buffed saline (PBS). 
 
2.1.1.3 Bacterial enumeration of F. tularensis 
To enumerate bacteria, samples were subjected to ten-fold serial dilutions in PBS (100 µl sample into 
900 µl PBS). Subsequently, 100 µl of the appropriate dilutions were plated onto BCGA plates and 
incubated at 37oC until colonies could be seen (approximately 3 days). 
 
2.1.1.4 Preparation of F. tularensis genomic DNA 
Genomic DNA was prepared using the Gentra Puregene Yeast/Bacteria Kit (Qiagen, UK), according to 
manufacturer’s instructions. Bacterial colonies harvested from plates were inoculated into 300 µl 
cell lysis solution and the sample was mixed by pipetting and incubated at 80oC for 5 min. RNA 
contamination was removed by adding 1.5 µl RNase A solution, mixing by inversion 25 times, and 
incubation at 37oC for 60 min. The samples were chilled on ice for 1 min and 100 µl protein 
precipitation solution was added. The samples were vortexed for 20 s and protein was pelleted by 
centrifugation at 10,000 rpm for 3 min. DNA was precipitated by adding the supernatant into 300 µl 
isopropanol, inverting 50 times and centrifuging at 10,000 rpm for 1 min. The supernatant was 
discarded and the pellet was air-dried and then washed with 300 µl of 70% (v/v) ethanol followed by 
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centrifugation at 10,000 rpm for 1 min. The supernatant was discarded and the DNA pellet was air 
dried for 5 min before being rehydrated through addition of 100 µl DNA hydration buffer, vortexed 
for 5 s and incubated at 65oC for 1 h. To ensure full rehydration the DNA samples were incubated 
overnight at room temperature with gentle shaking. The samples were stored at -20oC. To determine 
the concentration of the DNA preparations the OD was measured at 260 nm using a NanoDrop 1000 
(Thermo Scientific, UK) according to manufacturer’s instructions. For assays requiring stimulation by 
genomic DNA, the DNA was diluted in DNA hydration buffer (Qiagen, UK) to the required 
concentration. 
 
2.1.2 Cell culture techniques 
2.1.2.1 Acquisition and maintenance of cell lines 
J774A.1 (macrophage-like) and MH-S (alveolar macrophage-like) cell lines were obtained from the 
European Collection of Cell Cultures (ECACC) (HPA, UK). The TLR4-knockout, TLR2-knockout and 
parental BMDM cell lines were a kind gift from Dr K. Fitzgerald (University of Massachusetts Medical 
School, US). The HEK-Blue™ hTLR9 and HEK-Blue™ Null1 cell lines were obtained from (InvivoGen, 
France). HEK-BlueTM cell lines have been transfected with an NF-κB-inducible secreted embryonic 
alkaline phosphatase (SEAP) reporter gene. This allows the degree of stimulation of the cells to be 
determined by a colour change in the supernatant upon combining with a QUANTI-BlueTM 
(InvivoGen, France) reagent, a substrate for the SEAP enzyme. J774A.1 cells were maintained in 
endotoxin-free Dulbecco’s modified Eagle’s medium (DMEM) (Gibco®, UK) supplemented with 10% 
foetal calf serum (FCS) (Gibco®, UK) and 2 mM L-glutamine (Sigma-Aldrich, US). MH-S cells were 
maintained in endotoxin-free Roswell Park Memorial Institute medium (RPMI) supplemented with 
10% FCS and 2 mM L-glutamine. BMDM cell lines were maintained in DMEM supplemented with 
10% FCS and 2mM L-glutamine. The HEK-Blue™ cell lines were resuscitated from frozen stocks by 
culturing for two passages in DMEM supplemented with 10% FCS and 2 mM L-glutamine. 
Subsequent passages of HEK-Blue™ hTLR9 cells included 100 µg/ml Normocin™, 10 µg/ml Blasticidin 
and 100 µg/ml Zeocin™, (InvivoGen, France), in addition to FCS and L-glutamine. Subsequent 
passages of HEK-Blue™ Null1 cells included 100 µg/ml Normicin™ and 100 µg/ml Zeocin™ in addition 
to FCS and L-glutamine. All cells were maintained at 37oC, 5% carbon dioxide (CO2) and 95% humidity 
in vented tissue culture flasks (Corning, US). 
 
Cell line stocks were stored in liquid nitrogen. To produce stocks, cells were grown to 90% 
confluence and then scraped into 10 ml of suitable media. The cells were centrifuged at 1000 rpm 
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for 5 min and then re-suspended in 3 ml culture supernatant. To this, 3 ml of freezing medium (20 % 
Dimethyl sulfoxide (DMSO) in FCS) was added and then the cells were split into 1 ml aliquots. These 
were slowly frozen overnight to -70oC and then transferred into liquid nitrogen. When needed, cells 
were resuscitated by rapid thawing and culturing in suitable media. 
 
2.1.2.2 LVS infection 
J774A.1 or MH-S cells were seeded into 6-well plates (Corning, US) at 4 x 105 cells/ml and incubated 
overnight at 37oC to allow the cells to adhere. Supernatants were then removed and replaced with 
1.5 ml of the LVS inoculum (Section 2.1.1.2). Plates were incubated at 37oC for 2 h (the uptake 
period) to allow for internalisation of the bacteria and then the supernatants were removed and 
replaced with 1.5 ml fresh media. The plates were incubated at 37oC and, at a range of timepoints, 
supernatants were removed and stored at -20oC for cytokine analysis (Section 2.3.1). The cells were 
washed once with chilled PBS and then lysed by adding 350 µl PhosphoSafe™ extraction reagent 
(Merck, US) and incubating on ice for 5 min. Full cell recovery was ensured by scraping wells with a 
rubber policeman (Corning, US). 100 µl of the lysate was used for bacterial enumeration (Section 
2.1.1.3), and a further 250 µl was centrifuged at 13,000 rpm for 5 min to remove cell debris before 
being stored at -20oC for analysis by western blotting (Section 2.2.2).  
 
For the treatment of infection with a MAPK inhibitor, cells were treated at either 0 h or 2 h after the 
uptake period. PD0325901 (InvivoGen, France), a MAPK kinase-1/2 (MEK-1/2) inhibitor, was used at 
a final concentration of 0.05 µM 343,344. At 0 h, the inhibitor was prepared to the correct 
concentration in growth media and then added to the cells instead of fresh media. At 2 h, the 
inhibitor was added directly to the supernatants in the wells to the required final concentration. 
 
2.1.2.3 LVS infection and TLR-blocking 
Into the wells of a 96-well plate, 20 µl of a TLR4-blocking antibody, IMG-428E (Imgenex, US) (50 
µg/ml – 5 ng/ml), or a TLR9 antagonist, G-ODN (InvivoGen, France) (100 µg/ml – 10 ng/ml), or both 
were added. Subsequently, 20 µl LVS was added to a final multiplicity of infection (MOI) of 150 and 
then 140 µl MH-S cells were seeded into the wells at 60,000 cells/well. The wells were made up to 
200 µl with RPMI. A summary of the plate layout is shown in Figure 2-1. The plates were incubated at 
37oC in 5% CO2 for 24 h before samples of supernatants were collected. Stimulation of signalling by 
LVS or inhibition of signalling by the antagonists was determined by measuring the levels of 
inflammatory cytokines in the supernatants (Section 2.3.1). 
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2.1.2.4 SchuS4 infection 
MH-S cells were seeded into 6-well plates at 4 x 105 cells/ml and incubated overnight at 37oC in 5% 
CO2 to allow the cells to adhere. The supernatants were removed and 1.5 ml of SchuS4 inoculum 
(Section 2.1.1.2) was added to each well. Plates were incubated at 37oC, 5% CO2 for 45 min to allow 
for internalisation of the bacteria and then the supernatants were removed and replaced with 1.5 ml 
fresh media. Plates were incubated at 37oC, 5% CO2 then, at specific time points, supernatants were 
removed and stored at -20oC for cytokine analysis (Section 2.3.1). The cells were washed once with 
chilled PBS and then 500 µl PhosphosafeTM lysis buffer (Merck, US) was added to each well to lyse the 
cells. The plates were incubated on ice for 5 min and, to ensure full cell recovery, the wells were 
scrapped with rubber policemen. Subsequently, 100 µl of the lysate was serially diluted and used for 
bacterial enumeration (Section 2.1.1.3). The remaining 400 µl was filter sterilised using a 0.2 µm 
syringe filter (Sartorius Stedim Biotech, France) to remove any bacteria and then stored at -20oC for 
subsequent screening by western blotting (Section 2.2.2) to measure signalling protein activation. 
 
2.1.2.5 Genomic DNA stimulation of HEK-Blue™ or MH-S cells 
All wells were set up as shown in Figure 2-2. Genomic DNA purified (Section 2.1.1.4) from F. tularensis 
was ten-fold serially diluted in DNA hydration buffer (Qiagen, UK) to give all required concentrations, 
(10 µg/ml – 1 ng/ml). Subsequently, 20 µl genomic DNA or DNA hydration buffer was added to each 
well. A known TLR9-agonist, ODN-2395, (InvivoGen, France) and its non-stimulatory partner, ODN-
2395 control, (InvivoGen, France) were used as positive and negative controls, respectively. For HEK 
stimulation, suspensions of HEK-Blue™ hTLR9 or HEK-Blue™ Null1 cells were prepared at 3.5 x 105 
cells/ml in DMEM and then 180 µl was added to each well. For MH-S stimulation, a suspension of 
MH-S cells was prepared at 3.75 x 105 cells/ml in RPMI and 160 µl was added to each. To simulate a 
lack of TLR9, when using MH-S cells, 20 µl of the TLR9-antagonist G-ODN (InvivoGen, France) or DNA 
hydration buffer was added to each well. The cells were incubated at 37oC in 5% CO2 for  
24 h and then 50 µl supernatant was removed and stored at -20oC for cytokine analysis (Section 
2.3.1) and the degree of cell stimulation was measured (Section 2.1.2.6). 
 
2.1.2.6 Measurement of HEK-Blue™ stimulation 
The degree of HEK cell stimulation was measured using an NF-κB-inducible SEAP reporter gene 
expressed by the cells. In a 96-well plate, 20 µl cell supernatant was added to 180 µl re-suspended 
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QUANTI-Blue™ (InvivoGen, France). The production of SEAP enzyme by stimulated cells enables the 
conversion of the QUANTI-Blue™ substrate from a pink to a blue colour. The plate was incubated at 
37oC for 40 min and the SEAP levels were determined by measuring the absorbance at 620 nm using 
a spectrophotometer (Thermo Scientific, US). 
 
2.1.2.7 Cytotoxicity measurements 
The degree of cell lysis was measured using the CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega, UK) according to manufacturer’s instructions. This assay quantitatively measures the 
amount of LDH which is a cytosolic enzyme released upon cell lysis. Briefly, 50 µl samples of cell 
supernatant were combined with 50 µl reconstituted substrate mix in a 96-well plate. The plate was 
incubated for 30 min in the dark before the addition of 50 µl stop solution. The degree of 
cytotoxicity was determined by measuring the absorbance at 490 nm using a spectrophotometer 
(Thermo Scientific, US). 
 
2.1.2.8 Priming of MH-S cells with pure LPS 
To the wells of a 96-well plate, 20 µl LPS or PBS was added in the presence of either 20 µl of the 
TLR4-neutralising antibody IMG-428E or PBS. A suspension of MH-S cells was prepared at 5 x 105 
cells/ml and 120 µl of the cell suspension was added to each well. The wells were made up to 200 µl 
using RPMI. The plates were incubated for 2 h at 37oC in 5% CO2 to allow priming by ultrapure E .coli 
LPS (InvivoGen, France) to occur. After priming, the supernatants were removed and 20 µl genomic 
DNA, ODN2395 positive control, ODN2395 negative control or DNA hydration buffer was added to 
each well. To block TLR9 signalling in specific wells, 20 µl of the TLR9 antagonist G-ODN was added. 
The wells were made up to 200 µl using RPMI. The plates were incubated for 24 h at 37oC in 5% CO2 
and then supernatants were removed and stored at -20oC for cytokine analysis (Section 2.3.1). A 
schematic diagram of the assay layout is shown in Figure 2-3. 
 
2.2 Protein techniques 
2.2.1 SDS-PAGE 
Samples of cell lysates were prepared for sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) by mixing in a ratio of 1:1 with 2x Laemmli buffer (Sigma-Aldrich, US) before 
boiling for 5 min. Subsequently, 19 µl of each sample was loaded into the wells of a 4 – 20% gradient  
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tris-glycine polyacrylamide gel (Invitrogen, UK). Cell lysates from stimulated or unstimulated cells 
(New England Biolabs, UK) were used as positive and negative controls, respectively. Routinely, two 
protein standards were used: 4 µl SeeBlue® Plus2 pre-stained standard (Invitrogen, UK) was used to 
visualise the running of the gels and 0.5 µl MagicMark™ XP Western Protein Standard (Invitrogen, 
UK) was used to visualise bands after western blotting and chemiluminescent detection (Section 
2.2.2). The standards were mixed and loaded into the end wells of each gel. Once loaded, the gels 
were run for 2 h at 125 V and 200 mA submerged in running buffer (900 ml dH2O and 100 ml Novex® 
Tris-Glycine Running Buffer 10x (Invitrogen, UK)). 
 
2.2.2 Western blotting 
Proteins were transferred from polyacrylamide gels onto Invitrolon™ Polyvinylidene fluoride (PVDF) 
membranes (Invitrogen, UK) using a Novex® Semi-Dry Blotter (Invitrogen, UK) according to 
manufacturer’s instructions. Briefly, PVDF membranes were activated in methanol for 1 min, washed 
in dH2O for 1 min, and then soaked in transfer buffer (820 ml ultrapure H2O (Millipore, US), 100 ml 
methanol and 80 ml Novex® Tris-Glycine Transfer Buffer 25x (Invitrogen, UK)). The gel was carefully 
removed from its plastic cassette and, with 4 filter papers, was soaked in transfer buffer. The 
separate components were then stacked into the Semi-Dry Blotter (Figure 2-4) and the transfer was 
run for 45 min at 10 V and 250 mA. To detect proteins of interest, the PVDF membranes were 
blocked for 2 h at room temperature using Blotto (5% (w/v) skimmed milk powder and 0.1% Tween® 
20 (Sigma- Aldrich, US) dissolved in PBS). They were then washed for 5 min in wash buffer (0.1% 
Tween® 20 in PBS) before being incubated over night at 4oC with the primary antibody at a dilution 
of 1:1000 in Blotto. Table 2-1 shows the primary antibodies used in this study. The membranes were 
then rinsed twice for 5 min in wash buffer and then incubated for 1 h at room temperature with the 
secondary antibody (goat anti-rabbit IgG conjugated to horseradish peroxidise (HRP) (Bio-Rad, US)) 
at a dilution of 1:3000 in Blotto. The membranes were rinsed 4 times in wash buffer for 2 x 5 min, 1 x 
15 min and 1 x 5 min. The membranes were developed using enhanced chemiluminescence (ECL) 
Plus detection reagents (GE Healthcare, UK) according to manufacturer’s instructions. Briefly, the 
membranes were placed on a plastic sheet and 3 ml of detection reagent was added. The 
membranes were incubated for 5 min and then the detection reagent was drawn off using 
absorbent paper. The membranes were placed in a film cassette and exposed to ECL hyperfilm (GE 
Healthcare, UK) for 5 s – 2 h. 
 
If the membranes were to be re-probed, they were removed from the cassette and washed twice for 
5 min in wash buffer. They were then stripped for 2 h at room temperature in 100 mM glycine  
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Figure 2-4: Stacking order of components for semi-dry transfer of proteins 
Two transfer buffer-soaked filter papers are placed onto the anode plate of the semi-dry blotter. The activated 
PVDF membrane is placed onto the filter papers with the gel placed on top. Finally two filter papers are placed 
onto the gel and the cathode plate is lowered gently onto the stack and loosely secured. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cathode plate 
PVDF membrane 
Filter paper x 2 
Gel 
Filter paper x 2 
Anode plate 
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Target protein (site 
of phosphorylation) 
Molecular weight 
(kDa) 
Manufacturer Antibody name 
Working 
dilution 
IRAK-1 80 Abcam, UK 
Rabbit polyclonal to 
IRAK (ab238) 
1:1000 
P-IRAK-1 
(Thr209) 
77 Abcam, UK 
Rabbit polyclonal to 
IRAK (phospho T209) 
(ab61799 
1:1000 
TAK-1 81 NEB TAK1 (#4505) 1:1000 
P-TAK-1 
(Thr184/187) 
82 NEB Phospho-TAK1 (#4531) 1:1000 
SAPK/JNK 46 (JNK-1), 54 (JNK-2/3) NEB SAPK/JNK (#9252) 1:1000 
P-SAPK/JNK 
(Thr183/Tyr185) 
46 (JNK-1), 54 (JNK-2/3) NEB 
Phospho-SAPK/JNK 
(#9251) 
1:1000 
p38 43 NEB 
p38α MAPKinase 
(#9218) 
1:1000 
P-p38 43 NEB 
Phospho-p38 
MAPKinase (#9211) 
1:1000 
ERK-1 44 NEB 
p44 MAPKinase 
(#4372) 
1:1000 
ERK-2 42 NEB 
p42 MAPKinase 
(#9108) 
1:1000 
P-ERK-1/2 
(Thr202/Tyr204) 
44 (ERK-1), 42 (ERK-2) NEB 
Phospho-p44/42 MAPK 
(#9101) 
1:1000 
IKK-α 85 NEB IKKα (#2682) 1:1000 
IKK-β 87 NEB IKKβ (#2684) 1:1000 
P-IKK-α/β 
(Ser176/180) 
85 (IKK-α), 87 (IKK-β) NEB 
Phospho-IKKα/β 
(#2687) 
1:1000 
IKK-γ 48 NEB IKKγ (#2685) 1:1000 
P-IKK-γ 
(Ser376) 
50 NEB Phospho-IKKγ (#2689) 1:1000 
IκBα 39 NEB IκB-α (#9242) 1:1000 
IκBβ 48 NEB IκBβ (#9248) 1:1000 
MKP-1 39 Abcam, UK 
Rabbit polyclonal to 
DUSP1 (ab61201) 
1:1000 
P-MKP-1 (Ser359) 40 NEB 
Phospho-MKP1 
(125E2) (#2857) 
1:1000 
β-actin 45 NEB Β-Actin (#4967) 1:4000 
 
Table 2-1: Details of the primary antibodies used in this study  
NEB – New England Biolabs, UK. 
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(Sigma-Aldrich, US) pH 3 made up in dH2O. After stripping, the membranes were washed twice for 5 
min in wash buffer and then re-blocked in Blotto. Detection using primary and secondary antibodies 
followed by ECL detection was then carried out as before. Exposed hyperfilm was developed by 
immersion in Kodak® developer solution (Sigma-Aldrich, US) for 1 min followed by washing in dH2O 
for 1 min, then immersion in Kodak® fixer solution (Sigma-Aldrich, US) for 1 min followed by a final 
wash in dH2O for 1 min. The hyperfilm was allowed to air-dry for at least 2 h before further analysis 
by densitometry. 
 
2.2.3 Densitometry 
The hyperfilms were scanned using a GS-800 Imaging Densitometer (Bio-Rad, US) combined with 
Quantity One® analysis software v 4.2.1 (Bio-Rad, US) set to transmissive-scan gray X-ray film (Figure 
2-5A). Each lane of the gel was overlaid onto the image using anchoring lines to match the contours 
of the gel (Figure 2-5B). Once the lanes had been mapped, the background intensity of the film could 
be removed so that only the intensity of the bands is measured. Using the analysis software, bands 
could be identified and classified as proteins of interest, loading controls or standards (Figure 2-6) 
The software allocates a value to each band according to the area under the band’s intensity curve 
(trace quantity). This value is then converted to a normalised quantity which accounts for loading 
differences. The normalised quantity is the trace quantity of a band expressed as a percentage of a 
selected band (β-actin) in the same lane (Figure 2-7A). A report containing the relevant band values 
was produced and this was exported into Microsoft Office® Excel® 2007 (Figure 2-7B). In Excel®, a 
formula was used to normalise the data collected from repeated experiments. This was performed, 
using the equation shown in Figure 2-8, to account for variations in the separate exposures 345. A 
flowchart displaying the individual stages of the densitometry analysis is shown in Figure 2-9. 
 
2.3 Immunological techniques 
2.3.1 BD™ Cytometric bead array (CBA) 
The secreted levels of specific cytokines released into the cell supernatants were measured using 
BD™ cytometric bead array (CBA) technology (BD Biosciences, US) on a BD™ FACScan flow cytometer 
(BD Biosciences, US) according to manufacturer’s instructions. Samples obtained from J774A.1, MH-
S and BMDM cells were screened using the BD™ mouse inflammation CBA kit (BD Biosciences, US). 
Samples obtained from HEK cells were screened using the BD™ human flex CBA set (BD Biosciences, 
US). Into the wells of a 96-well plate 50 µl of either test sample or standard were added. The capture  
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Figure 2-5: Densitometry: Scanning and applying lanes 
A. Selection of the appropriate film category (red box) applies default settings to filter type and scanning mode 
(blue box). B. The lanes (red lines) are manually applied using anchors (white dashed lines) fitting the lanes to 
the contours of the gel. The background intensity is also removed at this stage. 
 
 
A 
B 
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Figure 2-6: Densitometry: Band identification and classification 
Known bands (green) are manually selected and matched bands (red) of equal molecular weight are identified 
automatically using the standards (blue). 
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Figure 2-7: Densitometry: Generation of band values 
A. Values are allocated to each band depending on size and intensity. “Mol. Wt.” (purple box) is the molecular 
weight of the band as related to the chosen standard. “Peak Density” (red box) is the intensity of the bands 
peak. “Trace Qty” (blue box) is the area under the band’s intensity profile curve. “Normalized Qty” (green box) 
is the trace quantity of a band expressed as a percentage of a selected band in the same lane. B. A report is 
generated containing the selected criteria. This report is exported to Microsoft Office® Excel® 2007 for further 
analysis. 
A 
B 
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Figure 2-8: Densitometry: Normalisation to account for exposure variations 
The values produced by densitometry for each signalling protein were normalised across the three repeat 
experiments performed in duplicate. This was performed using the equation shown to account for variations in 
the separate exposures. Equation used from Chopard et. al., 2000 
345
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Time (h) Rpt 1 Rpt 2 Rpt 3 Rpt 4 Rpt 5 Rpt 6
Naive 127.008 46.309 45.413 60.735 45.175 99.647
0 71.591 13.587 28.854 1.866 1.8165 3.025
0.08 30.947 17.726 17.517 46.178 18.996 74.718
0.25 32.031 9.436 14.712 36.805 54.5625 51.157
0.5 15.274 3.781 8.608 5.84 5.421 6.145
0.75 6.734 0.973 4.775 5.812 4.3895 7.5835
1 8.456 4.113 7.546 29.997 29.371 29.728
1.5 83.207 34.888 42.915 91.826 96.5955 78.233
2 70.202 34.232 60.805 72.8565 74.2735 48.1605
4 125.869 87.565 105.602 83.8205 73.3125 55.9295
6 119.629 92.011 95.563 58.178 71.928 66.0995
24 2.149 1.812 6.385 1.359 0 0
Total 693.097 346.433 438.695 495.273 475.841 520.426
Grand Total 2969.765
Time (h) Rpt 1 Rpt 2 Rpt 3 Rpt 4 Rpt 5 Rpt 6
Naive 90.70012642 66.16327322 51.23754847 60.69671921 46.99018295 94.77113395
0 51.12522637 19.41221778 32.55473594 1.864823875 1.889489039 2.876982551
0.08 22.10015757 25.32575053 19.76368301 46.14889437 19.75928092 71.06194453
0.25 22.87427366 13.48154022 16.5989213 36.7818021 56.75488339 48.65381697
0.5 10.90761 5.402045737 9.712038782 5.836319094 5.638821954 5.844316619
0.75 4.808946297 1.390158821 5.387428576 5.808336742 4.565875109 7.212428817
1 6.038676847 5.876385643 8.513829536 29.97809313 30.55116023 28.27336769
1.5 59.42055161 49.8456947 48.41916175 91.7681228 100.4768172 74.4049507
2 50.13330085 48.90844477 68.60368473 72.81057912 77.25789382 45.80393988
4 89.88673321 125.1071502 119.1462267 83.7676686 76.25827975 53.19279192
6 85.43056676 131.4593045 107.8196517 58.14133087 74.81814896 62.8651597
24 1.534663735 2.588867198 7.203922818 1.358143433 0 0
Activated ERK-1
Normalised for Intensity variations
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Figure 2-9: Flowchart of densitometry process 
A simple flowchart showing the individual steps in the densitometry process from the original scanning of the 
film to the final normalised values. 
Normalise values to account for exposure variations 
Export report to Microsoft Office® Excel® 2007 
Generation of band values 
Molecular weight Peak density Trace quantity 
Normalised 
quantity 
Band identification and Classification 
Known Matched Standard 
Apply lane template 
Anchor lines Background removal 
Select scanning mode 
X-ray film Gray film 
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beads specific for each of the cytokines IFN-γ, IL-6, IL-10, IL-12p70, TNF and MCP-1 were combined in 
equal amounts and then 25 µl aliquots were added to the samples. The plate was incubated for 1 h 
at room temperature in the dark with gentle shaking. Subsequently, 25 µl PE detection reagent (BD 
Biosciences, US) was added to each well and the plate was re-incubated for 1 h. An extra 100 µl 
wash buffer (BD Biosciences, US) was added to the plate which was then centrifuged at 1,350 rpm 
for 5 min. The supernatant was removed and 150 µl fresh wash buffer was added to each well. The 
beads were re-suspended by gentle pipetting. The plate was then run on the FACs machine (BD 
Biosciences, US) and, using the standards on the same plate to generate a standard curve, the 
concentration of each cytokine was interpolated using GraphPad Prism® 5.01 software (GraphPad, 
US). 
 
2.4 Animal studies 
2.4.1 Preparation of inoculum 
LVS was grown overnight on BCGA plates incubated at 37oC (Section 2.1.1.2). The following day, 
bacteria were added to 10 ml PBS to an OD600 of 0.15 (~1 x 10
9 CFU/ml). This solution was diluted to 
give a final concentration of ~5 x 105 CFU/ml. To confirm the CFU/ml of the final dose, dilutions of 
both the ~1 x 109 CFU/ml and the ~5 x 105 CFU/ml solutions were plated onto BCGA plates which 
were incubated at 37oC for subsequent bacterial enumeration (Section 2.1.1.3). 
 
2.4.2 Animals and suppliers 
All animal studies were carried out in accordance with the UK Scientific Procedures Act 1986. Animal 
handling and infection procedures were carried out by trained staff at Dstl. Pathogen-free 6-8 week 
old female BALB/c mice were obtained from Charles River Laboratories, UK, and housed in high-
efficiency particulate air-filtered barrier units. Mice were provided with a continuous supply of food 
and water and allowed to acclimatise to new surroundings for at least a week before experimental 
procedures were done. The mice were kept at 25oC with alternating 12 h periods of light and dark to 
simulate day and night. Animals that reached the humane endpoint, described in the UK Home 
Office project license used for this work, were culled by cervical dislocation. 
 
2.4.3 LVS infection 
Thirty-six, 6-8 week old, female BALB/c mice (Charles River, UK) were infected via the intranasal 
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route with ~1 x 104 CFU of LVS. Groups of 5 mice were culled at 0 h (naive), 2 h, 12 h, 24 h, 48 h, 72 
h, and 96 h and the lungs, liver, spleen and blood were removed into aliquots of 2 ml PBS. The 
organs were homogenised through a 0.2 µm cell sieve (BD Biosciences, US). The blood and 
homogenates were screened for the levels of cytokines (Section 2.3.1), activation of signalling 
proteins (Section 2.2.2) and bacterial enumeration (Section 2.1.1.3). 
 
2.4.4 PD0325901 treatment 
Sixty-five, 6-8 week old, female BALB/c mice (Charles River, UK) were separated into 4 groups based 
on treatment type. All mice, except group IV, were treated daily with either PBS or PD0325901 by 
oral-gavage at a dose of 100 µl. Groups I and II were treated from 1 day pre-infection whilst group III 
was treated from 2 days post-infection. Mice were challenged with 2.5 x 104 CFU LVS by the 
intranasal route. Weighing and scoring of the mice occurred twice daily throughout the study. On 
day 2 and day 4 post-challenge, 5 mice from groups I, II, and IV were culled and the lungs, liver and 
spleen were removed and placed into aliquots of 2 ml PBS. Ten mice from groups I, II and III were 
monitored for changes in survival. A summary of the study protocol is shown in Table 2-2.  Organs 
were homogenised though a 0.2 µm cell sieve (BD Biosciences, US). Serial dilutions of 100 µl of the 
homogenates were plated onto BCGA for bacterial enumeration (Section 2.1.1.3). Cytokine analysis 
was carried out on 100 µl samples (Section 2.3.1) and 300 µl was mixed with 300 µl PhosphosafeTM 
(Merck, US) and analysed for signalling protein activation (Section 2.2.2). 
2.5 Statistics 
All transformations of data and statistical tests were performed using GraphPad Prism® 5.01 
software (GraphPad, US). A p-value of <0.05 was considered significant for all studies. The specific 
statistical tests used are detailed in the results chapters. 
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 Day 
Group 
Treatment and 
Route 
-1 
Infect 
0 
1 2 3 4 >4 
I 
PBS 
Oral-gavage 
P (20) P (20) P (20) 
P (15) 
Cull 5 
P (15) 
P (10) 
Cull 5 
L
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fo
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s
u
rv
iv
a
l 
II 
PD0325901 
Oral-gavage 
PD (20) PD (20) PD (20) 
PD (15) 
Cull 5 
PD (15) 
PD (10) 
Cull 5 
III 
PD0325901 
Oral-gavage 
- - - PD (15) PD (15) 
PD (10) 
Cull 5 
IV 
Uninfected 
Untreated 
- - - 
- 
Cull 5 
- 
- 
Cull 5 
 
Table 2-2: PD0325901 – Inoculation and treatment schedule 
Mice in group I were treated daily for 6 days with PBS from 1 day pre-challenge. Mice in group II were treated 
daily for 6 days with PD0325901 from 1 day pre-challenge. Mice in group III were treated daily for 3 days with 
PD0325901 from 2 days post-challenge. Mice in group IV remained untreated and uninfected for the duration 
of the study. Numbers in brackets show the number of animals treated in each group. 
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Chapter 3: Characterisation of TLR signalling induced by 
infection with F. tularensis 
3.1 Introduction 
The generation of an immune response to any pathogen relies heavily upon immune and epithelial 
cells being able to detect and respond appropriately to the invading organism 312,346. One of the first 
lines of defence for a host is the innate immune system and the “watchmen” of this system are the 
PRRs 2. One family of PRRs that, along with their associated signalling pathways, has received intense 
scrutiny is the TLR family of receptors. TLRs convert the ligand-binding event into an intracellular 
signalling cascade, involving numerous signalling proteins, resulting in the secretion of immune 
mediators and, ideally, clearance of the pathogen 305,347,348. A better understanding of how TLR 
signalling pathways induce a specific response to specific pathogens could enable the identification 
of the key signalling components that are essential to generating an optimal immune response 
leading to pathogen clearance. The full characterisation of a signalling cascade requires several 
pieces of information to give a complete picture of signalling events. The identity of proteins 
involved in a specific signalling response and their function within the pathway needs to be 
determined. This process has been demonstrated in the characterisation of the two major signalling 
cascades; the MyD88-dependent and TRIF-dependent signalling pathways 45,108,349. For example, TAK-
1 is known to have a role in MyD88-dependent signalling and functions as a diverging point 
bifurcating into the MAPK and the NF-κB branches of signalling 123,124. Equally, knowledge of the 
interactions between separate signalling proteins provides valuable information about the sequence 
in which the proteins become involved in the pathway. This has been demonstrated through the 
solving of the structure of, and therefore the interactions within, the Myddosome 110,111. In this case, 
IRAK-4 was shown to be recruited to the complex first followed by the addition of IRAK-2, providing 
insight into how these two proteins regulate each other 111. Additional information can be provided 
through determining the actual time course of activation of specific proteins within a pathway. This 
can be carried out through the direct measurement of protein activation that occurs predominantly 
through phosphorylation of specific residues within their structure 125,141,163,350. This information 
enables the identification of signalling proteins that are important in the early response to infection 
and those that function later in an infection. 
 
Previous studies have examined the net effect of TLR signalling induced by F. tularensis infection 
composed of the production of immune mediators such as cytokines and chemokines 293,296,309. For 
example, TLR2 activation by F. tularensis has been shown to induce the secretion of IFN-γ, IL-1β, IL-
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12p40, RANTES and TNF 298. Furthermore, the secreted cytokines can be categorised using temporal 
factors as the secretion of specific cytokines peaked at 3 different time points after stimulation: pre-
8 h (TNF), 8-12 h (IL-12p40) or post-12 h (IFN-γ) 298. Secretion of TNF and IFN-γ has also been 
observed in several other studies 306,308,334. TLR2-deficiency in vivo resulted in lower levels of TNF but 
increased amounts of IFN-γ indicating differential regulation of the production of these two 
cytokines 41. These data suggested a synergistic action of these cytokines with the microbicidal 
activity of IFN-γ being reduced in the absence of TNF 41.  
 
The outcome of F. tularensis infection, with regards to the cytokine output, has been closely 
examined but there has been less focus upon examining the time course of signalling activation after 
infection. An understanding of this process is particularly important for a pathogen such as F. 
tularensis whose infection strategy in vivo relies upon suppressing the immune response early in 
infection but subsequently over-activating it 296. This pattern of immune response to infection 
suggests that F. tularensis is modifying signalling responses to prevent bacterial clearance and the 
resolution of infection.  
 
Characterisation of signalling pathways has greatly enhanced our understanding of the pathogenesis 
of several other pathogens. For example, studies of two strains of Legionella pneumophila identified 
an up-regulation and sustained activation of p38 and JNK signalling proteins only in the virulent 
AA100 strain 351. This highlights key differences between virulent and avirulent Legionella strains and 
similar studies with strains of F. tularensis therefore has potential to identify signalling proteins 
correlating with virulence. Signalling characterisation can also lead to novel therapeutic approaches. 
For example, during infection of HEK-293 cells, herpes simplex virus type 2 (HSV-2) induced 
sustained ERK activation and targeting of an up-stream signalling protein with an inhibitor reduced 
viral propagation 352. Similarly, transient activation of p38 after Mycobacterium avium subspecies 
paratuberculosis infection of bovine monocytes was identified as being a key mechanism for 
bacterial survival within these cells 353. Blockage of the p38 pathway altered the cytokine output and 
increased phagosome acidification resulting in improved pathogen killing by infected cells 353. As 
with these examples, a more detailed understanding of the TLR signalling response to F. tularensis 
infection could underpin approaches aiming to improving the outcome of infection to this bacterial 
pathogen. 
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3.1.1 Aims 
The aim of this chapter was to characterise the intracellular signalling cascades within host cells 
infected with F. tularensis using both in vitro and in vivo infection models. Initial studies were 
performed using the low virulence F. tularensis strain LVS before characterising the signalling 
response to the highly virulent SchuS4 strain.  
 
The specific aims of this chapter were to: 
 Establish and optimise an in vitro infection protocol to enable consistent measurement of 
TLR signalling cascades. 
 Select signalling proteins for focussed screening of signalling in further studies 
 Compile a profile of the signalling response to F. tularensis LVS consisting of the activation of 
specific proteins during infection and the resulting cytokine output in both in vitro and in 
vivo infection models. 
 Compile a profile of the signalling response to F. tularensis SchuS4 for comparison to the LVS 
profiles. 
 
3.2 Results 
3.2.1 In vitro assay optimisation 
3.2.1.1 Standardisation of bacterial inoculum 
In order to enable consistent preparation of bacterial inoculum for infection assays, a standard curve 
was produced correlating absorbance measurements to bacterial concentration. Specifically, several 
LVS broth samples were prepared by resuspending LVS colonies in appropriate cell culture media 
with absorbance readings (A600) between 0.1 and 0.6. The preparations were then plated onto BCGA 
for bacterial enumeration. The calculated CFU/ml was plotted against the known absorbance 
readings and a best-fit line was calculated (Figure 3-1). From the graph it was possible to interpolate 
that an absorbance reading of 0.15 correlates with the desired starting inoculum of approximately 
1x109 CFU/ml. 
 
3.2.1.2 Optimisation in J774A.1 cells 
An in vitro infection model was established to enable the characterisation of TLR signalling in 
response to F. tularensis. The macrophage-like J774A.1 cell line was initially selected for optimisation  
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Figure 3-1: Correlation between spectrophotometer reading and CFU/ml of F. tularensis  
The CFU/ml correlating to specific spectrophotometer readings was determined by diluting LVS in DMEM and 
then reading the absorbance at 600 nm. A best-fit line is shown which was used to determine which 
absorbance level correlated to approximately 1x10
9 
CFU/ml. 
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of the infection protocol since this cell line is very well characterised and expresses all TLRs of 
interest to this study 354-356. In addition, J774A.1 cells support infection and replication of F. tularensis 
239,246,260,261. Therefore, the cells were considered suitable for the study of TLR signalling induced by 
an LVS infection. It was important to determine which multiplicity of infection (MOI) to use in the 
infections since high MOIs could result in high levels of host cell death and low MOIs might not 
create an established infection model. F. tularensis enters host macrophages through phagocytosis, 
requiring CR3 alone or in cooperation with mannose receptors (MRs) and scavenger receptor-A (SR-
A), and does not actively invade these cells 240,241,246.  J774A.1s were infected with MOIs ranging from 
10 to 150. The cells were incubated for 2 h to phagocytose the bacteria and then at several time 
points after uptake cells were lysed and enumeration of bacteria was performed on BCGA plates 
(Figure 3-2). As expected, the number of bacteria at 0 h (which corresponds to 2 h after infection) 
increased with an increase in MOI. Over the following 72 h, the growth pattern of LVS was the same 
irrespective of the starting MOI. There was an initial decrease in bacterial numbers over the first 2 h 
after uptake followed by a 3 x log increase in bacterial numbers at 24 h. From this time point 
through to the end of the time course, at 72 h, there was no increase in bacterial numbers. For 
subsequent infections, an MOI of 150 was chosen as this value generated an established infection 
within host cells without causing a high rate of host cell death. 
 
3.2.1.3 Optimisation in MH-S cells 
The J774A.1 cell line is classified as a macrophage-like cell line and readily uptakes bacteria. 
However, for the modelling of F. tularensis infection, specifically via the inhalational route, a lung-
associated macrophage may more fully represent the natural infection. Therefore, optimisation of F. 
tularensis infection in the alveolar macrophage-like MH-S cell line was performed. To ensure that 
MH-S cells display similar infection characteristics to the J774A.1 cell line, which was used in the 
preliminary optimisation studies, a LVS growth curve in MH-S cells was generated and then 
compared to the growth curve from J774A.1 cells (Figure 3-3). Both cell lines were infected with F. 
tularensis LVS at an MOI of 150 and incubated for 2 h to phagocytose the bacteria. After uptake the 
cells were lysed and bacterial enumeration was performed on BCGA plates. Both cell lines were able 
to phagocytose LVS to the same degree with bacterial numbers of around 5x105 CFU/ml at 0 h 
(which equates to 2 h post-infection). Indeed, the initial infection and survival of LVS within the two 
cell types was near identical with a decrease of bacterial numbers in the first 2 h followed by an 
increase back to original values at 6 h. However, from this point the two growth profiles diverge. In 
J774A.1 cells, LVS replicated at a greater rate than in MH-S cells, reaching 5x1011 CFU/ml compared 
to 1x108 CFU/ml by 24 h. Therefore, although the initial infection demonstrates large similarity  
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Figure 3-2: The effect of MOI on the growth pattern of F. tularensis LVS within J774A.1 macrophages 
J774A.1 macrophages were infected with one of four MOIs and bacteria were enumerated at a range of time 
points after uptake. The experiment was performed in duplicate (n = 2) and each replicate was performed in 
duplicate. Error bars show the standard deviation. 
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Figure 3-3: Comparison between survival and growth of F. tularensis LVS within J774A.1 macrophages and 
MH-S macrophages 
J774A.1 and MH-S cells were infected with F. tularensis LVS at an MOI of 150 and at specific times (0 h, 2 h, 4 
h, 6 h, 24 h) after uptake bacteria were enumerated to determine intracellular bacterial numbers. This 
experiment was performed in triplicate (n = 3) and each replicate was performed in duplicate. Error bars show 
the standard deviation. Significance, between the two cell types at each time point, was determined by two-
way ANOVA and a Bonferroni post-test (* = p<0.001)  
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between the cells, the later stages of infection show differences in how the host cells handle 
infection. 
 
3.2.2 In vitro characterisation of the immune response to F. tularensis 
LVS 
The MH-S model of F. tularensis LVS infection was selected for the measurement of signalling 
protein activation and cytokine secretion. Since it was likely that significant changes in signalling 
protein activation could occur at the earliest stages of infection the assay was further developed to 
include a series of new time points at 5 min, 15 min, 30 min, 45 min, 1 h, and 1.5 h post-uptake. As 
shown in Figure 3-4, the bacterial numbers decreased throughout the pre-2 h time points and at 2 h 
is significantly lower than the number of bacteria originally taken up by the cells. From 2 h, however, 
bacterial numbers increase and replication is maintained through to 24 h. 
 
Signalling proteins to include in the preliminary screening panel were selected based on their known 
function and position within signalling pathways (IRAK-1, TAK-1, JNK-1/2/3, p38, ERK-1/2, MAPK 
phosphatase-1 (MKP-1), IKK-α, IKK-β, IKK-γ, IκBα, IκBβ). Importantly, these proteins are known to be 
intimately involved in signalling downstream of TLR2 and TLR4 activation 111,124,188,357,358. F. tularensis 
expresses several factors that are possible ligands for these two receptors suggesting that they are 
likely detectors of a F. tularensis infection 300,304. As such, the signalling proteins located within their 
downstream pathways have the most potential for activation and modulation by this pathogen and 
warrant examination. In total, the preliminary screen contained 14 proteins and their respective 
phosphorylated states (Table 3-1). The progression of signalling in response to infection was 
examined by immunoblotting lysates collected from LVS-infected MH-S cells. Briefly, MH-S cells were 
incubated for 2 h in the presence of LVS and then at multiple time points supernatants were 
collected and cells were lysed. Lysates were used for bacterial enumeration and also screened by 
western blotting for the levels of un-phosphorylated and phosphorylated proteins. Semi-quantitative 
values were allocated to the levels of expressed and activated signalling proteins by densitometer 
analysis of the images created by western blotting.  
 
The preliminary screen identified five proteins (IRAK-1, TAK-1, IKK-α, IKK-β, IKK-γ) which were not 
easily visualised by western blotting due to high levels of non-specific binding or those whose 
activation did not appear to be affected by LVS infection (black text in Table 3-1). Nine proteins (JNK-
1/2/3, p38, ERK-1/2, MKP-1, IκBα, IκBβ) were measured in further studies (red text in Table 3-1). 
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Figure 3-4: The growth and replication of F. tularensis LVS within MH-S cells  
The bacterial burden of MH-S cells was determined at several time points (0 h, 0.08 h, 0.25 h, 0.5 h, 0.75 h, 1 h, 
1.5 h, 2 h, 4 h, 6 h, 24 h) after the 2 h uptake period. The experiment was performed in triplicate (n = 3) and 
each replicate was performed in duplicate. Error bars show the standard error of the mean. Significance, 
compared to 0 h, was determined by one-way ANOVA and a Dunnett’s multiple comparison post-test (* = 
p<0.05). 
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Protein 
Molecular weight 
(kDa) 
Phosphorylated 
residues 
Function 
IRAK-1 80 - Recruited to the membrane-bound 
receptor complex. Subsequent 
recruitment of TRAF-6 leads to its 
degradation and release of the 
signalling complex into the cytoplasm 
P-IRAK-1 77 Thr209 
TAK-1 80 - A MAP3K which forms a complex 
with TAB2 and TAB3 leading to a 
divergence in the pathway down 
both the NF-κB and MAPK branches, 
through activation of the IKK complex 
and MAPKs respectively 
P-TAK-1 
82 Thr184 
82 Thr187 
82 Thr184 ; Thr187 
JNK-1 / 
2,3 
46 / 54 - MAPK phosphorylated by MKK4 and 
MKK7, upstream of AP-1 
transcription 
P-JNK-1 / 
2,3 
46 / 54 Thr183 ; Tyr185 
p38 43 - MAPK phosphorylated by MKK3 and 
MKK6, upstream of AP-1 
transcription P-p38 43 Thr180 ; Tyr182 
ERK-1 44 - 
MAPK phosphorylated by MKK1 and 
MKK2, upstream of AP-1 
transcription 
ERK-2 42 - 
P-ERK-1 / 
2 
44 / 42 
Thr202 ; Tyr204 , Thr185 ; 
Tyr187 
MKP-1 40 - Negative regulator of MAPKs, 
particularly p38 P-MKP-1 40 Ser359 
IKK-α 85 - 
Together form the IKK complex 
responsible for inducing the 
phosphorylation and degradation of 
IκB proteins 
IKK-β 87 - 
P-IKK-α / 
β 
85 / 87 Ser176 
85 / 87 Ser180 
85 / 87 Ser176 ; Ser180 
IKK-γ 48 - 
P-IKK-γ 50 Ser376 
IκBα 39 - 
Negative regulator of NF-κB 
P- IκBα 36 Ser32 ; Ser36 
IκBβ 48 - Negative regulator of NF-κB 
 
Table 3-1: Signalling proteins measured in infected cells 
Red text denotes proteins that were down-selected due to occupying key positions in TLR signalling pathways 
or displaying significant alterations in activation in preliminary screens. Black text denotes proteins that were 
removed from the panel due to unclear western blot images or because their activation was not altered during 
infection. 
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3.2.2.1 MAPK proteins 
A class of proteins which, as a group, showed the greatest change in activation during F. tularensis 
LVS infection of MH-S cells were the MAPKs. JNK, p38, and ERK are key proteins located on the  
MAPK-branch of the MyD88-dependent pathway and are primarily responsible for activating 
transcription by the transcription factor called AP-1 which is a heterodimer formed of a Fos domain 
and a Jun domain 359. Although the MAPKs major link is to transcription via AP-1, links to NF-κB have 
also been observed 360-362. 
 
Figure 3-5 shows the expression and activation profiles of the three JNK proteins over the course of 
infection. No alteration in the levels of activated protein for any of the JNK proteins was detected, 
apart from at 24 h where a decrease in the level of activated JNK-2/3 from 0.75 h and 6 h was 
detected (Figure 3-5D). The expression of JNK-2/3 also remained constant but there was a slight 
decrease in the expression of JNK-1 from 6 h through to 24 h post-uptake (Figure 3-5A).  
 
The expression and activation profiles of p38 and one of its regulators MKP-1 over the course of 
infection are shown in Figure 3-6 and Figure 3-7, respectively. MKP-1 is a negative regulator of p38 and 
is therefore responsible for the inactivation of this protein. Similar to the JNK proteins, the 
expression of p38 remained constant during the infection. However, there was a significant change 
in the activation profile. A rapid increase in activation was seen immediately after the uptake of LVS. 
This was a transient response and the levels of activated protein returned to naïve levels by 0.5 h. 
After the rapid and transient activation of p38 there was no re-activation throughout the rest of the 
infection. Similarly, there was no significant change in the expression of MKP-1 although significant 
changes in the level of activated protein did occur. Simultaneously with p38, MKP-1 became 
activated but MKP-1 displayed an extended period of activation, compared to p38, which lasted until 
0.75 h, just after the activation of p38 had returned to naïve levels. 
 
The final MAPKs to be screened were the two ERK proteins, the expression and activation of which 
are shown in Figure 3-8. As with the other MAPKs, the expression of both ERK-1 and ERK-2 did not 
alter at any time point during the infection. The activation profiles of these two proteins, however, 
did display some interesting features. There appeared to be two phases of protein activation, 
particularly for ERK-2. In the first hour after uptake a transient activation pattern was observed. 
However, from 1.5 h there was a sustained activation of the two ERK proteins which was maintained 
through to 6 h. 
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Figure 3-5: The expression and the levels of activated JNK-1 and JNK-2/3 in MH-S cells throughout the course 
of a F. tularensis LVS infection  
The expression of JNK-1 (A) and JNK-2/3 (C) and the levels of activated JNK-1 (B) and JNK-2/3 (D) were 
determined at several time points after the 2 h uptake period. Representative western blots are shown below 
the corresponding graphs. The experiment was performed in triplicate (n = 3) and each replicate was 
performed in duplicate. Error bars show the 95% confidence interval. Significant difference from naïve levels 
was determined by one-way ANOVA and a Dunnett’s multiple comparison post-test (* = p<0.05). Western blot 
image: L – MagicMark™ ladder; N – naïve; +ve – positive control. 
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Figure 3-6: The expression and the levels of activated p38 in MH-S cells throughout the course of a F. 
tularensis LVS infection 
 The expression of p38 (A) and the levels of activated p38 (B) were determined at several time points after the 
2 h uptake period. Representative western blots are shown below the corresponding graphs. The experiment 
was performed in triplicate (n = 3) and each replicate was performed in duplicate. Error bars show the 95% 
confidence interval. Significant difference from naïve levels was determined by one-way ANOVA and a 
Dunnett’s multiple comparison post-test (* = p<0.05). Western blot image: L – MagicMark™ ladder; N – naïve; 
+ve – positive control. 
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Figure 3-7: The expression and the levels of activated MKP-1 in MH-S cells throughout the course of a F. 
tularensis LVS infection 
 The expression of MKP1 (A) and the levels of activated MKP-1 (B) were determined at several time points after 
the 2 h uptake period. Representative western blots are shown below the corresponding graphs. The 
experiment was performed in triplicate (n = 3) and each replicate was performed in duplicate. Error bars show 
the 95% confidence interval. Significant difference from naïve levels was determined by one-way ANOVA and a 
Dunnett’s multiple comparison post-test (* = p<0.05). Western blot image: L – MagicMark™ ladder; N – naïve; 
+ve – positive control. 
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Figure 3-8: The expression and levels of activated ERK-1/2 in MH-S cells throughout the course of a F. 
tularensis LVS infection 
The expression of ERK-1 (A) and ERK-2 (C) and the levels of activated ERK-1 (B) and ERK-2 (D) were determined 
at several time points after the 2 h uptake period. Representative western blots are shown below the 
corresponding graphs. The experiment was performed in triplicate (n = 3) and each replicate was performed in 
duplicate. Error bars show the 95% confidence interval. Significant difference from naïve levels was 
determined by one-way ANOVA and a Dunnett’s multiple comparison post-test (* = p<0.05). Western blot 
image: L – MagicMark™ ladder; N – naïve; +ve – positive control.  
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3.2.2.2 IκB proteins 
The second branch of the MyD88-dependent pathway results in the activation of the transcription 
factor NF-κB. The two major members of the NF-κB family, RelA and p65, reside in an inactivated 
form in the cytoplasm generally bound to one of a family of IκB proteins. When the IκB protein is 
phosphorylated it degrades releasing NF-κB which can then be phosphorylated and translocates to 
the nucleus initiating transcription. Therefore, one method of observing the activation of the NF-κB 
branch of signalling is in measuring the level of IκB expression. If levels decrease, degradation of this 
protein likely indicates activation and initiation of NF-κB-controlled transcription. Two members of 
the IκB family were included in the screening panel and these were IκBα and IκBβ (Figure 3-9).  
 
The expression of IκBα does show a trend towards decreased expression from naïve levels between 
0 h and 0.75 h followed by an increase above naïve levels at 2 – 4 h, although this trend was not 
statistically significant. No statistically significant change was seen in the expression profile of IκBβ 
although large variability was seen in the repeated screens for this protein. 
 
3.2.2.3 Cytokines 
An end result of the signalling pathways examined is the production of immune mediators such as 
cytokines and chemokines. The secretion of IFN-γ, IL-6, IL-10, IL-12p70, TNF and MCP-1 was 
investigated in the supernatants collected from LVS-infected MH-S cells using flow cytometry. Of the 
six cytokines screened, only 3 (MCP-1, TNF and IL-6) were detected (Figure 3-10). MCP-1 was rapidly 
secreted during the early stages of infection and reached maximum levels of detection (2500 ρg/ml) 
by 1.5 h. TNF was secreted at a slower rate than MCP-1 and by 6 h after uptake of LVS by MH-S cells 
was detected at 1000 ρg/ml compared to 2500 ρg/ml for MCP-1. IL-6 was not secreted immediately 
after uptake and was only detected at a level significantly above naïve levels at 6 h and 24 h. 
 
3.2.1 In vivo characterisation of the immune response to F. tularensis 
LVS 
After gaining insight into the activation of specific proteins located within the MyD88 signalling 
pathway in an in vitro model, samples from an in vivo infection with F. tularensis LVS were screened 
for comparison. The samples obtained for screening were taken from an experiment performed by 
colleagues, Riccardo D’Elia, Tom Laws and Dominic Jenner, involved with a different study. As such, 
the group sizes and time points at which samples were taken were limited by the study protocol.  
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Figure 3-9: The expression of IκBα and IκBβ in MH-S cells throughout the course of a F. tularensis LVS 
infection  
The expression of IκBα (A) and IκBβ (B) was determined at several time points after the 2 h uptake period. 
Representative western blots are shown below the corresponding graphs. The experiment was performed in 
triplicate (n = 3) and each replicate was performed in duplicate. Error bars show the 95% confidence interval. 
Significant difference from naïve levels was determined by one-way ANOVA and a Dunnett’s multiple 
comparison post-test (* = p<0.05). Western blot image: L – MagicMark™ ladder; N – naïve; +ve – positive 
control. 
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Figure 3-10: The secretion of cytokines by MH-S cells in response to a F. tularensis LVS infection  
The secretion of cytokines into the supernatant was measured at several time points after the 2 h 
uptake period. IL-1β, IFN-γ, IL-10, and IL-12p70 (not shown) were undetectable. The experiment was 
performed in triplicate (n=3). Error bars show the standard deviation. Significant difference from the 
secretion level at 0 h was determined by one-way ANOVA and a Dunnett’s multiple comparison 
post-test (* = p<0.05). 
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Briefly, groups of 5 mice were challenged with ~ 1 x 104 CFU of LVS via the intranasal route. At 
specific time points (2 h, 12 h, 24 h, 48 h, 72 h, 96 h) after infection mice were culled and the blood, 
lungs, spleen and livers were removed. Bacterial enumeration was performed on all organs and the 
lungs were homogenised and screened for the expression and activation of the MyD88-dependent 
signalling proteins. The survival and replication of LVS within distinct organs of the mouse is shown 
in Figure 3-11. F. tularensis LVS was first detected in the lungs at 2 h, then the liver at 24 h and finally 
the blood and spleen at 48 h. LVS replicated well in the lungs and at 72 h there was nearly a 3 x log 
increase over the 2 h count. Interestingly, at 96 h there was a drop in bacterial numbers detected in 
the lungs. LVS was also found in increasing numbers in all other organs during the course of the 
infection and at 96 h there was the same number of bacteria in the lung, liver and spleen. 
 
The lung homogenates were screened using the same western blotting approach as for the in vitro 
samples for the presence of activated signalling proteins. However, it was found that, with the 
experimental protocol used, there was large variation in the results obtained between samples 
taken from different mice in the same group. Despite carrying out five replicate screens, and the 
observation of trends in the phosphorylation profile of ERK (Figure 3-12), no significant change in 
activation levels could be detected for any of the proteins of interest (Figure 3-13, Figure 3-14). 
Therefore, it was decided to continue with subsequent investigations in the in vitro model of LVS 
infection in MH-S cells.  
 
Cytokine secretion was also measured in the lung homogenates by flow cytometry screening for 
MCP-1, TNF, IL-6, IFN-γ, IL-10, IL-12p70, MIP-1α, MIG, IL-17, IL-13, GM-CSF and RANTES (Figure 3-15). 
For all cytokines screened, except MIG, significant levels of secretion could not be detected until 72 
h after the initial infection. In all cases, once secretion began, the levels continued increasing 
through to the final time point of 96 h. 
 
3.2.1 In vitro characterisation of immune response to F. tularensis 
SchuS4 infection 
F. tularensis LVS may be used as a model for the more virulent type A strains, such as F. tularensis 
SchuS4, which is able to cause severe disease in humans. The severity of disease combined with the 
lack of a sufficiently characterised vaccine means that this strain is only handled in ACDP level 3 
containment. Using LVS enables research to be done without the restrictions that working in 
containment can have. However, it is appropriate to validate work done using LVS through an in   
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Figure 3-11: The bacterial burden of murine organs at several time points after intranasal infection 
with F. tularensis LVS 
Groups of 5 mice (n = 5) were challenged via the intranasal route with 13,700 CFU of F. tularensis 
LVS. At 2 h, 12 h, 24 h, 48 h, 72 h, and 96 h post-infection the lungs, liver, spleen and blood were 
removed and the bacterial burdens were determined. The black lines show the position of the mean 
for each group. 
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Figure 3-12: The expression and the levels of activated ERK-1 and ERK-2 in the lungs of Balb/c mice infected 
with F. tularensis LVS 
The expression of ERK-1 (A) and ERK-2 (B) and the levels of activated ERK-1 (C) and ERK-2 (D) were determined 
at several time points after infection, via the intranasal route, with 13,700 CFU of F. tularensis LVS. 
Representative western blots are shown below the corresponding graphs. Samples were taken from 5 mice at 
each time point (n = 5). Error bars show the standard error of the mean. Western blot image: L – MagicMark™ 
ladder; N – naïve; +ve – positive control. 
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Figure 3-13: The expression and the levels of activated JNK-1 and JNK-2/3 in the lungs of Balb/c mice 
infected with F. tularensis LVS 
The expression of JNK-1 (A) and JNK-2/3 (B) and the levels of activated JNK-1 (C) were determined at several 
time points after infection, via the intranasal route, with 13,700 CFU of F. tularensis LVS. Representative 
western blots are shown below the corresponding graphs. Samples were taken from 5 mice at each time point 
(n = 5). Error bars show the standard error of the mean. Western blot image: L – MagicMark™ ladder; N – 
naïve; +ve – positive control. 
A: JNK-1 B: JNK-2/3 
C: P-JNK-1 
kDa 
kDa 
 
 
60 
50 
40 
 
30 
 
20 
 
40 
 
30 
- JNK-2/3 
- JNK-1 
 
 
 
- β-actin 
- P-JNK-1 
 
 
 
 
- β-actin 
 
50 
 
40 
 
30 
 
 
20 
 
40 
 
30 
L           0 h          2 h        12 h       24 h      48 h       72 h         96 h      +ve        L 
L         0 h         2 h       12 h      24 h     48 h     72 h       96 h      -ve    +ve        L 
108 
 
 
 
0 2 12 24 48 72 96
0
20
40
60
80
100
Time post-infection (h)
O
p
ti
c
a
l 
d
e
n
s
it
y
re
la
ti
v
e
 t
o
-a
c
ti
n
 
0 2 12 24 48 72 96
0
20
40
60
80
100
Time post-infection (h)
O
p
ti
c
a
l 
d
e
n
s
it
y
re
la
ti
v
e
 t
o
-a
c
ti
n
 
 
 
 
 
 
 
 
 
 
 
 
0 2 12 24 48 72 96
0
50
100
150
200
250
Time post-infection (h)
O
p
ti
c
a
l 
d
e
n
s
it
y
re
la
ti
v
e
 t
o
-a
c
ti
n
 
0 2 12 24 48 72 96
0
2
4
6
8
10
Time post-infection (h)
O
p
ti
c
a
l 
d
e
n
s
it
y
re
la
ti
v
e
 t
o
-a
c
ti
n
 
 
 
 
 
 
 
 
 
Figure 3-14: The expression and the levels of activated p38 and MKP-1 in the lungs of Balb/c mice infected 
with F. tularensis LVS 
The expression of p38 (A) and MKP-1 (B) and the levels of activated p38 (C) and MKP-1 (D) were determined at 
several time points after infection, via the intranasal route, with 13,700 CFU of F. tularensis LVS. 
Representative western blots are shown below the corresponding graphs. Samples were taken from 5 mice at 
each time point (n = 5). Error bars show the standard error of the mean. Western blot image: L – MagicMark™ 
ladder; N – naïve; +ve – positive control. 
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Figure 3-15: Cytokine secretion in lungs of mice infected with LVS 
The secretion of MCP-1 (A), TNF (B), IFN-γ (C), IL-6 (D), GM-CSF (E), MIP-1α (F) and MIG (G) in the lungs of mice infected via 
the intranasal route with 13,700 CFU of F. tularensis LVS was measured by flow cytometry. Samples were taken from 5 
mice at each time point (n = 5). Error bars show the 95% confidence interval. Significant difference from 0 h was 
determined by a one-way ANOVA and a Dunnett’s multiple comparison post-test (* = p<0.05). 
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vitro infection of MH-S cells using a F. tularensis strain such as SchuS4. As for the LVS infection 
assays, samples of supernatants and lysates were collected at several time points following uptake 
of bacteria into the cells. Cytokine levels were measured in the supernatants, signalling protein 
activation was measured in the lysates and bacterial enumeration was also performed. 
 
In the first 6 h of infection, there was very little increase in bacterial numbers (Figure 3-16). Similarly 
to LVS, there was a slight decrease in bacterial numbers in the first 2 h of infection and then a 
plateau until the 6 h time point. Samples were taken for bacterial enumeration at 24 h post-uptake 
but viable bacteria could not be detected possibly due to high levels of cell death as a result of 
overwhelming bacterial numbers. Due to the requirement for this infection assay to be performed at 
ACDP level 3 there were no opportunities for the experiment to be repeated further for this study. 
 
The activation of signalling proteins was also measured using the cell lysate samples. From the 
western blots for JNK-1 and JNK-2/3, no significant alterations in the levels of activated protein could 
be detected throughout the infection (Figure 3-17). There appeared to be some down-regulation of 
activated protein when compared to the naïve cells but, due to the high level of error associated 
with the naïve samples, the down-regulation was only significant at a few of the time points 
measured. This data has similarity with the signalling profiles generated by F. tularensis LVS infection 
that also did not identify any alteration in JNK activation during infection (Figure 3-5). The activation 
profile for p38 is similar to that of JNK-1 and JNK-2/3. No significant alterations in the activation 
state of this protein was detected throughout the course of the infection (Figure 3-18) and, as for 
the JNK proteins, there was some indication of down-regulation in the infected cells compared to 
the naïve levels, which was only significant only at a few time points due to the large variability 
observed in the naïve cells. A lack of p38 activation by F. tularensis SchuS4 is in contrast to what was 
seen in MH-S cells infected with F. tularensis LVS. With LVS, although no late activation of p38 was 
observed, there was a transient activation of this protein very soon after infection (Figure 3-6). The 
issue of large variability in the naïve cell levels of proteins also meant that any alteration in the 
expression of IκBα and IκBβ could not be significantly differentiated from the levels of these proteins 
in uninfected cells (Figure 3-19). 
 
In contrast to the JNK proteins and p38, the screening of the ERK proteins during F. tularensis SchuS4 
infection shows some interesting alterations in their activation profiles (Figure 3-20). At 0 h post-
uptake there is a significant increase in activation of ERK-1 and ERK-2 compared to naïve cells. 
However, the activation is transient and decreases to the level observed in uninfected cell levels by 5  
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Figure 3-16. The survival of F. tularensis SchuS4 within MH-S cells  
MH-S cells were infected with F. tularensis SchuS4 at an MOI of 10. At 0 h, 0.08 h, 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 
h, 2 h, 4 h, and 6 h after the 30 min uptake period cells were lysed and bacteria were enumerated. Bacterial 
enumeration at 24 h (not shown) was not detectable. The experiment was performed in triplicate (n = 3) and 
each replicate was performed in duplicate. Error bars show the standard error of the mean.  
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Figure 3-17. The levels of activated JNK-1 and JNK-2/3 in MH-S cells throughout the course of a F. tularensis 
SchuS4 infection 
The levels of activated JNK-1 (A) and JNK-2/3 (B) were determined at several time points after the 30 min 
uptake period. A representative western blot is shown below the corresponding graphs. The experiment was 
performed in triplicate (n = 3) and each replicate was performed in duplicate. AU = arbitrary units. Error bars 
show the standard deviation. Significant difference from naïve levels was determined by one-way ANOVA and 
a Dunnett’s multiple comparison post-test (* = p<0.05). Western blot image: lane 1 – MagicMark™ ladder; lane 
2 – naïve; lane 3 – 0 h; lane 4 – 0.08 h; lane 5 – 0.25 h; lane 6 – 0.5 h; lane 7 – 0.75 h, lane 8 – 1 h; lane 9 – 1.5 
h; lane 10 – 2 h; lane 11 – 4 h; lane 12 – 6 h; lane 13 – 24 h; lane 14 – +ve; lane 15 – MagicMark™ ladder. 
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Figure 3-18. The levels of activated p38 in MH-S cells throughout the course of a F. tularensis Schu4 infection  
The level of activated p38 was determined at several time points after the 30 min uptake period. A 
representative western blot is shown below the corresponding graph. The experiment was performed in 
triplicate (n = 3) and each replicate was performed in duplicate. AU = arbitrary units. Error bars show the 
standard deviation. Significant difference from naïve levels was determined by one-way ANOVA and a 
Dunnett’s multiple comparison post-test (* = p<0.05). Western blot image: lane 1 – MagicMark™ ladder; lane 2 
– naïve; lane 3 – 0 h; lane 4 – 0.08 h; lane 5 – 0.25 h; lane 6 – 0.5 h; lane 7 – 0.75 h, lane 8 – 1 h; lane 9 – 1.5 h; 
lane 10 – 2 h; lane 11 – 4 h; lane 12 – 6 h; lane 13 – 24 h; lane 14 – +ve; lane 15 – MagicMark™ ladder. 
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Figure 3-19. The expression of IκBα and IκBβ in MH-S cells throughout the course of a F. tularensis Schu4 
infection  
The expression of IκBα (A) and IκBβ (B) was determined at several time points after the 30 min uptake period. 
Representative western blots are shown below the corresponding graphs. The experiment was performed in 
triplicate (n = 3) and each replicate was performed in duplicate. AU = arbitrary units. Error bars show the 
standard deviation. Significant difference from naïve levels was determined by one-way ANOVA and a 
Dunnett’s multiple comparison post-test (* = p<0.05). Western blot image: lane 1 – MagicMark™ ladder; lane 2 
– naïve; lane 3 – 0 h; lane 4 – 0.08 h; lane 5 – 0.25 h; lane 6 – 0.5 h; lane 7 – 0.75 h, lane 8 – 1 h; lane 9 – 1.5 h; 
lane 10 – 2 h; lane 11 – 4 h; lane 12 – 6 h; lane 13 – 24 h; lane 14 – +ve; lane 15 – MagicMark™ ladder. 
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Figure 3-20. The levels of activated of ERK-1 and ERK-2 in MH-S cells throughout the course of a F. tularensis 
SchuS4 infection  
The levels of activated of ERK-1 (A) and ERK-2 (B) were determined at several time points after the 30 min 
uptake period. A representative western blot is shown below the corresponding graphs. The experiment was 
performed in triplicate (n = 3) and each replicate was performed in duplicate. AU = arbitrary units. Error bars 
show the standard deviation. Significant difference from naïve levels was determined by one-way ANOVA and 
a Dunnett’s multiple comparison post-test (* = p<0.05). Western blot image: lane 1 – MagicMark™ ladder; lane 
2 – naïve; lane 3 – 0 h; lane 4 – 0.08 h; lane 5 – 0.25 h; lane 6 – 0.5 h; lane 7 – 0.75 h, lane 8 – 1 h; lane 9 – 1.5 
h; lane 10 – 2 h; lane 11 – 4 h; lane 12 – 6 h; lane 13 – 24 h; lane 14 – +ve; lane 15 – MagicMark™ ladder. 
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min post-uptake. The second feature of ERK activation in response to SchuS4 infection begins at 
approximately 0.25 h post-uptake and is characterised by a sustained activation which lasts through 
to 6 h post-uptake. The activation profile of ERK in response to F. tularensis SchuS4 infection closely 
matches the profile obtained from a F. tularensis LVS infection (Figure 3-8). In both cases a rapid yet 
transient early activation is followed by a late sustained activation of the ERK proteins. One 
difference in profiles observed between the two strains is the time at which the sustained activation 
begins. For F. tularensis SchuS4 the sustained activation of ERK occurs rapidly after infection (0.25 h) 
whereas for F. tularensis LVS the same pattern of sustained activation is not seen until later (1.5 h). 
 
3.3 Discussion 
The optimisation of in vitro F. tularensis LVS infection models involved establishing an inoculum 
preparation protocol and the determination of the appropriate MOI to use. This work was initially 
carried out in the J774A.1 macrophage-like cell line although optimisation was subsequently 
performed using the alveolar macrophage-like cell line, MH-S cells. A range of MOIs (10 – 150) were 
tested as previous studies have used various MOIs depending upon the aspect of infection being 
studied and the cell line being used 240,296,297,363. One study observed that to obtain high cytokine 
secretion, MOIs of above 100 were required, although this was in hepatic lymphocytes 364. In this 
study, an MOI of 150 established a strong infection with a high level of intracellular replication 
without inducing a significant amount of cell death in the time frame being examined and so a MOI 
of 150 was used for subsequent studies. Although the MOI selected may seem high, a previous study 
observed that murine macrophages required a MOI ten times higher than human macrophages to 
induce the same level of infection 307. After preliminary optimisation in J774A.1s, the infection model 
was altered to use MH-S cells. These cells are considered a more appropriate cell line to model a F. 
tularensis infection via the inhalational route as alveolar macrophages are one of the first cells to 
come in contact bacteria when the lung is the primary site of infection 38,93,285. Comparison of the 
growth curves of LVS within J774A.1s to those obtained from MH-S cells showed that uptake of the 
bacteria was similar in the two cell lines. Interestingly, the alveolar macrophages exhibited a 
superior resistance to intracellular growth (Figure 3-3) demonstrating nearly a 4 x log lower 
intracellular bacterial burden at 24 h post-uptake when compared to J774A.1s. This suggests that 
MH-S cells are more resistant to infection than J774A.1 and are likely a better model for in vivo lung 
macrophages whose function is to deal with pulmonary infection. 
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A more detailed examination of the bacterial burdens after infection showed that there is a 
significant decrease in bacterial numbers by 2 h after-uptake of LVS (Figure 3-4). This indicates that, 
at the early time points, the host cell is able to prevent replication of the bacteria and actually 
reduces the bacterial population by about 0.5 x log. Interestingly, a similar decrease in bacterial 
numbers is also observed with the more virulent SchuS4 strain suggesting that, at the early stages of 
infection at least, host cells are able to deal with even highly virulent F. tularensis. These early time 
points could correlate to the period of time the bacteria spend within the phagosome, exposed to 
bacterial killing mechanisms 230. However, upon escape from the phagosome F. tularensis is free to 
replicate and this is clearly observed in the growth profile of LVS which shows a 1.5 x log increase in 
bacterial numbers from 2 h to 24 h. A similar growth profile was observed in a study that infected 
J774A.1 cells with F. tularensis LVS where rapid bacterial replication was only present between 12 
and 24 h 365. In contrast, bacterial numbers of F. tularensis SchuS4 remain low until 6 h and no 
counts could be obtained from 24 h. One possibility is that the MH-S cells were able to limit the 
replication of F. tularensis SchuS4 and therefore clear the infection. This is doubtful as the cells were 
unable to prevent F. tularensis LVS infection and are therefore unlikely to be able to control infection 
by a more virulent strain. The more likely reason is that F. tularensis SchuS4 induced rapid cell death 
and was therefore lost into the supernatant giving a falsely low bacterial enumeration value. 
 
The rapid induction of cell death by SchuS4 may be due to the activation of the cytoplasmic 
receptor, AIM-2, that was recently identified as responsible for the detection of F. tularensis DNA 
329,329. Importantly, subsequent to AIM-2 activation is the construction of the caspase-1 
inflammasome complex which is integral to the secretion of IL-1β, IL-18 and the induction of cell 
death 29,30. Therefore, through the stimulation of AIM-2 signalling cascades, F. tularensis would be 
able to induce host cell death. Interestingly, in AIM-2-deficient mice, bacterial loads after F. novicida 
infection were greatly increased compared to wild-type mice indicating that AIM-2 is essential for 
generating an effective innate immune response 329. It would seem that the activation of AIM-2 is a 
fine balance between stimulating the cells to secrete pro-inflammatory cytokines and the induction 
of cell death. In this study, the ability of F. tularensis SchuS4 to induce cell death more rapidly than F. 
tularensis LVS could be due to a greater stimulation of AIM-2. This could be attributed to faster 
cytoplasmic replication or possibly a higher efficacy of F. tularensis SchuS4 DNA for AIM-2 compared 
to that of F. tularensis LVS DNA. 
  
In addition to the typical caspase-3-induction of cell death, signalling via the MAPK pathways has 
been linked to apoptosis.  Hrstka et. al. observed that a reduction in p38 activation and an increase 
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in ERK activation, after LVS infection, correlated with increased apoptosis 282. The in vitro signalling 
profiles generated in this study confirm these findings. Both F. tularensis LVS and SchuS4 infections 
displayed a suppression of p38 activation. LVS retained an early and transient activation of p38 but 
lacked any subsequent re-activation and SchuS4 demonstrated a sustained inactivation throughout 
the infection. The observed activation of p38 is in agreement with previous studies which showed 
that, in response to LVS infection, p38 is rapidly activated and demonstrated reduced activation by 2 
h 296. In contrast to p38, both strains of F. tularensis induced a sustained level of ERK activation 
although SchuS4 induced this earlier in infection. It is possible that F. tularensis induces apoptosis 
through the MAPK pathway enabling it to proliferate throughout the host. Although sustained 
activation of JNK has previously been correlated to cell death, this study detected no significant 
alteration in the activation state of JNK indicating that cell death induced by F. tularensis may only 
require the p38 and ERK pathways 152,366.  
 
The profiles observed in this study demonstrate a crucial aspect of signalling pathways; that it is not 
only whether a protein is activated or not that is important but also the temporal dynamics of the 
activation 152,367. Previous work has demonstrated differing roles for transient compared to sustained 
activation of both JNK and ERK proteins 154,367,368. In some cases, transient activation leads to cell 
survival whereas prolonged activation leads to cell apoptosis 152,282. By screening the activation of 
signalling proteins at multiple time points throughout infection, this study is able to discriminate 
between the two phases of signalling observed after LVS infection. The first phase, characterised by 
an early transient response of both p38 and ERK, and the second phase, characterised by repressed 
p38 activation and sustained ERK activation. In addition, a correlation can be made between the 
signalling phases and the intracellular life-cycle and replication of F. tularensis LVS. At 2 h after 
uptake the second phase of signalling begins and it is at this point that the bacterial numbers stop 
decreasing and begin increasing. It is possible that this switch correlates with the transition from the 
phagosome into the cytoplasm enabling the bacteria to replicate freely. At the same time, the 
change in intracellular compartment might induce the transition of signalling activation from the first 
phase to the second phase beginning the process of inducing apoptosis. The coordination of 
signalling and replication would enable F. tularensis to replicate to sufficient levels prior to being 
released from the cell via induction of apoptosis. 
  
To confirm that cytokines were being produced as a result of the infection, the levels of several pro-
inflammatory cytokines were measured in the supernatants collected from the F. tularensis LVS 
infected cells. This measurement showed that three cytokines were secreted at detectable levels. 
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Interestingly, each cytokine detected was secreted with a different temporal profile (Figure 3-10) an 
observation that has been seen in a previous study 298. MCP-1 was secreted rapidly after infection, 
TNF showed a more gradual secretion profile and IL-6 exhibited late stage secretion. The late 
secretion of IL-6 could be due to an induction mechanism involving TNF signalling via NF-κB 164. In 
LVS-infected MH-S cells, IL-6 only reached detectable levels in the supernatants late in infection. In 
contrast, TNF secretion began early in infection but at a relatively slow rate. Therefore, TNF may only 
have reached threshold levels for IL-6 induction at the later stages of infection explaining the delay 
until 6 h seen for IL-6 secretion. The rapid secretion of MCP-1 is perhaps not surprising as MCP-1 is a 
chemokine involved in attracting neutrophils to the site of infection. Neutrophils are one of the cell 
types that are heavily involved in the clearing of infection and therefore would be recruited soon 
after the detection of an invading organism. However, the recruitment of neutrophils could also be 
advantageous to the bacteria as F. tularensis has been shown to invade and replicate within this 
immune cell type 246-248. TNF was also secreted to a high level but this was a more gradual production 
exhibiting at least two “spikes” of secretion early after infection. TNF, IFN-γ and IL-12p70 have all 
been implicated in the resolution of F. tularensis infection and their secretion and function appear to 
be tightly linked through the mechanism of induction and synergy 41,297,308,309,311,334,335,364. Although no 
significant secretion of IL-12p70 or IFN-γ was detected from MH-S cells, it could be that this cell type 
is not responsible for the large amount seen in studies using in vivo models 306,308. Another study 
observed that although both macrophages and DCs could produce IL-12p40, only DCs could secrete 
IL-12p70 297. One reason for this may be that, in order to prevent an exacerbated immune response, 
different cell types are required to be present at the site of infection. If multiple cell types are 
recruited to the site of infection, the necessary signals to induce cytokine secretion will occur and 
the synergy between these cytokines produces the required immune response. If conditions to 
recruit multiple cell types are not met, only a mild response will be generated preventing damage 
through exacerbated inflammation. The response to LVS infection in this study is in agreement with 
an earlier study which observed secretion of MCP-1, IL-6 and TNF but not IL-12p70 or IFN-γ in LVS-
infected peritoneal macrophages 369. 
 
It is important to ascertain whether in vitro observations correspond to those observed in vivo. The 
cytokine analysis of the in vivo F. tularensis LVS infection verify the in vitro results as TNF, MCP-1 and 
IL-6 secretion was observed in the lungs of infected mice. Confirming earlier studies, IFN-γ was also 
detected 297,308. Interestingly, and in agreement with other studies, the secretion of all detected 
cytokines was delayed until 72 h after LVS infection 200,287. The reason for the delayed response is not 
fully understood as there is no evidence that F. tularensis secretes any immune-modulatory factors 
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although it does seem that it has a number of “passive” strategies for evading immune detection. 
Despite the massive secretion of cytokines late in infection, F. tularensis is not cleared from the host 
and the mice succumb to infection. This suggests that the level of cytokines produced is actually 
detrimental to the host as has been suggested by previous studies 200,370. In moribund mice, high 
levels of IL-6 and MCP-1 were detected in the lungs and spleen at day 7 post-challenge. In 
comparison, the levels of these two cytokines were very low in surviving animals 370. Similarly, 
elevated levels of IL-6 were found in mice infected with F. novicida when they were near death 200. 
These observations indicate that an immune response involving excessive secretion of MCP-1 and IL-
6 is actually detrimental and suggests that a less severe response may be beneficial to the host. 
 
As seen in the in vitro infection, it could be that F. tularensis modulates specific signalling proteins 
such as p38 and ERK, and the result of this is the delayed secretion of cytokines. However, it is 
difficult to tell from this study whether the in vitro activation of signalling proteins is apparent in an 
in vivo model. This is due to large variability in the levels of activation seen between lung 
homogenates and thus the ability to distinguish significant changes from uninfected controls is very 
difficult. To account for the variation between mice, another study could have been conducted using 
larger groups of mice at each time point. However, as the in vitro model is well defined and the 
cytokine profiles correlated well with those observed from the in vivo model, further studies into the 
signalling response generated by F. tularensis infection were continued using in vitro models. 
 
In summary: 
 MH-S cells initially demonstrate successful control and killing of LVS. However, from 2 h after 
uptake the numbers of intracellular bacteria increase through to 24 h. 
 In response to in vitro infection several signalling proteins, particularly p38 and ERK, display 
changing activation levels and the secretion of MCP-1, TNF and IL-6 is induced. 
 LVS successfully infects the lungs of BALB/c mice and replicates within this organ before 
proliferating into the liver, spleen and blood. 
 The cytokine response to in vivo infection is delayed until 72 h post-infection. 
 Increased virulence of F. tularensis SchuS4 compared to LVS could be in part due to an 
elongated and earlier period of sustained ERK activation inducing greater cell death. 
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Chapter 4: Targeted immune modulation 
 
4.1 Introduction 
Numerous pathogens, including bacteria and viruses, have developed mechanisms of evading or 
altering the immune response to their advantage. For most pathogens it involves the secretion of 
immuno-modulatory proteins that are able to interact with host signalling proteins and either block 
or enhance signalling 313-315,371,372. Vaccinia virus secretes two proteins named A52R and A46R that 
prevent signalling at two stages in the TLR-signalling cascade 314,315. A46R is able to bind to all four 
major TLR adaptors and prevent their recruitment to the TIR domain region of TLRs 314. A52R acts 
downstream and inhibits the formation of the TRAF-6 / IRAK-2 signalling complex, preventing the 
progression of signalling to NF-κB 315. Several bacterial species also use secreted proteins to interfere 
with host signalling. Salmonella enterica secretes protein A that impairs the TLR and MyD88-
associated activation of NF-κB 313. These modulation strategies involve the suppression of signalling. 
However, in some cases an up-regulation of the immune response is required for successful 
proliferation of the pathogen. For example, Yersinia sp. secrete a virulence factor called LcrV that 
signals through TLR2 inducing the secretion of IL-10, a potent immune-suppressive cytokine 371. The 
intracellular pathogen Listeria monocytogenes, also uses signalling activation to enhance its 
pathogenicity. Similarly to F. tularensis, L. monocytogenes, requires host cells to replicate within 
373,374. By up-regulating NF-κB activation, L. monocytogenes increases the expression of adhesins and 
the secretion of chemokines at the site of infection subsequently attracting phagocytes thereby 
increasing its replicative niche 372,375.  
 
F. tularensis also modulates innate immune signalling albeit with a more subtle approach than most 
other pathogens, resulting in it being designated, by some, as a stealth pathogen 317. Whilst situated 
outside a host cell, F. tularensis prevents its detection by expressing tetra-acylated LPS that exhibits 
a lower stimulatory action upon TLR4 than other LPS structures 322. This pathogen is also able to 
utilise complement, usually a host defence mechanism, to gain access to host cells without 
generating an immune response 320,321. Within host cells, F. tularensis continues to modulate the 
immune response. Inside the phagosome, F. tularensis prevents the correct assembly of oxidative 
species-producing complexes and within the cytosol it inhibits signalling induced by the NLR family 
of receptors 323-326. Clearly, at every stage of its intracellular lifecycle, from initial host cell entry 
through to the induction of apoptosis and subsequent re-infection, F. tularensis is interacting with 
immune signalling to create a more hospitable niche for its survival. The result is a complex immune 
122 
 
response characterised primarily by a suppression of cytokine secretion followed, after sufficient 
replication, by delayed and overwhelming inflammation 200.  
 
As a greater understanding of the variety of strategies used by pathogens to modulate the immune 
system has been generated, research has begun to examine the possibility of using the pathogens’ 
strategies as a template for therapeutic intervention 316,336,376,377. Initial research examined the use of 
TLR agonists and antagonists to stimulate or block particular pathways 340,376. Despite the ease with 
which modulation can be brought about with direct receptor stimulation, this approach to 
therapeutic intervention does have disadvantages. As the target is the first step in the pathway the 
modulation of signalling has a broad range of downstream effects. For example, by blocking TLR4 
activation, both the MyD88-dependent and TRIF-dependent pathways would be suppressed leading 
to widespread inhibition of transcription from IRFs, NF-κB and AP-1 transcription factors 101,132,134,378. 
Direct stimulation of PRRs as a therapeutic strategy has a high chance of activating numerous 
downstream signalling pathways leading to extensive cytokine production and, potentially, 
overwhelming inflammation. Stimulation of TLR9 with purified bacterial DNA in mice has induced 
protection from subsequent challenge with Listeria monocytogenes 336. In contrast though, 
treatment with CpG motifs adversely affected the survival of mice infected with F. tularensis SchuS4 
339. CpG stimulation had a beneficial outcome in another bacterial infection and protected mice 
challenged with B. pseudomallei 339. These data indicate that the success of therapeutic modulation 
is highly pathogen specific. 
 
The “next generation” of therapeutic modulation revolves around a more refined approach of 
targeting specific proteins located within the signalling pathways downstream of the PRRs. Signalling 
pathways respond to multiple and diverse stimuli therefore therapeutics designed to modify signal 
transduction have been investigated for many diseases as well as infection. Research has been 
carried out across numerous medical disciplines including Parkinson’s disease, hepatocellular 
carcinoma, rhabdomyosarcoma, septic shock and rheumatoid arthritis 316,344,377,379-381. Drugs 
specifically targeting the MAPK pathway have been used to treat both viral and bacterial infections 
382,383. Aerosol administration of the MEK inhibitor, U0126, successfully protected mice against a 
100x lethal viral challenge with Influenza A subtype H1N1 382. The entry of Yersinia into HeLa cells 
was prevented using wortmannin, a specific PI3-K inhibitor 383. Targeting signal transduction 
pathways, however, has rarely been completely successful. Mice pre-treated with the p38 inhibitor, 
SB203580, and subsequently challenged with intratracheal E. coli exhibited increased lung injury and 
decreased survival 384. The failure of targeting the signal transduction pathways has probably been 
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due to the lack of selectivity of inhibitors for a specific kinase, but as drug selectivity improves this 
problem is likely to diminish. 
 
Treatment of F. tularensis infection with immune-modulatory drugs has received less attention. One 
study has identified the signalling protein GSK3B as being a potential therapeutic target in F. 
tularensis infection 209. Inhibition of GSK3B, using lithium, reduced the inflammatory cytokine 
response and increased survival of mice challenged with F. tularensis LVS 209. As F. tularensis 
interacts with TLRs and has been shown to subvert innate immunity, immune signalling pathways 
are a potential target for drug therapeutics in the future. 
 
4.2 Aims and Objectives 
The aim of this chapter was to investigate whether inhibition of specific signalling proteins could 
alter the outcome of infection with F. tularensis. 
 
The specific aims of this chapter were to: 
 Determine whether ERK inhibition affects the survival of LVS within MH-S cells. 
 Determine the effect of ERK inhibition on the secretion of cytokines by MH-S cells in 
response to LVS infection. 
 Determine whether ERK inhibition improves the outcome of F. tularensis LVS infection in 
mice. 
 
4.3 Results 
4.3.1 Targeting ERK activation in vitro 
My work and published data shows that infection of cells by F. tularensis induces a signalling 
response, involving the activation of multiple proteins, partly induced by TLRs (Section 3.2) 
300,305,328,363,369. Characterisation of the signalling cascade identified the signalling protein ERK as being 
important in the response to F. tularensis LVS. The stimulation of ERK, by F. tularensis LVS infection 
in vitro, resulted in a very clear bi-phasic profile, with early transient activation and late sustained 
activation (Figure 3-8). Previous studies have observed a detrimental effect of sustained MAPK 
activation on host cells and, in this study, sustained ERK activation coincided with bacterial 
replication (Figure 3-4) 140,282,366,385. Inhibition of ERK, during the late stages of infection, could re-
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balance the response preventing F. tularensis LVS replication and possibly aiding the resolution of 
infection.  
 
Several ERK inhibitors are commercially available. PD0325901 can be given by oral gavage and has 
demonstrated a high degree of specificity and good efficacy in previous in vivo studies 343,344,386. In a 
study treating cancerous cells in the flanks of mice, PD0325901 was given by oral gavage and 
systemic inhibition of ERK was shown even 24 h after treatment 344. Importantly, PD0325901 is not a 
direct ERK inhibitor and interacts with the upstream protein MEK-1/2 343. However, the MEK proteins 
have very specific substrates and so it is likely that inhibition of MEK will only prevent the activation 
of ERK and not the other major MAPKs, JNK and p38 96,367. 
 
The potential for PD0325901 to inhibit ERK activation was first examined in vitro using the murine 
alveolar macrophage-like MH-S cell line infected with F. tularensis LVS. The cells were infected with 
F. tularensis LVS (t = -2 h) and the cells were allowed to take up the bacteria for 2 h. Media was 
removed and free bacteria were washed off the cells with PBS and fresh media added (t = 0 h). As a 
control, some cells were left uninfected (naïve). PD0325901 was added to the cells at either 0 h or 2 
h after the removal of free bacteria. At multiple time points after infection, supernatants and cell 
lysates were collected for cytokine analysis and screening for signalling protein activation and 
bacterial enumeration was also carried out.  
 
Consistent with published data, PD0325901 specifically inhibited ERK activation (Figure 4-1 A, B) 
343,344,386. When the cells were treated at the point of removing free bacteria (0 h) there was no 
measurable activation of ERK and this was maintained through to 24 h. When addition of PD0325901 
was delayed until 2 h post-infection, the level of ERK activation at 0 h was no different than in cells 
without PD0325901. However, as expected, from 4 h the activation of ERK was entirely suppressed 
and this was maintained through to 24 h. To ensure PD0325901 was specifically inhibiting the 
activation of ERK and not other, structurally similar, MAPKs the activation of p38 was also measured. 
No significant inhibition was observed in either of the two PD0325901 groups when compared to 
untreated controls (Figure 4-2). The effect of ERK inhibition on the production of immune mediators 
was determined by measuring the level of inflammatory cytokine secretion. The inhibition of ERK 
activation correlated with a decrease in cytokine secretion in response to LVS infection (Figure 4-3 
A,B). Secretion of IL-6 showed a significant decrease in both PD0325901 groups at 24 h compared to 
the levels observed in untreated controls (Figure 4-3 A). When PD0325901 was added at 0 h, the 
secretion of TNF showed a reduced level from 1 h post-uptake through to 24 h. 
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Figure 4-1: The levels of activated ERK-1 and ERK-2 in PD0325901-administered MH-S cells throughout the 
course of a F. tularensis LVS infection 
The levels of activated ERK-1 (A), ERK-2 (B) were determined at several time points after the uptake of LVS. 
Representative western blots are shown on the opposite page. The experiment was performed in triplicate 
(n=3) and each replicate was performed in duplicate. Error bars show the min and max. Western blot images: L 
– Ladder; N – Naïve. 
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Figure 4-2: The levels of activated p38 in PD0325901-treated MH-S cells throughout the course of a F. 
tularensis LVS infection 
The levels of activated p38 were determined at several time points after the uptake of LVS. Representative 
western blots are shown above the corresponding graph. The experiment was performed in triplicate (n=3) 
and each replicate was performed in duplicate. Error bars show the min and max. Western blot image: L – 
Ladder; N – Naïve. 
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Figure 4-3: The secretion of cytokines and bacterial burdens of MH-S cells treated with PD0325901 (0.05 µM) 
and infected with F. tularensis LVS 
The secretion of IL-6 (A) and TNF (B) was determined at several time points after the uptake of LVS. 
Enumeration of bacteria was also performed (C). The experiment was performed in triplicate (n=3) and each 
replicate was performed in duplicate. Error bars show the min and max. Significant difference from untreated 
levels was determined by a one-tailed, unpaired t-test (* = p<0.05). 
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However, when PD0325901 was added at 2 h a reduced level of TNF secretion, compared to 
untreated, was only observed from 4 h (Figure 4-3 B). This indicates that the reduction in the levels 
of cytokine secretion is specifically due to ERK inhibition by PD0325901 as a reduction of TNF 
secretion is only observed after addition in each case. Finally, bacterial enumeration was carried out 
to see if ERK inhibition resulted in a lower bacterial burden within the host cells. 
 
Despite the differences observed in ERK activation and cytokine secretion, no alteration in 
intracellular bacterial numbers was seen in either PD0325901 group compared to untreated cells 
(Figure 4-3 C). The growth profiles from all groups displayed the usual pattern of limited replication 
in the first 4 h followed by an increase in bacterial numbers up to 24 h. 
 
4.3.1 Cytotoxicity of PD0325901 
The activation of ERK has been shown to closely correlate with the balance between cell survival and 
apoptosis 282. Whether activation is prolonged or transient seems to determine the outcome of the 
signalling pathway. As F. tularensis infection causes apoptosis of host cells, the effect of ERK 
inhibition on cell death is an important factor to take into account when considering signalling 
modulation 284,287,288. 
 
To determine the effect upon cell death of PD0325901 in infected and uninfected cells, PD0325901 
was added to MH-S cells at a range of concentrations (0.005 µM – 5 µM) for 24 h. The level of 
cytotoxicity induced by LVS and PD0325901 addition was examined using an LDH assay (Figure 4-4). 
In addition, supernatants were collected to allow analysis of the impact of PD0325901 concentration 
on cytokine secretion (Figure 4-5). At all concentrations tested, except 0.005 µM, and in both the 
presence and absence of LVS, PD0325901 induced significantly higher cell death than naïve cells. 
However, LVS also induced greater cytotoxicity than naïve cells and only PD0325901 given at 0.5 µM 
and 5 µM at 0 h in the presence of LVS induced significantly greater cell death than LVS only. This 
indicates that PD0325901, at low concentrations, does not enhance the cytotoxicity already induced 
by LVS. From the data collected from LVS-infected cells, it can be seen that for the three highest 
concentrations there is a significant decrease in cytotoxicity observed if addition of PD0325901 is 
delayed for 2 h when compared to the same concentration given at 0 h (Figure 4-4 B). The difference 
when PD0325901 is added at 0 h and 2 h is only seen when LVS is present and is absent from the 
data collected from uninfected cells (Figure 4-4C). 
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Figure 4-4: The cytotoxicity induced by F. tularensis LVS infection and PD0325901 (µM) treatment of MH-S 
cells 
The % cytotoxicity was determined, using a LDH assay, 24 h after infection of MH-S cells with F. tularensis LVS. 
(A)Full range of treatment groups. (B) Focussed on LVS infected cells. (C) Focussed on uninfected cells. The 
experiment was performed in triplicate (n=3) and each replicate was performed in duplicate. Error bars show 
the min and max. Significant difference from either untreated or LVS only was determined by one-way ANOVA 
and a Dunnett’s multiple comparison post-test (* = p<0.05). Significant difference between treatment times 
was determined by a one-tailed, unpaired t-test (* = p<0.05). 
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Figure 4-5: The secretion of cytokines by MH-S cells infected with F. tularensis LVS and treated with 
PD0325901 (µM) 
The secretion of IL-6 (A) and TNF (B) was measured 24 h after infection of MH-S cells with F. tularensis LVS. The 
experiment was performed in triplicate (n=3) and each replicate was performed in duplicate. Error bars shows 
95% confidence interval. Significant difference from LVS only was determined by one-way ANOVA and a 
Dunnett’s multiple comparison post-test (* = p<0.005). Significant difference between treatment groups was 
determined by a one-tailed, unpaired t-test (* = p<0.05) 
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From the same experiment, supernatants were collected to observe the effect of PD0325901 
concentration on the secretion of IL-6 and TNF (Figure 4-5). Infection of cells with LVS induced a 
strong secretion of both IL-6 and TNF which was not observed in naïve cells. Secretion of IL-6 and 
TNF exhibited a clear dose-dependent inhibition independent of whether PD0325901 was added to 
the cells at 0 h or 2 h post-uptake. All concentrations of PD0325901, except 0.005 µM, irrespective of 
the time it was added, significantly reduced the level of IL-6 secretion compared to the level seen in 
LVS only cells (Figure 4-5 A). Addition of PD0325901 at each concentration at 0 h, except 0.005 µM, 
reduced IL-6 secretion to lower levels than seen in the 2 h groups given the same concentration. For 
TNF, only PD0325901 at 0.05, 0.5 and 5 µM given at 0 h significantly reduced secretion below that 
seen in LVS only cells (Figure 4-5 B). Every concentration of PD0325901, given at 0 h, significantly 
reduced TNF secretion below the level observed in the corresponding 2 h groups. 
 
4.3.2 Targeting ERK activation in vivo 
The potential for ERK inhibition, through PD0325901 addition, to improve the outcome of infection 
in vivo was determined using the murine model of infection. Groups of Balb/c mice were infected via 
the intranasal route with a lethal dose of LVS (2 x 104 CFU). The mice were either left untreated, 
treated daily from 24 h pre-infection or daily from 48 h post-infection. Groups of mice were culled at 
48 h and 96 h and the lungs, liver and spleen were removed and analysed for cytokine secretion and 
bacterial counts. The level of activated ERK was also determined in the lungs. 
 
The level of ERK activation in the lung was determined by western blot analysis of the homogenates 
using antibodies specific for the phosphorylated states of ERK-1 and ERK-2. In naïve mice, no 
elevation in the level of ERK activation was observed across the 96 h indicating that it is infection by 
F. tularensis LVS that is the cause of ERK activation (Figure 4-6 A, B). In mice infected with LVS and 
treated with PBS there was a substantial increase in the level of ERK activation from 48 h to 96 h. 
Daily treatment with PD0325901 significantly reduced the level of both ERK-1 and ERK-2 activation in 
the lungs of mice compared to PBS treated mice at 96 h (Figure 4-6 A, B). This was the case for both 
the treatment groups irrespective of whether the treatment began at 24 h pre-infection or 48 h 
post-infection. Interestingly, at 48 h PD0325901-treated mice demonstrated an increase in ERK 
activation compared to PBS-treated mice. This is in contrast to the expected result as PD0325901 is 
an ERK inhibitor but in this case it seems to be enhancing ERK activation. 
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Figure 4-6: The levels of activated ERK-1 and ERK-2 in the lungs of F. tularensis LVS infected Balb/c mice 
treated with either PBS or PD0325901 (0.05 µM) 
 
Groups of 5 mice (n = 5) were challenged via the intranasal route with 20,000 CFU of F. tularensis LVS.  On day 
2 and 4 post-challenge, the lungs were removed, homogenised and screened for the levels of activated ERK-1 
(A) and ERK-2 (B). Naïve = uninfected, PBS = infected and treated daily with PBS from 24 h pre-challenge, PD (-
1) = infected and treated daily with PD0325901 from 24 h pre-challenge, PD (+2) = infected and treated daily 
with PD0325901 from 48 h post-challenge. Representative western blots are shown on the opposite page. 
Significant difference from PBS-treated group was determined by a one-tailed, unpaired t-test (* = p<0.05). 
Error bars show the min and max. Western blot image: L – Ladder; N – Naïve; -ve – negative control; +ve – 
Positive control. 
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Similarly to the treatment of in vitro LVS infection, the effect of in vivo ERK inhibition on the 
inflammatory response was examined by measuring the secretion of downstream inflammatory 
cytokines in the lungs, liver and spleen of naïve, PBS treated or PD0325901 treated Balb/c mice 96 h 
after infection. Despite the observed inhibition of ERK activation in the lungs of mice at 96 h, no 
reduction in the secretion of any of the measured cytokines (IFN-g, MCP-1, IL-6 and TNF) was seen at 
the primary site of infection, the lungs (Figure 4-7 A-D). In addition, there was no observed decrease 
in the secretion of any cytokine in the liver of pre-treated compared to PBS treated mice. In mice 
treated 48 h post-infection with PD0325901 there was a significant increase in IFN-γ and MCP-1 in 
the liver compared to PBS treated mice. However, the greatest effect of ERK inhibition was observed 
in the spleen. No change in cytokine secretion was observed in mice treated post-infection but, for 
all cytokines screened, a significant reduction in secretion was observed in the spleen of pre-treated 
mice compared to PBS treated mice. 
 
To examine the effect of ERK inhibition on bacterial loads in the organs of mice, bacterial 
enumeration was carried out on samples taken from the lungs, liver and spleen 96 h post-infection. 
In agreement with the in vitro data, where ERK inhibition had no effect on bacterial burdens (Figure 
4-3), there was no significant difference in the numbers of bacteria present in the lungs of either 
PD0325901 treated groups compared to PBS treated mice (Figure 4-8 A). In contrast, although no 
changes were seen in mice treated post-infection, bacterial burdens in both the liver and spleen 
were reduced in the pre-treated groups compared to PBS treated mice (Figure 4-8 A). However, 
despite the successful inhibition of ERK in the lungs and the reduced bacterial burdens in the spleen 
and liver, there was no alteration in survival of any of the PD0325901 treated groups compared to 
the PBS treatment groups as all the mice, except one from the PBS group, were culled on either day 
8 or day 9 after infection (Figure 4-8 B). 
 
4.4 Discussion 
The characterisation of TLR signalling induced by F. tularensis infection suggested ERK was a 
potential target for therapeutic immune-modulation. PD0325901 was selected from a range of 
commercial inhibitors and its suitability for use as an immune-modulator was assessed firstly in vitro 
and subsequently in vivo. PD0325901 functions by binding to a non-adenosine triphosphate binding 
site on MEK-1/2 inducing a conformational change that prevents the subsequent binding and 
activation of ERK 387. PD0325901 has previously been used in the treatment of cancer in several 
murine models and was demonstrated to be specific and efficacious in its ability to inhibit ERK   
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Figure 4-7: Cytokine secretion in the organs of Balb/c mice infected with F. tularensis LVS and treated with 
PBS or PD0325901 (0.05 µM) 
 
Groups of 5 mice (n = 5) were challenged via the intranasal route with 20,000 CFU of F. tularensis LVS. On day 
4 post-challenge the organs or infected mice were removed, homogenised and the levels of IFN-γ (A), MCP-1 
(B), IL-6 (C) and TNF (D) were determined. Naïve = uninfected, PBS = infected and treated daily with PBS from 1 
day pre-challenge, PD (-1) = infected and treated daily with PD0325901 from 24 h pre-challenge, PD (+2) = 
infected and treated daily with PD0325901 from 48 h post-challenge. Significant difference from PBS-treated 
group was determined using a one-tailed, unpaired t-test (* = p<0.05).Error bars show the min and max.  
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Figure 4-8: Bacterial burdens of organs and survival of Balb/c mice infected with F. tularensis LVS and 
treated with PBS or PD0325901 (0.05 µM) 
 
Groups of 5 mice (n = 5) were challenged via the intranasal route with 20,000 CFU of F. tularensis LVS. On day 
4 post-challenge the organs or infected mice were removed, homogenised and bacterial enumeration was 
performed (A). PBS = infected and treated daily with PBS from 24 h pre-challenge, PD (-1) = infected and 
treated daily with PD0325901 from 24 h pre-challenge, PD (+2) = infected and treated daily with PD0325901 
from 48 h post-challenge. Significant difference from PBS-treated group was determined using a one-tailed, 
unpaired t-test (* = p<0.05). Error bars show the min and max. (B) 10 mice in each group were used for a 
survival study (n=10). Balb/c mice were infected via the intranasal route with 20,000 CFU F. tularensis LVS and 
treated daily with either PBS or PD0325901. The animals were scored daily and were culled upon reaching the 
humane endpoint. No significant difference was observed in survival for any treatment group when compared 
to PBS-treated animals. 
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activation 344,388. After dosing by oral-gavage, the systemic activation of ERK is inhibited for up to 24 
h in both the flanks and prostates of mice 344,388. As in previous studies, administration of PD0325901 
in vitro initially demonstrated good specificity and efficacy as it suppressed the activation of ERK for 
at least 24 h whilst not affecting the activation of another MAPK, p38 (Figure 4-1). In addition, 
targeted inhibition of ERK strongly correlated with the suppression of IL-6 and TNF secretion (Figure 
4-3 A and B).  
 
Interestingly, even when ERK was inhibited from 0 h there was an initial secretion of TNF observable 
at 1 h post-uptake. This may be explained by the role that ERK activation plays in the secretory 
pathway of TNF. TNF secretion involves several stages including transcription, transport of mRNA 
from the nucleus to the cytoplasm and then translation 389-391. ERK activation is required for the 
transport of TNF mRNA into the cytoplasm 392. Therefore, in the presence of PD0325901, the 
transport of newly transcribed mRNA cannot take place and only mRNA already present in the 
cytoplasm can be translated resulting in a plateau of TNF secretion at 500 ρg/ml. The importance of 
ERK activation for efficient secretion of TNF is consistent with previous studies 392,393. One group 
examining the role of a signalling protein upstream of ERK observed that TNF secretion by peritoneal 
macrophages and BMDMs, in response to LPS stimulation, was completely abrogated in the absence 
of ERK activation 392. Similarly, inhibition of ERK activation using U0126 prevented TNF secretion by 
monocytes stimulated with a biological response modifier, OK-432 393. For the 2 h treated group, the 
plateau of TNF levels occurs at a slightly higher concentration (750 ρg/ml) than the 0 h treated group 
possibly due to a greater amount of nucleocytoplasmic transport of TNF mRNA before the inhibitor 
is added. However, once the effects of ERK inhibition are imposed mRNA transport ceases and TNF 
levels plateau. The levels of IL-6 in both treated groups were significantly lower than in untreated at 
24 h. However, for all groups, IL-6 levels are a lot higher than the levels of TNF produced by the same 
cells. The greater levels of IL-6 compared to TNF could be explained by the differences in their mRNA 
stability. The half-life of IL-6 mRNA, in stimulated macrophages, is more than 20 h whereas for TNF 
mRNA is nearer 75 min 394. Therefore, the majority of the IL-6 mRNA present in the cytoplasm prior 
to ERK inhibition would still be present for translation throughout the time course of the 
experiment. In contrast, the TNF mRNA rapidly degrades and would require constant replenishment 
from the nucleus to obtain similar secretion levels to IL-6. The correlation of mRNA stability with 
secretion levels has been demonstrated in a separate study which observed a 70% decrease in IL-6 
protein biosynthesis when the half-life of IL-6 mRNA was reduced from 20 h to 2 h 394. Similarly, the 
secretion of TNF was enhanced by stimulation of RAW264.7 macrophages with LPS and this 
correlated with an increase in half-life from 30 min to 80 min 395.  
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However, despite successful inhibition of both protein activation and cytokine secretion there was 
no observable alteration in bacterial numbers (Figure 4-3 C). Irrespective of treatment group, LVS 
successfully replicated within MH-S cells throughout the course of the infection. This is in agreement 
with another study that exhibited an unaltered increase in bacterial numbers despite successful 
inhibition of ERK signalling inhibition, albeit with a different inhibitor to the one used in my work 282.  
 
One explanation for the observed result could be the close link between ERK activation and the 
regulation of cell death 385,396. From my work the induction of MCP-1 secretion in MH-S cells was a 
result of F. tularensis infection and the production of this chemokine could lead to the recruitment 
of immune cells such as neutrophils. Other studies have also observed an influx of immune cells 
following F. tularensis infection 397,398. As an intracellular pathogen F. tularensis requires host cells to 
replicate and it could be that the recruitment of immune cells is a pathogenic strategy to enlarge its 
replicative niche. Other intracellular pathogens use the recruitment of immune cells to ensure 
efficient replication and proliferation. L. monocytogenes secretes listeriolysin O that activates the IKK 
complex inducing transcription by NFκB resulting in the up-regulation of adhesion molecules on 
endothelial cells 372,375. These adhesins “trap” immune cells, such as neutrophils, providing a 
replicative niche for the bacteria. F. tularensis LVS was recently shown to not only survive and 
replicate within neutrophils but also inhibit the induction of apoptosis 399, a survival mechanism used 
by other pathogens such as N. gonorrhoeae and C. pneumoniae 396,400,401.  The treatment of MH-S 
cells with PD0325901, inhibiting ERK activation and thereby delaying the induction of cell death, 
potentially increases the number of cells available for LVS to invade and survive within. This 
hypothesis is consistent with a previous study that demonstrated that the inhibition of ERK, using 
the indirect MEK-inhibitor PD098059, prevents macrophage apoptosis and necrosis after LVS 
infection 282. To determine if a reduction in ERK-mediated apoptosis was causing the lack of 
difference between treated and untreated bacterial counts, a LDH assay was done to measure the 
level of cell death. In contrast to the previous study, which observed a decrease in cell death 
correlating to ERK inhibition 282, treatment of MH-S cells with PD0325901 did not reduce the level of 
cell death (Figure 4-4). In fact, at high concentrations of PD0325901, there was a slight increase in the 
level of cell death. A possible reason for the discrepancy between these studies is the use of 
different cell lines as the infection model. The previous study used the macrophage-like J774.2 cell 
line whereas this study used the alveolar macrophage-like MH-S cell line. From the preliminary 
experiments carried out at the start of this study comparing the growth of LVS in two separate cell 
lines, it is clear that there are major differences between cell types (Figure 3-3). In J774 cells, LVS is 
able to replicate to a much larger degree than in MH-S cells indicating different abilities of these cell 
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types to respond to infection. The altered growth rate, and corresponding bacterial burden at 24 h 
after infection, could explain the different effects of ERK inhibition observed between cell lines.  In 
J774A.1 cells the high bacterial burden induces cell death mechanisms which can be inhibited by 
PD0325901. However, the reduced growth rate seen in MH-S cells may not generate the required 
bacterial burden threshold to induce cell death and so there is no signalling activation for 
PD0325901 to inhibit. As such, no significant difference in cell death can be observed between un-
treated and PD0325901-treated MH-S cells. The possibility of slower growth preventing apoptosis is 
confirmed by other studies that demonstrate a reduction of cell death when bacterial replication is 
prevented 365,402,403. One study observed that rapid intracellular growth of F. tularensis in J774A.1 
cells resulted in pronounced apoptosis 365. However, if intracellular bacteria were prevented from 
replicating host cell cytopathogenicity and apoptosis was prevented 365. Another difference between 
the two studies is the inhibitor administered to inhibit ERK signalling. The previous study used 
PD098059 and this study used PD0325901 282. Although both are commercially available and are 
described as MEK-specific inhibitors, it is possible that the specificity of each of these inhibitors 
differs leading to a variation in their effect on signalling pathways. It seems then, at least in vitro, a 
link between ERK inhibition and the prevention of cell death does not explain the lack of a reduction 
in F. tularensis LVS numbers. 
 
Although, there are limitations in characterising the potential benefit of an ERK inhibitor in an in 
vitro model, the data does provide essential information on the specificity and efficacy of 
PD0325901. For example, in a natural infection different cell types work in synchrony in order to 
produce a full and effective immune response. This has been demonstrated in the hepatic response 
to F. tularensis infection where natural killer cells, T cells and DCs were required to generate the full 
cytokine response 297. In contrast, the in vitro model has only one cell type present preventing the 
usual cell-cell interaction and cooperation found in a natural infection. Therefore, an in vivo study 
was carried out to enable the analysis of a more complex immune response generated by F. 
tularensis LVS and modulated by treatment with PD0325901. 
 
The ERK inhibitor, PD0325901, has previously been administered in an in vivo setting examining its 
possible use as an anti-tumour treatment 344,388. From these previous studies, information about the 
route of dosing and the pharmacokinetics of the drug was available. It was decided to dose Balb/c 
mice daily via oral-gavage. One alteration to the dosing schedule used in other studies is the 
concentration of drug used. The preliminary investigations carried out in this study showed that 
PD0325901 demonstrated good efficacy at lower concentrations (0.05 µM) than the supplier’s 
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suggested working concentration (0.5 µM). In addition, high concentrations display cytotoxic effects 
(Figure 4-4) and so the lower concentration (0.05 µM) was used. 
 
Treatment with PD0325901, via oral-gavage, suppressed the systemic level of activated ERK protein 
in the lungs of treated mice at 96 h (Figure 4-6) 344,388. Surprisingly, at 48 h, mice pre-treated with 
PD0325901 displayed an increase in ERK activation in the lungs compared to PBS-treated mice. One 
possible explanation for this is related to the way that PD0325901 prevents ERK activation. 
PD0325901 functions as a competitive inhibitor by binding to a non-adenosine triphosphate binding 
site on MEK-1/2 inducing a conformational change that prevents the binding of ERK (Figure 4-9A) 387. 
It is possible that F. tularensis may secrete a protein that is able to prevent ERK activation in a 
manner similar to PD0325901. Although no effector proteins have been confirmed in F. tularensis, 
this pathogen does express a type VI secretion system 261. Type VI secretion systems are used by 
numerous pathogens including Burkholderia mallei, Vibrio cholera and P. aeruginosa to secrete 
effector proteins into target cells 404-408. It is highly likely that un-identified effectors exist that are 
secreted through the F. tularensis type VI secretion apparatus. The delay in cytokine secretion in 
response to F. tularensis infection in vivo further supports the theory of secreted effector proteins 
modulating immune signalling. If either PD0325901 or the putative F. tularensis protein is present 
alone they would bind to MEK-1/2 and interrupt ERK activation (Figure 4-9B). However, in my work, 
when PD0325901 and F. tularensis are present in the lungs at the same moment there is actually an 
increase in ERK activation. One mechanism whereby the combination of two inhibitors could induce 
an increase in ERK activation is if there is an interaction between the inhibitors themselves that 
prevents their correct binding to their target, MEK-1/2 (Figure 4-9C). This would enable MEK-1/2 to 
activate ERK in the usual manner leading to the increase in ERK activation observed at 48 h in 
PD0325901-treated mice challenged with F. tularensis LVS. Further studies would be required to 
identify potential F. tularensis effector proteins and determine if an interaction with PD0325901 is 
possible. This is not the only potential explanation for the observed result as the regulation of ERK 
activation is highly complex involving at least two negative regulators MKP-3 and phosphatase of 
activated cells (PAC)-1) 409,410. The activity of MEK-1/2 is also regulated by phosphorylation of specific 
serine residues 411. Phosphorylation of Ser298 and Ser212 can enhance or decrease MEK-1/2 activity, 
respectively 412,413. Clearly, there are multiple pathways by which F. tularensis could modulate ERK 
activation. Indeed several bacterial pathogens interact with and modulate ERK activation in different 
ways. Staphylococcus aureus secretes haemolysins that modulate ERK activation whereas L. 
monocytogenes activates ERK via the TLR2 and RIP-2 pathways inducing autophagy 272,414. In contrast 
to 48 h, ERK activation at 96 h is dramatically increased in PBS- 
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Figure 4-9: Theoretical models of ERK inhibition and activation involving interactions between PD0325901, 
MEK-1/2 and an unidentified F. tularensis effector protein 
The usual activation of ERK (A) involves the binding of ERK to MEK-1/2 inducing the phosphorylation of specific 
residues. PD0325901 inhibits the activation of ERK by binding to a non-adenosine triphosphate binding site on 
MEK-1/2 causing a conformational change that prevents the binding of ERK (B). It is possible that an 
unidentified F. tularensis protein (Ft #1) also indirectly inhibits the activation of ERK through MEK-1/2 binding. 
Therefore, when PD0325901 or the unknown protein is present MEK-1/2 is unable to activate ERK (B). In the 
case where both PD0325901 and the F. tularensis protein are present an interaction between these two 
inhibitors prevents them binding to MEK-1/2 (C). Therefore, MEK-1/2 does not undergo a conformational 
change and ERK can be activated in the usual manner. 
 
 
 
 
 
 
 
A 
B 
C 
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treated mice indicating that the mechanism of ERK inhibition has been released. In PD0325901-
treated mice, although the F. tularensis-associated inhibition has been released, the inhibition due 
to PD0325901 is still present and so the level of ERK activation is decreased compared to PBS-
treated mice.  
 
Interestingly, although ERK activation is significantly reduced in the lungs of infected mice at 96 h, 
there was no alteration in bacterial burden or cytokine secretion in this organ, the primary site of 
infection. One explanation for the lack of a decrease in cytokine expression in the lungs, despite 
effective ERK inhibition, could be the requirement for a controlled, rapid and robust immune 
response in order to resolve infection 415,416. Due to their location and function as an air-fluid 
interface, the lungs are particularly susceptible to infection by multiple pathogens and the potential 
outcomes of respiratory infection are severe 417. As such, it may be that the signalling pathways 
activated in pulmonary immune and epithelial cells contain a high level of redundancy or complexity 
to ensure that a proportional yet robust immune response is generated irrespective of the pathways 
involved. If this is case, inhibition of ERK alone would not be sufficient to affect cytokine secretion 
and inhibition of multiple MAPKs or members of other signalling protein families may be required to 
dampen the cytokine response. For example, using a human lung slice model of B. anthracis 
infection a combination of three inhibitors targeting p38, JNK and ERK were required to prevent 
cytokine secretion 415. 
 
In contrast to the data from the lungs, a reduced bacterial burden was observed in the liver and 
spleen indicating that the treatment was decreasing the systemic spread of F. tularensis LVS to 
secondary sites of infection (Figure 4-8). The reason behind reduced systemic spread could be down 
to the link between ERK activation and host cell death. In several other bacterial infections, an 
association between ERK and the induction of apoptosis has been observed, although the exact 
correlation differs depending on the infecting organism 385,396. It seems that the anti-apoptotic 
properties of Chlamydia are due to the activation of the Raf/MEK/ERK pathway whereas 
Helicobacter pylori induces ERK-dependent AP-1 transcription to bring about apoptosis in 
macrophages 385,396. Although in vitro data from this study indicates that ERK inhibition does not 
affect cell death, it is possible that in an in vivo setting this may not be the case. The induction of cell 
death by apoptosis is a strategy of F. tularensis to promote its survival and proliferation as it releases 
the bacteria allowing systemic spread 284,287,288. In this study, by reducing the level of ERK activation 
in the lung, the infected immune cells at the primary site of infection might exhibit reduced cell 
death. This would trap the bacteria within alveolar macrophages and neutrophils reducing the 
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number that are able to escape the lung and disseminate to other organs. This hypothesis fits the 
bacterial counts observed in this study, as there is no alteration in numbers of LVS present in the 
lung, where bacteria are potentially trapped within immune cells, but a decrease in both the liver 
and spleen is observed compared to PBS-treated controls. The mechanism of “trapping” bacteria 
within lung macrophages, and thereby restricting bacterial dissemination from the lungs to other 
organs as a therapeutic approach, has not been widely examined. However, one field of research 
that has received much interest is that of sepsis. Bacterial sepsis develops when the bacteria 
overwhelm the local containment and enter the general circulation causing excessive systemic 
inflammation that may eventually lead to multi-organ failure and death 418. As such, the possibility of 
restricting the dissemination of bacteria from the local containment has been studied as a 
therapeutic approach. One study observed that blocking scavenger receptors prevented bacterial 
proliferation from local containment and increased survival of C57BL/6 mice after cecal ligation and 
puncture-induced sepsis 418.  Outside sepsis research, it has been observed that intratracheal 
instillation of heparin in A/J mice improved survival after infection by the intracellular pathogen 
Legionella pneumophila 419. This result correlated with a prevention of bacterial dissemination from 
the lung to other organs such as the spleen and liver and an improvement in bacterial clearance 
from the lungs 419. These data suggests that restriction of F. tularensis to the lung, through inhibition 
of apoptosis, demonstrates potential as a therapeutic approach. 
 
No alteration in cytokine secretion was observed in the lungs whereas a significant reduction in 
secretion was seen in the spleens of pre-treated mice. It is possible that the reduced secretion in the 
spleen is due to the lower bacterial colonisation of this organ compared to the lungs. This 
explanation is in line with the bacterial burdens observed in these two organs as no decrease in 
bacterial colonisation is seen in the lungs compared to the significant reduction seen in the spleen. 
However, it could be that pre-treatment with PD0325901 does not inhibit ERK activation only in the 
lungs but also targets this protein systemically. This has been observed in other studies that showed 
oral gavage administration of PD0325901 inhibiting ERK activation in the flanks of mice as well as 
other organs 344. In this case, it could be that PD0325901 is inhibiting, not only ERK activation in the 
lungs but also in the spleen and liver. This could interrupt the signalling required to induce cytokine 
secretion to the levels seen in PBS-treated mice. This theory cannot be confirmed in this study as 
ERK activation was not determined from the liver and spleen. However, the systemic bioavailability 
of PD0325901, after oral gavage, has been demonstrated in other studies 344,388. Further studies 
could examine the systemic inhibition of ERK and determine if the reduction of cytokine secretion in 
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liver and spleens of infected mice is due to decreased bacterial numbers or a decrease in levels of 
activated ERK. 
 
Despite reduced bacterial burdens in the liver and spleen no improvement in survival was observed 
in any mice treated pre- or post-infection with PD0325901. This suggests that the inhibition of ERK 
activation alone is not an appropriate therapeutic strategy. However, the principle of specifically 
targeting a signalling protein has been demonstrated. In the in vitro model of infection, ERK has 
been specifically inhibited without significantly affecting the activation of other MAPKs, particularly 
p38. As a result of this inhibition, cytokine secretion was reduced in both in vitro and in vivo models 
of F. tularensis infection. Additionally, bacterial burdens in the spleen and liver of infected mice were 
shown to be reduced in PD0325901 treated groups.  
 
Two approaches could be investigated to enhance the action of PD0325901. Firstly, an increased 
concentration of PD0325901 may further reduce bacterial burdens and result in an increased 
survival of infected mice. Alternatively, administering an immune modulator, such as PD0325901, in 
combination with a traditional therapeutic such as an antibiotic might show improved survival rates. 
The combined administration of two forms of therapeutic has been used previously 340,420. Mice 
challenged via the intranasal route with F. tularensis LVS or SchuS4 displayed a 0% survival rate, at 
day 15, even when treated with the antibiotic levofloxacin. However, if the mice were given the 
synthetic TLR3 agonist poly(I:C) 1 h after challenge and then given levofloxacin on day 5, 100% 
survival was observed 340. Successful combination therapy has been demonstrated with other 
intracellular pathogens such as Leishmaniasis 420. In this case, TLR4 and TLR9 agonists combined with 
a poly-protein vaccine candidate reduced the parasite burden in combination-treated mice when 
compared to single therapy mice 420. Similarly, although PD0325901 did not reduce bacterial burdens 
in the lungs of treated mice and did not improve survival, the reduction of bacterial spread from the 
lungs could enhance the effect of alternative therapies, such as antibiotics. This has been seen 
previously where the blocking of scavenger receptors combined with antibiotic treatment prevented 
bacterial dissemination after the induction of sepsis resulting in decreased systemic inflammation 
and an increased survival rate of C57BL/6 mice from 6% to 27% 418. 
 
In summary:  
 PD0325901 treatment inhibits the activation of ERK by F. tularensis infection in vitro resulting 
in the suppression of IL-6 and TNF secretion but without decreasing bacterial numbers. 
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 PD0325901 treatment of F. tularensis infection in vitro does not increase the level of cell 
death compared with untreated cells. 
 In a murine model of F. tularensis infection, PD0325901 treatment decreases the level of ERK 
activation in the lungs and reduces the proliferation of bacteria from local containment to the 
spleen and liver.  
 No significant increase in survival is seen in PD0325901-treated mice compared to untreated 
groups. 
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Chapter 5: TLR2 and TLR4 initiate signalling 
5.1 Introduction 
The binding of a ligand to the LRR domain of a TLR is the initial step in the induction of an immune 
response 47. The role of the TLR is not just to convert the binding event into a signalling cascade but 
to also confer a degree of specificity to the system as individual TLRs are able to detect specific sets 
of ligands. Each TLR feeds into distinct signalling pathways, for example TLR2 and TLR3 link to the 
MyD88-dependent and TRIF-dependent pathways, respectively, whereas TLR4 is able to induce 
signalling along both of these major pathways 44,45,101,103,132,378. The downstream signalling events and 
subsequent immune response depend heavily upon the identity of the TLR being activated. As a 
result, the determination of the receptors responsible for the detection of a specific pathogen can 
provide valuable insight into the signalling induced and possible immunological outcomes of 
infection. This has been demonstrated previously in studies examining the receptors involved in the 
detection and response to S. enterica and Chlamydia trachomatis 103,421. TLR4 was identified as being 
important in controlling the early growth of S. enterica but not for complete bacterial clearance 103. 
For C. trachomatis infection, TLR2 was seen to migrate to intracellular inclusions potentially 
identifying it, and its adaptor MyD88, as targets for therapeutic intervention 421. 
 
The ability of TLRs to detect PAMPs is conferred by the LRR domain and the macro-structure of this 
domain across the family of TLRs is highly conserved. Despite the structural homology, the unique 
ligand binding repertoire is maintained by alterations in key residues within the LRR structure and 
also minor structural changes such as loops and grooves 50,52-54. Both of these are found in TLR3 
whose LRRs express conserved phenylalanine and asparagine residues and LRR12 and LRR30 contain 
large protruding loops that are unique to TLR3 indicating a role in conferring ligand specificity 50,53. 
Similarly, the TLR2/TLR1 heterodimer was found to contain three hydrophobic pockets and a key 
glutamine at position 316 that interacted with its tri-acylated lipopetide ligand 52,54. It is not just the 
structure of TLRs that determine their ligand repertoire but also their location within the cell as this 
limits, by physical separation, the type of ligand that is able to associate with their binding region. 
TLRs are mainly located within either the cell surface membrane, such as TLR4 and TLR5, or the 
membranes surrounding endosomal compartments, for example TLR7 and TLR9, and are therefore 
able to detect extracellular or intracellular PAMPs, respectively 55,67,82.  
 
Much research has been focussed on identifying the ligands of TLRs and, as such, predictions of 
which TLRs are likely to be activated in the presence of certain pathogens can be theorised. 
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However, assumptions should not be made without experimental evidence as a pathogen can 
express a known TLR ligand without it actually activating the corresponding receptor. Transfection of 
TLRs with an appropriate reporter construct into HEKs, either stably or transiently, provides an 
excellent way of determining which PRRs are activated by specific pathogen-associated ligands. Care 
must also be taken when using purified pathogen components to test for their ability to stimulate 
TLRs. A purified component may be able to activate a receptor but this does not always correlate 
with the same effect when integrated as part of a whole organism. Contamination has also been a 
significant problem in the field of TLR ligand research. For example, in 1998 a group identified TLR2 
as the receptor mediating LPS-induced cellular signalling 422. Subsequently, repurification of the 
stimulatory LPS, by several groups, was found to eliminate the observed TLR-induced signalling and 
then two lipoprotein contaminants were identified as responsible for the stimulatory effect of 
unpurified E. coli LPS upon TLR2 423-425. More recently, another study demonstrated how 
peptidoglycan contaminants of LPS contribute to effects of LPS stimulation previously attributed to 
LPA alone 426. It is not only contamination of LPS that has been an issue. In fact contamination by LPS 
is just as big a problem and, during the initial stages of TLR research, many compounds that were 
“shown” to be TLR4 agonists turned out to be contaminated with LPS, the highly stimulatory agonist 
of TLR4 427. Contamination has been such a barrier to the correct identification of TLR ligands that a 
paper was published suggesting strategies to avoid mis-identification of TLR PAMPs 428. 
 
With regards to F. tularensis, predicting which TLRs this pathogen would most likely activate from 
the bacterial ligands it possesses suggests TLR4, TLR2/(1 or 6) and TLR9 are likely candidates. This is 
due to the fact that, as a Gram negative bacterium, it expresses LPS, lipopeptides and contains CpG 
DNA motifs 300,305,429. Similarly, as a non-motile organism, it is unlikely to stimulate TLR5 due to a lack 
of flagella 55. As discussed earlier though, assuming these are correct, without experimental 
evidence, would not be sensible and much research has been carried out examining which TLRs are 
responsible for initiating an immune response to F. tularensis. Initial work on the interaction of F. 
tularensis with TLRs led to the identification of TLR4 as the receptor involved in bacterial detection 
as TLR4-deficient C3H/HeJ mice displayed higher bacterial burdens and decreased NO2 production 
compared to C3H/HeN mice which express a fully functional TLR4 gene 293. However, a subsequent 
report ruled out TLR4 as playing an important role in generating an immune response as CSH/HeJ 
mice were no more susceptible to inhalational infection with F. tularensis than wild-type mice 295. 
Similarly, TLR4-KO BMDMs were still able to respond to F. tularensis LVS infection through the 
secretion of pro-inflammatory cytokines and the LPS of F. tularensis is now thought to be non-
stimulatory for TLR4 212,301. Recent work suggests that F. tularensis LPS does play a role in the host 
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response to F. tularensis although it is unlikely to be through TLR4. It appears that the low potency 
of F. tularensis LPS can be enhanced in the presence of other F. tularensis factors. For example, the 
heat-shock protein GroEL synergistically enhanced the secretion of IL-8 by human monocyte-derived 
macrophages stimulated with LPS 304. In addition, the antibody response that contributes to the 
protection of wild-type mice from lethal challenge is partially dependent on the presence of F. 
tularensis LPS 305. Important to note though is that typical LPS is not the only agonist to display a 
stimulatory activity upon TLR4. Diverse ligands such as minimally modified low density lipoprotein 
(mmLDL) and Fimbriae H protein (FimH) have both been shown to activate TLR4 355,430. More 
recently, a Francisella cytoplasmic protein called elongation factor Tu (Ef-Tu) has been identified as a 
novel TLR4 agonist 431. This protein was only found in the proteomic analyses of virulent F. tularensis 
strains and not in an attenuated F. novicida strain suggesting that this protein may be a virulence 
factor as well as a TLR4 agonist 431. It would certainly seem that the TLR4-F. tularensis story 
continues to be as enigmatic as ever.  
 
F. tularensis also expresses membrane bound lipopeptides and so TLR2 has received a high degree of 
scrutiny. The role of TLR2 seems to be much clearer than that of TLR4 and TLR2 quickly replaced 
TLR4 as the likely candidate for F. tularensis detection and response initiation. Murine macrophages 
deficient in TLR2 failed to secrete pro-inflammatory cytokines to the level observed in wild-type 
macrophages 212,298. Furthermore, mice deficient in TLR2 exhibit an enhanced susceptibility to 
pulmonary infection by F. tularensis LVS and a reduced secretion of pro-inflammatory cytokines such 
as TNF and IL-6 41. More recently, two F. tularensis lipoproteins have been identified, TUL4 and 
FTT1103, which stimulate the TLR2/1 heterodimer inducing chemokine production in murine 
dendritic cells 300. TLR9 also has the potential to be a F. tularensis detector and this will be discussed 
in the subsequent chapter. 
 
5.2 Aims and Objectives 
The aim of this chapter was to determine the contribution of TLR2 and TLR4 to the initiation of 
signalling cascades after stimulation by F. tularensis LVS by using macrophage cell lines, with TLR2 or 
TLR4 knocked out, and measuring the activation profiles of downstream signalling proteins in 
comparison to wild-type cells. If no alteration in signalling is observed in TLR-KO cells it is likely that 
the specific TLR is not responsible for initiating a response to F. tularensis LVS. 
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The specific aims of this chapter were to: 
 Measure the activation of signalling proteins and secretion of cytokines in response to F. 
tularensis LVS infection of wild-type and TLR-KO cell lines. 
 Compare the signalling profiles and cytokine profiles generated from the different cell lines 
and identify where there are differences. 
 
5.3 Results 
5.3.1 Signalling proteins 
From the initial characterisation of LVS-induced signalling in MH-S cells, the three groups of MAPKs 
(JNK, p38, and ERK) and the two IκB proteins (α and β) were selected to characterise the roles of 
TLR2 and TLR4. The activation of these proteins was measured and analysed using western blotting 
and densitometry, generating activation profiles for each signalling protein. Similarly to the LVS 
infection of MH-S cells, samples of cell lysates and supernatants were collected at 12 time points 
throughout the course of a 24 h infection. 
 
Throughout the course of infection no significant change in activation was seen with either JNK-1 or 
JNK-2 in any of the cell lines infected (Figure 5-1). This is also the case for the two IκB proteins 
(Figure 5-2). The activation of both ERK-1 and ERK-2, however, do show alterations in signalling 
caused by the absence of either TLR2 or TLR4 (Figure 5-3). In wild-type cells, the activation of both 
ERK-1 and ERK-2 is elevated, compared to uninfected cells, until 1.5 h after uptake of the bacteria. 
However, in TLR4-KO and TLR2-KO cells the early elevation in the activation level of ERK-1 is not 
sustained, as in wild-type cells, and is significantly decreased at 0.5 h after bacterial uptake. The 
same pattern is observed for ERK-2 activation in TLR2-KO cells although there is a slight difference 
for TLR4-KO cells which display no elevation of ERK-2 activation at the early time points. As the 
activation of ERK is altered in both TLR2-KO and TLR4-KO cells it is likely that stimulation of both 
these receptors contribute to the regulation of ERK activation in response to F. tularensis. 
 
The biggest changes in signalling due to TLR-KO was seen in the activation profiles of p38 (Figure 
5-4). Similarly to ERK activation, p38 activation is affected, albeit in different ways, by the absence of 
either TLR2 or TLR4. The activation profile for p38 observed in wild-type BMDMs closely follows that 
of MH-S cells. This is characterised by an early activation of p38 followed by a maintained 
suppression of activation throughout the remaining time points. In TLR2-KO cells, the resting level of 
p38 activation is greatly increased and, upon infection by LVS, rises significantly above levels seen in 
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Figure 5-1: The levels of activated JNK-1 and JNK-2/3 in WT, TLR2-KO and TLR4-KO BMDMs throughout the 
course of a F. tularensis LVS infection  
The levels of activated JNK-1 (B) and JNK-2/3 (C) were determined at several time points after the uptake of 
LVS. Representative western blots (A) are shown on the opposite page. The experiment was performed in 
triplicate (n = 3) and each replicate was performed in duplicate. Error bars show 95% confidence interval. 
Significant difference from wild-type levels was determined by two-way ANOVA and a Bonferroni’s post-test  
(* = p<0.05). (WT) – Wild-type BMDMs; (2) – TLR2-KO BMDMs; (4) – TLR4-KO BMDMs.  
Western blot image: L – MagicMark™ ladder; N – naïve; +ve – positive control. 
B: P-JNK-1 
C: P-JNK-2/3 
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Figure 5-2: The expression of IκBα or IκBβ in WT, TLR2-KO and TLR4-KO BMDMs throughout the course of a 
F. tularensis LVS infection  
 
The expression of IκBα (B) and IκBβ (C) was determined at several time points after the uptake of LVS. 
Representative western blots (A) are shown on the opposite page. The experiment was performed in triplicate 
(n = 3) and each replicate was performed in duplicate. Error bars show 95% confidence interval. Significant 
difference from wild-type levels was determined by two-way ANOVA and a Bonferroni’s post-test (* = p<0.05). 
(WT) – Wild-type BMDMs; (2) – TLR2-KO BMDMs; (4) – TLR4-KO BMDMs.  
Western blot image: L – MagicMark™ ladder; N – naïve; +ve – positive control. 
 
 
B – IκBα 
C – IκBβ 
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Figure 5-3: The levels of activated ERK-1 and ERK-2 in WT, TLR2-KO and TLR4-KO BMDMs throughout the 
course of a F. tularensis LVS infection  
The levels of activated ERK-1 (B) and ERK-2 (C) were determined at several time points after the uptake of LVS. 
Representative western blots (A) are shown on the opposite page. The experiment was performed in triplicate 
(n = 3) and each replicate was performed in duplicate. Error bars show 95% confidence interval. Significant 
difference from wild-type levels was determined by two-way ANOVA and a Bonferroni’s post-test (* = p<0.05). 
(WT) – Wild-type BMDMs; (2) – TLR2-KO BMDMs; (4) – TLR4-KO BMDMs.  
Western blot image: L – MagicMark™ ladder; N – naïve; +ve – positive control. 
B – P-ERK-1 
C – P-ERK-2 
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Figure 5-4: The levels of activated p38 in WT, TLR2-KO and TLR4-KO BMDMS throughout the course of a F. 
tularensis LVS infection  
The levels of activated p38 were determined at several time points after the uptake of LVS. Representative 
western blots are shown above. The experiment was performed in triplicate (n = 3) and each replicate was 
performed in duplicate. Error bars show 95% confidence interval. Significant difference from wild-type levels 
was determined by two-way ANOVA and a Bonferroni’s post-test (* = p<0.05). (B) – Wild-type BMDMs; (2) – 
TLR2-KO BMDMs; (4) – TLR4-KO BMDMs. Western blot image: L – MagicMark™ ladder; N – naïve; +ve – 
positive control. 
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wild-type cells between 0 h and 0.25 h. Conversely, the resting level of p38 activation in TLR4-KO 
cells is identical to wild-type cells, but when the TLR4-KO cells are infected, p38 fails to become 
activated and remains significantly lower than the level seen in wild-type cells until 1.5 h. This data 
shows that p38 activation, like ERK activation, is dependent on the presence and activation of both 
TLR2 and TLR4. 
 
5.3.1 Cytokines 
To observe whether the absence of either TLR2 or TLR4 could affect the downstream result of 
signalling pathways the secretion of cytokines was measured in the supernatants sampled from the 
cells at each time point. The supernatants were screened for the production of IFN-γ, IL-6, IL-10, IL-
12p70, TNF and MCP-1. Of the 6 cytokines measured, only MCP-1 and TNF could be detected from 
the supernatants (Figure 5-5). MCP-1 is secreted rapidly in response to LVS infection in all three cell 
lines and does not show a greatly increased or decreased rate of secretion in either TLR2-KO or 
TLR4-KO cells when compared to wild-type. However, the secretion of TNF does show significant 
differences between the cell-lines tested. In wild-type cells, in the first 2 h after uptake, TNF is 
secreted rapidly and then at 6 h reaches maximum levels at about 3500 ρg/ml. In TLR2-KO cells the 
rapid secretion of TNF is completely abrogated and TNF levels are significantly lower than in wild-
type cells from 0.75 h through to 24 h after uptake, barely reaching 900 ρg/ml. In TLR4-KO cells, TNF 
is initially secreted at a similar rate to wild-type cells. However, at 1 h post-uptake, the levels of TNF 
plateau at lower values than for wild-type cells and the maximum value reached is about 1500 
ρg/ml, significantly lower than in wild-type cells. 
 
5.4 Discussion 
The involvement of TLR2 in initiating an immune response to F. tularensis infection is widely 
accepted. TLR2-KO macrophages fail to secrete pro-inflammatory cytokines in response to F. 
tularensis infection 212,298. TLR2-KO mice display an increase in bacterial burden in the lungs, liver and 
spleen after infection compared to wild-type mice 41. Important to note is that all the evidence 
pointing to TLR2’s involvement in the response to F. tularensis infection does not negate a 
requirement for other receptors, as a recent study demonstrated. A mutant strain of F. tularensis 
LVS was highly attenuated in a murine model and was able to induce a far more rapid and robust 
inflammation response than wild-type F. tularensis but this did not involve changes in TLR2 mediated 
signalling suggesting a contribution by other receptors 432. The examination of signalling proteins and 
cytokine secretion in my work confirms previous reports of TLR2’s role in the detection and response 
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Figure 5-5: Secretion of MCP-1 and TNF in WT, TLR2-KO and TLR4-KO BMDMs throughout the course of a F. 
tularensis LVS infection  
The secretion of MCP-1 (A) and TNF (B) into the supernatant was measured at several time points after the 
uptake of LVS. The experiment performed in triplicate (n = 3) and each replicate was performed in duplicate. 
Error bars show the standard error of the mean. Significant difference from wild-type levels was determined 
by two-way ANOVA and a Bonferroni’s post-test. Blue asterisk – significant difference to TLR2-KO. Green 
asterisk – significant difference to TLR4-KO. (* = p<0.05). (WT) – Wild-type BMDMs; (2) – TLR2-KO BMDMs; (4) 
– TLR4-KO BMDMs. 
  
A 
B 
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to F. tularensis as, although TLR2-KO did not significantly impact upon the activation of JNK or the 
expression of IκBα/β, significant changes were observed in both p38 and ERK activation. This result is 
in agreement with previous studies identifying a link between TLR2 stimulation and the activation of 
signalling proteins, in particular MAPKs 393,433-435. It is perhaps no surprise that JNK, and IκBα/β were 
not altered as their expression and activation were not greatly affected by F. tularensis infection in 
MH-S cells. In addition, JNK activation has been observed to be suppressed by F. tularensis infection 
in another study 436. In addition, this data shows that although ERK and p38 are both located within 
the MAPK branch of the signalling cascade and share a high degree of structural homology 143,146,437 
their activation by TLRs is different. In the absence of TLR2, the typically sustained activation of ERK 
is lacking and only an early and transient activation is seen. Therefore, it seems that TLR2 
stimulation, in wild-type macrophages, is responsible for inducing the signal to sustain the early 
activation. In another study stimulation of neutrophils with LPS induced a transient activation of ERK 
whilst P3CSK4-stimulation induced a sustained activation of ERK lasting for 1 h after stimulation 438. 
Although this study used a different cell line and pure ligand instead of bacterial-stimulation it does 
demonstrate the sustained activation of ERK brought about through TLR2 stimulation similar to that 
seen in my work. In contrast to ERK, p38 activation is significantly enhanced in TLR2-deficient cells 
suggesting that, in this case, TLR2 may be required to generate a suppressive signal, although this 
has not been observed previously. TLR2 appears to be able to simultaneously enhance the activation 
of one protein (ERK) whilst simultaneously suppressing the activation of another (p38) in response to 
F. tularensis detection. The ability of TLR2 stimulation to differentially regulate specific MAPKs has 
been observed previously. Stimulation of RAW264.7 macrophages with staphylococcal PGN, a TLR2 
agonist 439, induced a strong activation of ERK, moderately activated JNK and only weakly activated 
p38 440. 
 
Interestingly, TLR2 stimulation appears to not only regulate p38 activation in response to infection 
but also in naïve cells. This is demonstrated by a significantly higher level of p38 in uninfected TLR2-
KO compared to wild-type BMDMs and suggests that these cells are left in a highly stimulated state 
even when not subjected to exogenous stimuli. One possibility is that in wild-type cells a low level of 
TLR2 activation maintains the cells in a resting state preventing them from reacting excessively to 
non-pathogenic stimuli. When the steady-state of stimulation is removed, through knockout of TLR2, 
signalling induced through the stimulation of other PRRs is able to induce enhanced p38 activation. 
Low-level constitutive stimulation as a mechanism for maintaining cells in a homeostatic state has 
been investigated previously in the intestinal tract. In this context, commensal bacteria are 
continuously detected by TLRs expressed on epithelial cells 441. The constant stimulation does not 
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initiate an inflammatory response but instead maintains the cells in a steady-state ready to become 
activated by pathogenic stimuli 441. It is possible that, in BMDMs, low-level stimulation of TLR2 
prevents the cells from responding excessively to non-pathogenic stimuli and so when the cells lack 
this receptor they are unable to restrain this disproportionate response.  
 
Another explanation for the heightened level of p38 activation in resting cells could be related to the 
expression of other TLRs in the TLR2-KO cell-line. In 1999, it was demonstrated that an increased 
expression of TLR4 on mycocytes increased the activation of NF-κB suggesting that it is not only the 
stimulation of a TLR that determines the outcome but also the level of expression 442. Additionally, a 
cell’s expression of TLRs is strongly interlinked meaning that an alteration in the expression of one 
TLR can have significant effects on the expression of another. For example, in TLR2-KO mice infected 
with P. aeruginosa an up-regulation of TLR4 expression was observed that was not present in wild-
type C57BL/6 mice 443. Therefore, in the TLR2-KO BMDMs used in this study, there may be a similar 
up-regulation in TLR4, or other TLRs, which could explain the enhanced p38 response. To verify this 
possibility, expression of receptors could be measured using cell staining techniques and compared 
between the cell lines used. 
 
The alterations in signalling, brought about by the knock-out of specific TLRs, are also visible in the 
secretion profile of TNF. TNF is a pleiotropic cytokine, transducing diverse signals including cell 
activation, death and proliferation 444. With such a broad range of functions it is not surprising that 
the secretion of this cytokine is tightly regulated by a complex mechanism with two major stages of 
control 392. The transcription of DNA into mRNA is initiated and regulated by the transcription factor 
NF-κB 444 whereas the translation of TNF mRNA into protein is regulated by the MAPK signalling 
pathway 392. In resting cells there is a basal level of TNF transcription and translation although both 
these process are extremely inefficient 445. Upon stimulation, transcription is accelerated and 
translational derepression occurs resulting in a far more efficient message utilisation and rapid 
secretion of TNF 445. 
 
In TLR4-KO cells, the translation of TNF mRNA is still able to take place as the initial secretion of TNF, 
in the first 1.5 h, matches that observed in wild-type cells. However, TNF levels quickly plateau at 2 h 
reaching a maximum of 1500 pg/ml. This indicates that, although the TNF mRNA already present in 
the cell can be translated there is no de novo transcription occurring to continue TNF secretion as 
observed in wild-type cells. This indicates that TLR4 stimulation, and the signalling cascades initiated 
are required for the release of transcription repression. In resting cells there is a basal level of TNF 
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transcription which has been shown to rely on binding of only the p50 subunit of NF-κB to at least 
one of the four kB motifs present in the gene 446. Upon cell stimulation, an increase in nuclear NF-κB 
content is observed and it was proposed that binding of both the p50 and p65 subunits of NF-κB 
promote accelerated transcription 446. The result observed in this study, where a lack of TLR4 results 
in a plateau of TNF secretion, indicates a role for TLR4 stimulation in the acceleration of transcription 
involving NF-κB. Conversely, as the translation of TNF mRNA was unaffected in TLR4-KO cells, as 
shown by the unaltered initial rate of TNF secretion, TLR4 appears not to be critical in the regulation 
of this stage in the TNF secretory process. A role for TLR4 in the induction of TNF secretion has 
previously been demonstrated in alveolar macrophages that secreted TNF, in addition to IL-8 and 
MCP-1 when stimulated with LPS 434.   
 
In TLR2-KO cells, the initial rapid secretion of TNF seen in both wild-type and TLR4-KO cells is absent 
indicating that derepression of TNF translation has not occurred and the conversion of mRNA into 
secreted protein remains inefficient. This is likely to be due to altered MAPK signalling as the control 
of TNF translation has been studied in depth by several groups and is characterised to be under the 
regulation of the MAPK signalling pathway involving all three of the major MAPKs, p38, JNK and ERK 
in non-redundant roles 392. The role of p38 in TNF regulation involves the activation of its 
downstream substrate, MAPK-activated protein kinase-2 (MK-2) and the interaction between this 
signalling protein and the adenylate/uridylate-rich element (ARE) located in the 3’ untranslated 
region (3’UTR) of TNF mRNA 390,394. The importance of these proteins and elements has been 
comprehensively demonstrated by numerous groups utilising MK-2 deficient cells, p38 inhibitors and 
ARE-deleted TNF genes 390,391,394,447. Although, these elements were identified as critical some years 
ago, the exact mechanism of regulation has only recently begun to be elucidated. Initial studies 
observed that MK-2-deficiency did not alter the half-life of TNF suggesting that the p38 pathway is 
not involved in the stability of TNF mRNA 394. In contrast, however, more recent work has linked the 
p38 pathway and MK-2 activation to the regulation of TNF mRNA stability, possibly through the 
regulation of tristetrapolin 390,391,448. 
 
Despite the correlation reported in the literature between p38 activation and the increase of TNF 
secretion, my work appears, at first glance to disagree. In TLR2-KO cells the secretion of TNF was 
almost completely abrogated but this was associated with enhanced and not reduced p38 activation. 
This result may be explained by the activation profile of another signalling protein, ERK, in the TLR2-
KO cell-line. Unlike p38 and JNK, the ERK pathway is responsible for the transport of TNF mRNA from 
the nucleus into the cytoplasm 392. In TLR2-KO cells the activation of ERK is significantly reduced 
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compared to wild-type BMDMs and this could result in inhibition of the nucleocytoplasmic transport 
of TNF mRNA. In this case, although p38 activation is enhanced, usually correlating to enhanced TNF 
secretion, there is no cytoplasmic mRNA for it to positively regulate as it is all contained within the 
nucleus and therefore TNF secretion remains suppressed. In combination, the data presented here 
support a hypothesis whereby both TLR2 and TLR4 contribute, in distinct ways, to efficient secretion 
of TNF. TLR4 stimulation appears to be involved with the initiation of TNF transcription but not 
translation whereas TLR2 stimulation, via the MAPK cascade involving p38 and ERK, is critical in the 
regulation of TNF translation. Only with coordinated stimulation of both these TLRs is the whole 
mechanism required for efficient TNF secretion fully functional. In agreement with these results, 
coordinated signalling between TLR2 and TLR4 in the secretion of TNF has been observed previously. 
Simultaneous stimulation of fibroblasts with pure TLR2, TLR4 and TLR6 ligands synergistically 
increased the secretion of TNF 449. Similarly, dual blockade of TLR2 and TLR4 was required to inhibit 
TNF secretion from peripheral blood mononuclear cells upon infection with S. enterica 450. It also 
appears that synergy between TLR2 and TLR4 is not restricted to cytokine secretion and, in the case 
of M. tuberculosis infection of macrophages, cooperation between these two signalling pathways 
plays a critical role in regulating cell death 451. However, not all studies observe the same level of 
synergy with regards to TNF secretion. In dendritic cells, stimulated with ultra-pure LPS and 
Pam3CSK4 a synergistic enhancement of IL-10 was seen but not TNF 40. The differences between 
studies could be explained by the use of different cell-types but also whether the stimulation of the 
cells was brought about by infection or through the use of pure ligands. 
 
The observed response to F. tularensis infection in wild-type BMDMs cannot be fully explained by 
the contribution of one TLR alone. Although this study demonstrates that it is generated by the 
combination of at least TLR2 and TLR4, cooperation between TLR4 and other TLRs has been 
scrutinised previously 40,186. Pure TLR ligands were used to stimulate the cells and the synergistic 
cytokine response, when TLRs were stimulated simultaneously, was determined to be generated at 
the level of the MAPKs 40. This is in agreement with my work where either the absence of TLR2 or 
TLR4 affected the activation of MAPKs indicating that both receptors are required for the wild-type 
cell response. In addition, TLR cooperation has been observed in a mouse model of bacterial 
pneumonia indicating that it is not just an artefact of in vitro models 193. The results presented here 
also do not rule out the possibility of other PRRs contributing to the response, in fact the opposite is 
indicated. MCP-1 secretion was unaffected by either TLR2-KO or TLR4-KO supporting the hypothesis 
that additional PRRs are able to react to F. tularensis infection. Alternatively, it could be that either 
TLR2 or TLR4 stimulation can induce MCP-1 secretion, in a redundant fashion, meaning that in the 
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absence of one TLR the other can replace it. The influx of immune cells, stimulated in part by 
secretion of MCP-1, is a critical step in the resolution of infection. It is likely then that multiple TLRs 
can induce MCP-1 secretion to ensure that, whatever ligand the pathogen expresses, immune cell 
influx is initiated. In fact, direct stimulation of TLR2, TLR3, TLR4, TLR7/8 and TLR9 with their 
corresponding agonists all result in the secretion of MCP-1 452.  Additional receptors have also 
recently been identified such as the cytoplasmic receptor, AIM-2, that was characterised as a 
detector of DNA present in the cytoplasm in 2009 by two separate groups 29,30. Subsequently, AIM-2 
was identified as an additional receptor important in the macrophage response to F. tularensis 
triggering inflammasome assembly and cleavage of caspase-1 resulting in the secretion of IL-1β and 
IL-18 329. Further evidence for receptors other than TLR2 and TLR4 being involved in the response to 
F. tularensis is provided by a study using a galU mutant of F. tularensis LVS 432. In a murine 
pulmonary model of tularaemia, the galU mutant demonstrated reduced virulence correlating with a 
more rapid and robust inflammatory response 432. Importantly, the enhanced inflammation was 
brought about in the absence of any alteration in TLR2 or TLR4 signalling indicating the involvement 
of other receptors and signalling pathways. Almost certainly, there are other F. tularensis-responsive 
receptors yet to be identified.  
 
In summary: 
 
 TLR2 is able to simultaneously enhance the activation of one protein (ERK) whilst 
suppressing the activation of another (p38) in response to F. tularensis detection. 
 TLR2 stimulation, via the MAPK cascade involving p38 and ERK, is critical in the regulation of 
TNF translation in response to F. tularensis infection. 
 TLR4 stimulation and the signalling cascades initiated are required to release the repression 
of TNF transcription in response to F. tularensis infection. 
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Chapter 6: Priming of TLR9 response 
6.1 Introduction 
The sea urchin has a repertoire of 222 TLRs  35 and, with this arsenal available, it is easy to see how 
this organism can tailor a specific immune response to a wide variety of stimuli. In contrast, human 
cells have a much more restricted set of TLRs with which to react to an equally varied set of stimuli. 
Despite this, human cells are still able to generate specific immune responses. This leads us to the 
intriguing question: How does a limited set of receptors generate such a broad range of responses?  
 
One mechanism that can begin to explain this phenomenon is TLR cooperation or coordination. The 
three major mechanisms of cooperation are cross-talk, priming and tolerance 453. Cross-talk occurs 
when signalling proteins from one pathway modulate the activation of signalling proteins on another 
branch. For example, activated ERK is able to bind to MKP-3 enhancing its activity and subsequently 
applying a positive feedback loop upon p38 454. Priming is characterised by a preliminary stimulation 
event enhancing the response to a subsequent stimulation event 182,455. In contrast, tolerance is 
defined as the limiting of a response after pre-stimulation 183. This can occur either when the two 
stimulation events are by the same ligand or when the primary stimulation event is by a different 
ligand to the subsequent event; in this instance it is known as cross-tolerance 184. Because 
macrophages may encounter multiple TLR ligands during an infection, signalling cross-talk between 
TLR pathways is likely to be important for the tailoring of inflammatory responses to pathogens. 
 
Priming and cross-tolerance have been studied in depth in relation to the integration of multiple 
TLRs with TLR9 receiving the most attention with regards to its interaction with other TLRs, 
particularly TLR4. However, as usual in the field of TLR research, there are contrasting reports of the 
integration of TLR4 and TLR9 signalling. A recent study observed that pre-treatment of macrophages 
with LPS primed the cells for subsequent stimulation by CpG DNA correlating with enhanced MAPK 
activation 189. This priming effect is only apparent when subsequent stimulation is by a different 
ligand. A separate study that examined repeated stimulation with either LPS or CpG observed 
generation of tolerance to these ligands 183. In contrast to these studies, an earlier study observed 
the induction of hyporesponsiveness in RAW264.7 cells pre-treated with LPS upon subsequent re-
stimulation with CpG 187. The hyporesponsive state correlated with the suppression of TNF and IL-12 
production albeit with the potentiation of IL-6 production 187. This study suggests that 
hyporesponsiveness of RAW264.7 cells is due to a complicated re-programming of the cells and not 
just a simple exhaustion of cellular components 187. The order of stimulation events is also critical to 
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determining the outcome of signalling as the same stimulation in a different order results in 
significantly different outcomes. For example, priming of cells via CpG-induced TLR9 activation 
followed by LPS stimulation results in an augmented IL-12 production whereas the same stimuli but 
in the reverse order has no affect on the production of IL-12 by murine DCs 186. In an ex vivo 
experiment, purified human alveolar macrophages were removed from lungs of volunteers that had 
been instilled with LPS and they were re-stimulated 6 hours later with either TLR4 or TLR2 ligands 182. 
In both cases an elevated level of IL-1 and IL-6 secretion was observed and this correlated with a 
sustained activation of p38, although, due to ethical reasons p38 inhibition could not be carried out 
to confirm direct correlation 182. 
 
Although priming and tolerance have been observed in numerous cell types involving a variety of 
TLRs, the mechanisms that underlie these two phenomena are less well characterised. One 
mechanism suggested to contribute to priming effects is the cross-regulation of TLR expression.  
Within 1 h of LPS stimulation the expression of TLR9 was up-regulated in RAW264.7 cells and this 
correlated with the activation of NF-κB and MAPKs 188. However, this effect is cell and TLR specific as 
LPS stimulation of human AMs primed the cells for IL-1 and IL-6 secretion after TLR2 stimulation but 
this did not correlate with an increase in TLR4 or TLR2 expression 182. 
 
An added layer of complexity to the mechanisms of priming and tolerance is that TLRs can modulate 
the response of another TLR without becoming fully activated themselves. Sub-stimulatory or sub-
threshold concentrations of LPS have been used to prime murine peritoneal macrophages prior to 
re-stimulation with LPS. Although no measurable stimulation occurs after the priming step, an 
alteration in the cytokine response to the secondary stimulation is observed when compared to un-
primed cells 455,456. In addition, priming of cells does not universally up-regulate or down-regulate the 
response. LPS-primed macrophages demonstrated a suppression of NO production whilst 
simultaneously enhancing the secretion of TNF 456. The ability of cells to be selectively primed by 
sub-stimulatory concentrations of ligand indicates a complex mechanism of cellular reprogramming. 
 
As described previously, F. tularensis has the potential to activate several receptors including TLR2, 
TLR4 and TLR9 and my work has confirmed that both TLR2 and TLR4 certainly play a part in 
generating the response to this pathogen. However, through the mechanisms of TLR cooperation, 
these receptors, in addition to acting in isolation, may also integrate their signals generating 
additional unique immune responses. 
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6.2 Aims and Objectives 
The role of TLR2 in generating a response to F. tularensis is well characterised and my work has 
confirmed this. However, TLR4’s contribution remains the subject of much debate as it seems to play 
a role but the mechanism has not been elucidated. Previous research using pure ligands of TLR4 and 
TLR9 has demonstrated that TLR4 sub-stimulation is able to prime TLR9, enhancing the immune 
response 189. The cooperation between these two receptors may represent the mechanism by which 
TLR4 plays a role in the host response to F. tularensis and could explain the potentially detrimental 
immune response seen at later time points during infection. The aim of this chapter was to 
investigate whether sub-stimulation of TLR4 is able to prime TLR9 for an exacerbated response 
downstream of F. tularensis genomic DNA detection. The proposed mechanism behind priming of 
TLR9 by TLR4 is quite complex so it was decided to investigate the process in a step wise manner. In 
order to examine each step individually, within this complex process, a range of cell lines, ligands 
and receptor antagonists were used to isolate the function of each individual receptor.  
 
The specific aims of this chapter were to: 
 Determine whether TLR9 is able to detect genomic DNA purified from several Francisella 
sub-species in HEK-Blue™ and MH-S cells. 
 Investigate the integration of TLR4 and TLR9 signalling in response to F. tularensis. 
 Establish whether LPS, at very low concentrations, is able to prime the TLR9 response. 
6.3 Results 
6.3.1 HEK-TLR9 Blue cells 
Preliminary studies into the potential of Francisella genomic DNA to stimulate TLR9 were carried out 
in the HEK-Blue™ hTLR9 cell line. These cells express TLR9 with NF-κB and AP-1 controlled 
transcription linked to the production of SEAP. Levels of SEAP can be determined using the QUANTI-
Blue™ medium which turns blue in the presence of SEAP. Therefore, the degree of colour change is 
correlated to the level of TLR9 stimulation. As these cells also express endogenous TLR3, TLR5 and 
NOD1, the parental cell line HEK-Blue™ Null1 was used as a control. In addition to determining SEAP 
production, the secretion of cytokines was also measured. 
 
The level of SEAP production was measured by reading the absorbance at 620 nm on a 
spectrophotometer. Genomic DNA from all strains of Francisella was able to stimulate signalling 
through TLR9 (Figure 6-1). Interestingly, genomic DNA from the highly virulent SchuS4 strain  
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A – 10 µg/ml F – 10 µg/ml 
B – 1 µg/ml G – 1 µg/ml 
C – 0.1 µg/ml H – 0.1 µg/ml 
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Figure 6-1: The detection of F. tularensis genomic DNA by HEK-Blue™ cells  
Induction of signalling through TLR9 in HEK-Blue™ cells was determined by measuring the OD492 of the media 
(A-E) and secretion of MCP-1 (F-J) after 24 h of stimulation by genomic DNA used at varying concentrations (10 
µg/ml (A,F), 1 µg/ml (B,G), 0.1 µg/ml (C,H), 0.01 µg/ml (D,I), 0.001 µg/ml (E,J). The experiments were 
performed in triplicate (n = 3) and each replicate was performed in duplicate. Error bars show the min and 
max. Significant difference between TLR9 and Null1 cells was determined by a one-way ANOVA and individual 
one-tailed, unpaired t-tests (* = p<0.05)  
D – 0.01 µg/ml I – 0.01 µg/ml 
E – 0.001 µg/ml J – 0.001 µg/ml 
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stimulated these cells significantly more than DNA from lower virulence strains at 0.1 and 1 µg/ml 
and both SchuS4 and LVS were significantly more stimulatory at 10 µg/ml when compared to U112 
and FSC200 strains. The stimulatory properties of genomic DNA were also observed by measuring 
the secretion of MCP-1 24 h after stimulation. Similarly to the absorbance readings, SchuS4 DNA was 
able to induce significantly more secretion of MCP-1 than all other strains at both 1 and 10 µg/ml 
(Figure 4-1B). In contrast to absorbance readings, LVS DNA did not induce secretion of MCP-1 to a 
greater degree than other strains at any concentration used. 
6.3.2 MH-S cells 
6.3.2.1 TLR4 and TLR9 stimulation 
As it was demonstrated that genomic DNA could stimulate signalling through TLR9 in HEK-Blue™ 
cells the assay was transferred to the MH-S cell line because these cells are a better model for 
pulmonary immune cells. Transcription in these cells is not linked to the production of SEAP and 
therefore signalling could only be determined through the detection of cytokine secretion. MH-S 
cells were stimulated for 24 h with a range of concentrations of genomic DNA purified from the 
same four F. tularensis strains as used for the HEK-Blue™ stimulation assay. After 24 h incubation, 
supernatants were removed and screened for the secretion of cytokines. To account for signalling 
induced by any receptor other than TLR9 expressed by these cells, the stimulation was also 
performed in the presence of a TLR9 antagonist, G-ODN. DNA from all four strains was able to 
stimulate MH-S cells to secrete IL-6 (Figure 6-2). In each case, this was dependent on TLR9 as IL-6 
secretion was significantly reduced in the presence of the TLR9 antagonist, G-ODN. Differences 
between strains were also observed as genomic DNA from the highly virulent SchuS4 strain induced 
significantly greater IL-6 secretion than the less virulent LVS and U112 strains as well as the +ve 
control. 
 
6.3.2.2 Stimulation by whole LVS 
Although purified F. tularensis genomic DNA demonstrated the ability to induce a response via TLR9, 
the ability of a natural bacterial infection to do so remains unproven. For TLR9 stimulation to occur 
the DNA would need to be released from the bacteria, either through active secretion by bacteria or 
through lysis of the bacteria by the cell. To investigate this , MH-S cells were infected with live LVS in 
the presence of the TLR9-antagonist G-ODN (Invitrogen), the TLR4-blocking antibody IMG-428E 
(Imgenex), or both. Untreated MH-S cells were used as a control. Supernatants were collected 24 h  
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Figure 6-2: Secretion of IL-6 by MH-S cells in response to TLR9 stimulation by F. tularensis genomic DNA (10 
µg/ml) 
Secretion of IL-6 was determined 24 h after stimulation of MH-S cells by F. tularensis genomic DNA. The 
experiments were performed in triplicate (n = 3) and each replicate was performed in duplicate. Significant 
difference from antagonised cells was determined by one-way ANOVA and individual one-tailed, unpaired t-
tests (* = p<0.05). Error bars show the min and max. 
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after infection and screened for the presence of cytokines. Figure 6-3 shows the secretion of TNF 
and IL-6 in response to LVS infection in the presence of a range of concentrations of TLR antagonists 
alongside LVS alone. A high level of IL-6 was secreted and TNF was also released in response to LVS 
infection. When TLR9 signalling was blocked by G-ODN, the level of TNF secretion remained similar 
to that produced by infection with LVS alone for all concentrations except 100 µg/ml where there 
was a significant increase in secretion (A). In contrast, IL-6 secretion was significantly reduced in the 
presence of 100 µg/ml G-ODN (B). When TLR4 signalling was blocked by IMG-428E, a similar effect 
on secretion was observed, with TNF levels increasing at 50 µg/ml (A) and IL-6 levels decreasing at 
50 µg/ml (B) when compared to LVS alone. This data confirms the previous observations that both 
TLR9 and TLR4 play a role in the orchestration of a response to F. tularensis. 
6.3.2.3 LPS priming of TLR9 response 
This study has demonstrated the ability of purified F. tularensis genomic DNA to activate TLR9 and 
this has also been shown to occur in a live bacterial infection model. In addition, using a TLR4-
blocking antibody, the role of TLR4 in generating an immune response to F. tularensis has been 
confirmed. The next stage of the investigation was to determine whether alternative-activation of 
TLR4, by very low concentrations of LPS, is able to prime TLR9 for an enhanced response to 
subsequent activation by F. tularensis genomic DNA. 
 
Initially, a range of concentrations of E. coli LPS (0.01 – 10 ng/ml) were used to stimulate MH-S cells 
through TLR4 in order to determine the level that could be used as a “sub-stimulatory” 
concentration. The secretion of IL-6 and TNF by MH-S cells was used to measure the degree of TLR4 
activation (Figure 6-4). The secretion of IL-6 was negligible at 0.01, 0.1 and 1 ng/ml and only reached 
20 pg/ml when the cells were stimulated with 10 ng/ml LPS. TNF was secreted to a slightly higher 
level but the maximum concentration obtained was still only 150 pg/ml when the cells were 
stimulated with 10 ng/ml. Using these results, LPS at a concentration of 0.1 ng/ml was selected for 
use in subsequent experiments as the priming concentration.  
 
Subsequently, LPS (0.1 ng/ml) was used to prime MH-S cells for 2 h before stimulation with F. 
tularensis LVS, Schu S4 genomic DNA or either +ve or –ve control ODNs. As a measure of signalling 
activation, IL-6 secretion was determined (Figure 6-5). The +ve control ODN was able to stimulate 
the secretion of IL-6 and this was enhanced when the cells were primed with sub-stimulatory LPS. 
When TLR9 was blocked by G-ODN the level of IL-6 was dramatically reduced. Significant secretion of 
IL-6 was not observed when the –ve control ODN was used to stimulate MH-S cells, even when the 
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Figure 6-3: Secretion of TNF and IL-6 in the presence of TLR4 and TLR9 inhibitors after infection with F. 
tularensis LVS 
Secretion of TNF (A) and IL-6 (B) by MH-S cells was determined 24 h after infection by F. tularensis LVS in the 
presence of inhibitors of TLR4 or TLR9. The experiment was performed in triplicate (n = 3) and each replicate 
was performed in duplicate. Significant difference from LVS only was determined by one-way ANOVA and a 
Dunnett’s multiple comparison post-test (blue * = p<0.05). Significant difference between individual inhibitors 
and when used in combination was determined by one-tailed, unpaired t-test (black * = p<0.05). Error bars 
show the min and max. 
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Figure 6-4: Secretion of IL-6 and TNF by MH-S cells stimulated with low concentrations of ultrapure E. coli 
LPS 
Secretion of IL-6 (A) and TNF (B) by MH-S cells was determined 24 h after stimulation with ultrapure E. coli LPS 
at a range of low concentrations (0.01 ng/ml, 0.1 ng/ml, 1 ng/ml, 10 ng/ml). The experiment was performed in 
duplicate. Error bars show the standard deviation. 
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Figure 6-5: Secretion of IL-6, in response to DNA stimulation, by LPS-primed and un-primed MH-S cells 
MH-S cells were primed for 2 h with ultrapure E. coli LPS (0.1 ng/ml) or left untreated before being stimulated 
with F. tularensis genomic DNA or control ODNs. Secretion of IL-6 was determined 24 h after stimulation. (A) 
Stimulated with +ve ODN control (10 µg/ml). (B) Stimulated with -ve ODN control (10 µg/ml). (C) Stimulated 
with F. tularensis LVS genomic DNA (10 µg/ml). (D) Stimulated with F. tularensis SchuS4 genomic DNA (4 
µg/ml). +G = TLR9 antagonist present. (P) = primed with E. coli LPS (0.1 ng/ml). The experiment was performed 
in duplicate. Error bars show the standard deviation. Significant difference was determined by one-way 
ANOVA and a Tukey’s multiple comparison post-test (* = p<0.05). 
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cells were primed with LPS. The most dramatic enhancement was seen with genomic DNA from F. 
tularensis LVS. Alone, F. tularensis LVS DNA did not induce significant IL-6 secretion (< 200 pg/ml).  
However, when the cells were primed with LPS, secretion was significantly greater reaching > 1500 
pg/ml in 24 h. Unfortunately, no significant enhancement of IL-6 secretion was observed after F. 
tularensis SchuS4 DNA stimulation, although with a greater number of repeats the data may have 
obtained significance. 
 
6.4 Discussion 
 
The ability of TLRs to coordinate their signalling significantly enlarges the range and type of 
responses that can be generated by a defined and limited set of receptors. The data collected in this 
chapter demonstrate that the immune response to F. tularensis uses integration of TLR4 and TLR9 
signalling to dramatically enhance the secretion of cytokines after infection. The order of stimulatory 
events used in this study, where sub-stimulation of TLR4 by LPS occurs first followed by stimulation 
of TLR9 by genomic DNA, was designed to closely match the situation in a natural infection. F. 
tularensis first comes into contact with the immune cell membrane where the majority of TLR4 is 
located 56,241. Subsequently, the bacteria enter the phagosomal compartment where TLR9 is found 
56,58,252,254. Therefore the infective cycle of F. tularensis is consistent with the hypothesis that the 
TLR9 response is primed by prior (sub)-stimulation of TLR4. 
 
The data obtained in chapter 5 showed that TLR4 is involved in the detection of F. tularensis 
infection as BMDMs with TLR4 knocked out displayed an altered signalling and cytokine response to 
infection. The data from this chapter add to the findings that, in addition to TLR2 and TLR4, TLR9 is 
also able to respond to F. tularensis infection of MH-S cells. DNA purified from four strains of F. 
tularensis was able to stimulate MH-S cells inducing the secretion of cytokines and this response was 
abrogated when a TLR9 antagonist was present. To negate the requirement for an antagonist to 
confirm stimulation via TLR9 a TLR9-KO cell line could have been used. However, often cell lines that 
contain receptor-KO display altered expression of other receptors 443. The aim of this work was to 
investigate possible coordination between TLR4 and TLR9 signalling and a forced over-expression of 
receptors due to TLR9-KO may not provide accurate results. As such, work was carried out in MH-S 
cells using a TLR9 antagonist. The role of TLR9 in the detection of CpG DNA was first identified by a 
study in 2000 that showed that TLR9-deficient mice were unable to respond to CpG DNA as 
demonstrated by an abrogation of inflammatory cytokine production 67. My work confirms these 
findings as cells were unable to respond to bacterial DNA stimulation in the presence of a TLR9 
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antagonist. Interestingly, differences were seen in the potency of the DNA from the four strains. F. 
tularensis SchuS4 and FSC200 induced significantly greater IL-6 secretion than the LVS and U112 
strains. This is particularly interesting as SchuS4 and FSC200 are considered to be highly virulent 
strains of F. tularensis whereas LVS and U112 are considered low virulence strains 228,236,252,457. Could 
it be that the higher potency of SchuS4 and FSC200 DNA to TLR9 confers these strains with their 
virulence? In agreement with this data is a study which observed that DNA preparations from 15 
different bacteria demonstrated varying stimulatory activities on HEK293 cells stably transfected 
with TLR9 458. The stimulatory activity was associated with the GC dinucleotide content of the DNA as 
the two species that displayed the highest IL-8 secretion also had the greatest frequency of GC 
dinucleotides 458. It could be that, although the GC content of the different F. tularensis strains are 
very similar (~32%) 228,459, the frequency of GC dinucleotides differs between the strains resulting in 
enhanced stimulatory DNA in the more virulent strains. However, stimulatory DNA is unlikely to 
account entirely for increased virulence. A paper examining the beneficial effects of Bifidobacterium 
observed that immunostimulatory DNA, due to CpG-rich sequences, were partly responsible for 
these effects 460. Bifidobacteria are commensals of the human intestinal tract and can account for up 
to 90% of the total gut microbiota 461. Not only are they non-pathogenic, but they have been shown 
to have beneficial effects against numerous diseases 462. It would seem then that having 
immunostimulatory DNA does not confer enhanced virulence on its own and other factors, in 
addition to stimulatory DNA, must account for the increased virulence of F. tularensis strains such as 
SchuS4 and FSC200. It could be the ability of F. tularensis to stimulate TLR9 in combination with 
other TLRs, such as TLR4 and TLR2, which confers increased virulence, in contrast to Bifidobacterium 
species. 
 
 An explanation for increased virulence frequently observed in other bacterial species is the 
expression of virulence factors such as listeriolysin-O, a pore-forming exotoxin, that is secreted by L. 
monocytogenes aiding its escape from the phagosome 259. However, one of the enigmatic features of 
virulent F. tularensis strains is that they do not appear to have any classical virulence factors. There 
is a secretion system encoded on the FPI with similarities to the type VI secretion systems of V. 
cholerae and P. aeruginosa and the potential for this to be involved in pathogenesis has been 
scrutinised in depth 261,463. Although one protein, VgrG, has been shown to be secreted, the FPI is 
found in all the subspecies of F. tularensis indicating that the presence of this system does not 
account for the increased virulence of some strains. One significant difference between the strains 
can be found at the level of their DNA. Genomic alignments show that there is massive re-
arrangement across different subspecies and within Type A strains 228,236,464. However, further work 
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needs to be done to confirm the role of genomic re-arrangement as the mechanism behind 
increased virulence. Previously, it has been identified that bacterial DNA was a more potent 
stimulant of TLR9 than synthetic ODNs and the reason for this was elucidated by a paper observing 
the differences in macrophage activation by these two stimulants 87. It was found that the major 
contribution to potency was the length of the stimulatory DNA and synthetic ODNs of more than 44 
nucleotides in length were as immunostimulatory as bacterial DNA 87. The contribution of DNA 
length correlated with the presence of a length-dependent uptake process in macrophages 87. This is 
important as the quality of the DNA preparations used in these studies then becomes important. As 
research involving the two highly virulent strains (SchuS4 and FSC200) is carried out at containment 
level (CL) III the DNA preparations may be of different quality to those made at CL II (LVS and U112) 
leading to the differing efficiencies of TLR9 stimulation seen between these strains and not due to 
genomic re-arrangement. 
 
An intriguing question regards whether the integration of TLR4 with TLR9 signalling is advantageous 
to the host or the pathogen. The answer, as ever in the field of immunology, is not a simple one. The 
sequential activation and integration of TLRs may function as a control mechanism to limit the 
immune response from becoming excessive by requiring the activation of multiple TLRs. The initial 
contact with a primary TLR would prime the immune system but not initiate a full response. If, in 
time, no further activation of other TLRs occurs the system resets itself preventing an un-needed 
immune response from being generated. However, if a secondary TLR becomes stimulated it is likely 
that a pathogen is present and the system, due to priming, is prepared to launch a full and 
appropriate immune response. A well studied example of this is the secretion of IL-1 after F. 
tularensis infection which involves integration between two families of PRRs. Firstly, the activation of 
specific TLRs initiates NF-κB mediated transcription of the pro-IL-1β message 3,309. Subsequently, NLR 
stimulation leads to the activation of the caspase-1 inflammasome and the cleavage of the pro-form 
into active IL-1β 465. A recent review article theorised that the requirement for both TLR and NLR 
activation for the secretion of IL-1β was due to the need to have such a potentially dangerous pro-
inflammatory cytokine under tight control 466. The complex regulation, requiring at least two 
different stimuli, ensures secretion only occurs when absolutely needed. In the case of TLR4 and 
TLR9 integration from the F. tularensis infection model used in this study, TLR4 acts as the priming 
receptor. Importantly, the priming function seems to occur only when low levels of ligand are 
present as high concentrations of TLR4 ligand, such as LPS, have frequently been shown to induce an 
aggressive immune response without the requirement for subsequent TLR activation as in the case 
of sepsis 316. The role of secondary receptor for F. tularensis detection is played by TLR9 and several 
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characteristics make this receptor suitable for this role. TLR9 is mainly found on the membranes of 
intracellular compartments such as phagosomes and the ligand that it detects, CpG DNA motifs, is 
bacteria-specific 58,458. This means that the stimulation of TLR9 provides positive verification of the 
presence of an intracellular pathogen and a full immune response can be generated. The 
cooperation of TLR4 with TLR9 resulting in an aggressive immune response has been shown recently 
in a study investigating the therapeutic use of an inhibitor in the treatment of sepsis 467. This study 
found that, whereas single inhibitors targeting either LPS or CpG DNA are inefficient at combating 
sepsis, a dual inhibitor of these ligands, kukoamine B, protected mice against challenge with heat-
killed E. coli 467.  
 
Conversely, the coordination of the priming receptor with the secondary receptor may confer 
advantages to the pathogen instead of the host. The immune response to F. tularensis infection in 
vivo is well characterised by the absence of cytokine secretion in the first 72 h followed by an 
overwhelming and harmful inflammatory response 200. The delayed immune response is almost 
certainly due to the stealthy characteristics of F. tularensis, expressing non-stimulatory LPS and 
binding to and entering cells through non-inflammatory receptors. This enables the bacteria to 
colonise and replicate within cells undetected. However, during this time it could be that there is 
sub-stimulation of receptors occurring that begins to prime other TLRs, such as TLR9. When 
replication has taken place, a threshold may be reached where sufficient stimulation of TLR9 by CpG 
DNA occurs and a response is initiated that is enhanced by the previous sub-stimulation of TLR4. The 
mechanism for this rapid and severe secretion of proinflammatory cytokine may have similarity to 
the secretion of IL-1β. Activation of TLRs induces a build up of intracellular stores of pro-IL-1β which 
means that when secondary stimulation occurs secretion of large amounts of active IL-1β can occur 
extremely rapidly 466. Alternatively, priming may cause an up-regulation of MAPKs, particularly ERK, 
leading to an increased level of cytokine mRNA in the cytoplasm due to enhanced transport from the 
nucleus 392. Again this would mean that, upon secondary stimulation, the inflammatory response is 
rapid and exacerbated. To investigate and confirm this hypothesis more research into the properties 
of F. tularensis LPS is required. Similar studies to those carried out in this chapter would need to be 
done initially using ultra-pure F. tularensis LPS to prime the cells prior to secondary stimulation by 
genomic DNA. The mechanism behind the priming process could be examined using staining 
techniques to track the movement and accumulation of proinflammatory cytokine mRNA in primed 
cells. 
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The role of F. tularensis LPS in the generation of an immune response is a highly debated topic. F. 
tularensis LPS is considered non-stimulatory for TLR4 as demonstrated by a lack of cytokine 
secretion after exposure of TLR4 to this ligand 212,301. However, LPS does seem to play a role in 
immune stimulation although the exact mechanism has not yet been elucidated 304,305. It is possible 
that F. tularensis LPS is involved with the priming of the TLR9 response through sub-stimulatory 
binding to TLR4. Previous work identified that very low “sub-stimulatory” levels of E. coli LPS were 
unable to induce a cytokine response through TLR4 but could enhance the response of subsequent 
TLR stimulation 455,456. The data collected in this chapter confirm and extend these findings as sub-
stimulatory concentrations of E. coli LPS were able to enhance the response, not only to synthetic 
ODNs but also, to DNA purified from F. tularensis LVS. Due to the limitations associated with working 
with reagents requiring preparation at CLIII, sufficient repeats could not be carried out to determine 
significance for F. tularensis SchuS4 DNA stimulated cells. Despite this, the initial data looks 
promising. Although the priming studies used purified genomic DNA and not whole bacteria, it is 
highly likely that the same response enhancement would be observed with whole bacteria as TLR9-
dependent cytokine secretion was seen in earlier studies using whole F. tularensis (Section 6.3.2.2). 
Now that the TLR4-induced priming of the TLR9-dependent response to F. tularensis DNA has been 
observed the next step would be to determine whether the non-stimulatory LPS of F. tularensis is 
able to function as the priming ligand. F. tularensis LPS is known to not stimulate TLR4 in the usual 
manner, with no observable cytokine secretion response associated with LPS binding 301. However, 
the potential for sub-stimulatory binding has not been examined previously. 
 
In summary: 
 F. tularensis genomic DNA stimulates MH-S cells to secrete TNF and IL-6 in a TLR9-
dependent manner. 
 Sub-stimulation of TLR4 by LPS primes MH-S cells for an enhanced cytokine response upon 
secondary stimulation of TLR9 by F. tularensis DNA. 
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Chapter 7: General Discussion 
7.1 Activation of ERK and p38 induced by F. tularensis infection 
Detection of an invading organism by PRRs is a vital step in the generation of a rapid and specific 
innate immune response. Activation of PRRs initiates a downstream cascade involving the activation 
of multiple signalling proteins. Identification of the specific signalling proteins involved in the 
response to an infection can provide important information concerning the pathogenesis, the 
mechanisms of survival and immune evasion strategies used by the pathogen. This study identified 
that F. tularensis infection of MH-S cells was associated with significant alterations in the activation 
state of the MAPKs, p38 and ERK. As readings were taken at numerous time points throughout the 
course of infection this study was able to investigate the temporal dynamics of activation, which is as 
important in determining the subsequent response as activation itself, and identified a bi-phasic 
immune response to F. tularensis infection. This response was characterised by a rapid and transient 
activation of p38 followed by the complete suppression of p38 activation (Figure 3-6) and an early 
transient activation of ERK followed by a sustained activation (Figure 3-8).  
 
The temporal dynamics, particularly of ERK, provide important clues to the pathogenesis of F. 
tularensis. Transient activation of ERK has been demonstrated to correspond to host cell survival 
strategies whereas sustained activation is associated with cell death mechanisms 282,367. The data 
from this study, demonstrated by the transient activation of p38 and ERK, indicate that during the 
early stages of infection the host cells are adopting cell survival strategies. However, during the late 
stages of infection, the host cells are in the process of cell death, as evidenced by the lack of p38 
activation and the maintained level of ERK activation. This pattern of signalling activation points 
towards two possible hypotheses. The first hypothesis is that the host cell is initiating the conversion 
from survival to cell death in an effort to control the infection as has been seen for M. tuberculosis 
285. Similar to M .tuberculosis, F. tularensis is an intracellular pathogen and, as such, requires host 
cells to replicate within. Therefore, cell death by apoptosis may reduce the replicative niche 
available for bacterial replication. The importance of apoptosis in host defence is highlighted by the 
fact that many viral pathogens encode apoptosis-inhibitors that are vital to their successful 
colonisation of a host 468-470. However, the second, and possibly more likely, explanation is that F. 
tularensis is regulating this process as a mechanism of increasing its proliferation. The timing of the 
switch from transient to sustained activation correlates with the transition of F. tularensis from the 
phagosomal compartment into the cytoplasm 252,257,258. This would allow sufficient bacterial 
replication prior to being released from the cell by apoptosis in order to successfully proliferate to 
182 
 
neighbouring cells. Modulation of apoptotic pathways by bacterial pathogens has been observed 
previously, strongly supporting the theory that F. tularensis is interacting with these pathways 
through modulation of ERK. Chlamydiae species prevent the induction of apoptosis through 
interaction with the ERK signalling pathway enabling the bacteria to complete their obligate 
intracellular growth cycle 396. Helicobacter pylori infection induces the formation of an apoptosis 
complex that is again dependent on ERK signalling 385. It is possible that F. tularensis is similar to 
these two pathogens, using ERK signalling to alter the survival outcome of host cells. Supporting 
evidence for this has recently been provided by a study that demonstrated F. tularensis LVS 
inhibiting apoptosis of neutrophils via both the intrinsic and extrinsic pathways 399.  
 
In addition to influencing the outcome of infected cells, activation of these two MAPKs was 
associated with the secretion of the immune mediators MCP-1 and TNF. In F. tularensis-infected MH-
S cells, MCP-1 was rapidly secreted and TNF exhibited a more gradual increase throughout the 
infection (Figure 3-10). In agreement with other studies, these two cytokines were also detected in 
the lungs of mice 72 h after F. tularensis infection 298,306,369. The secretion of pro-inflammatory 
cytokines is complex and tightly regulated. TNF requires the release of two levels of control at both 
the transcriptional and the translational level regulated by NF-κB and the MAPK pathways, 
respectively 444,445. The activation of ERK is required for the transport of TNF mRNA from the nucleus 
into the cytoplasm and activation of p38, via its downstream substrate MK-2, is linked to increased 
TNF mRNA stability 392. 
 
The importance of ERK in coordinating the immune response to F. tularensis infection was analysed 
using the specific inhibitor, PD0325901. As expected, inhibition of ERK significantly reduced the 
secretion of TNF induced by F. tularensis infection (Figure 4-3), presumably through reduced 
nucleocytoplasmic transport. In addition, ERK inhibition reduced the systemic spread of F. tularensis 
in a murine model of infection. In comparison, there was no decrease in bacterial numbers in vitro 
and no increase in survival was observed in vivo (Figure 4-3 and Figure 4-8). However, it is perhaps not 
surprising that the administration of a single inhibitor did not sufficiently optimise the immune 
response for complete bacterial clearance. Signalling pathways are amazingly complex comprising 
numerous interactions and both positive and negative feedback mechanisms. It is likely then that 
the system is able to effectively respond to inhibition, possibly through functional redundancy. For 
example, ERK is activated by both MEK-1 and MEK-2 indicating that there is a level of redundancy 
incorporated into the system 367. Conversely, distinct functions have also been observed for these 
two signalling proteins 352. It is possible that the MEK proteins, and other signalling proteins, do not 
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exhibit complete redundancy but instead share a degree of overlapping functions whilst maintaining 
some level of specificity.  
 
A recent study examined how complex networks are controlled and hypothesised about what the 
best strategy for effective modulation might be 471. Networks can be described as a series of nodes 
that can be connected by critical (vital for the progression of signalling), redundant (two pathways 
leading to activation of the same substrate) or ordinary links. Nodes that need to be regulated to 
control the system are called driver nodes. Applying these terms to signalling pathways suggests that 
individual signalling proteins are nodes and the interaction between them, enabling progression of a 
signalling cascade, are links. Some links (critical) are essential for the progression of signalling, for 
example the recruitment of adaptors to the TIR domains of TLRs 101,131. In contrast, others may be 
ordinary or redundant links, such as the two MEK proteins upstream of each major MAPK 140,367. In 
order to optimally control the system, targeting of the driver nodes is required and it was found that 
sparse or heterogeneous networks, such as cell signalling pathways, require the highest number of 
driver nodes in order to control the system 471. If this theory is correct, it is likely that a single 
inhibitor would be unable to sufficiently control cell signalling in order to optimise the immune 
response and that multiple inhibitors, or activators, would be required 471.The success of using a 
combination of immune modulators has been demonstrated previously in the context of cutaneous 
leishmaniasis 420. Dual administration of a TLR4 and a TLR9 agonist in combination with a poly-
protein vaccine candidate resulted in a reduced parasite burden whereas a single agonist alone did 
not 420. It is possible that by identifying the critical links and driver nodes downstream of F. tularensis 
infection an immuno-modulatory combination therapy may be identified. 
 
In the course of examining the importance of ERK activation in generating an optimum immune 
response in vivo an interesting result was observed. In this work and in published studies PD0325901 
has been shown to inhibit ERK activation 344,386,472. Similarly, this work has shown that F. tularensis 
can inhibit the activation of ERK at 48 h in a murine model of infection whilst inducing activation at 
96 h (Figure 4-6). However, PD0325901 administration actually causes an increase in ERK activation in 
the lungs of F. tularensis-infected mice which is not present in mice given PBS (Figure 4-6). This result 
may shed some light on the mechanism by which F. tularensis suppresses the secretion of 
proinflammatory cytokines until late in infection 200. PD0325901 inhibits ERK activation by binding to 
its precursor, MEK-1/2, and inducing a conformational change 387. One mechanism by which the 
presence of F. tularensis could prevent this effect would be if a protein was secreted or expressed by 
F. tularensis that is able to block PD0325901 from interacting properly with its target substrate. It is 
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possible that such a protein would usually, in the absence of PD0325901, function in a similar 
manner to this inhibitor and be used by F. tularensis to inhibit ERK activation, leading to a delay in 
cytokine production. When both “inhibitors” are present an interaction between them could prevent 
the correct inhibition of MEK-1/2 and the signalling pathway is able to advance leading to ERK 
activation. A secretion system with some homologous components to the type-VI secretion system 
of V. cholerae is encoded by the FPI of F. tularensis and, although no effector proteins have been 
identified within the FPI, there could be effectors encoded elsewhere in the genome 261. 
 
7.2 Integration of TLR signalling enhances the immune response to F. 
tularensis 
 
The binding of a ligand to the LRR domain of a TLR initiates the signalling cascades required to 
induce an appropriate immune response. As such, the downstream signalling events and subsequent 
response rely heavily upon the identity of the TLR being activated. In addition, signalling pathways 
activated by distinct TLRs are known to integrate with each other providing further specificity to the 
system 40,182,183. An improved knowledge of the TLRs responsible for initiating a response to F. 
tularensis, and the potential for signalling integration, can provide essential information about how 
this stealth pathogen interacts with the host response. TLR2 has previously been shown to become 
activated by F. tularensis infection and there is strong debate around the role of TLR4 212,298,300,301,431. 
This work has demonstrated that both TLR2 and TLR4 contribute to the immune response to F. 
tularensis. Furthermore, I have shown that not only can TLR9 respond to the genomic DNA of F. 
tularensis but that this response can be primed and enhanced by the sub-stimulation of TLR4 using 
low concentrations of LPS. 
 
Infection by F. tularensis induces the activation of p38 and ERK resulting in the secretion of MCP-1 
and TNF. Using BMDMs with either TLR2 or TLR4 knocked out this work has shown that both of 
these receptors contribute to the immune response to F. tularensis. It was shown that TLR2 is able to 
simultaneously enhance ERK activation while suppressing p38 activation and that stimulation of 
TLR2 is critical in the regulation of TNF translation (Figure 5-5). However, TLR2 does not act alone and 
this study observed that TLR4 stimulation is required to release the transcriptional regulation 
imposed on TNF secretion (Figure 5-5). These data indicate that coordinated activation of both TLR2 
and TLR4 is required to obtain efficient secretion of TNF. As TNF is a highly pro-inflammatory 
cytokine, it is likely that the coordination of multiple TLR pathways is used to ensure that secretion 
occurs only when the initial detection of a pathogen is confirmed by a secondary detection event. 
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This is the case for another proinflammatory cytokine, IL-1β. The initial detection of a pathogen 
induces the production of the inactive pro-form of the cytokine 3,309. However, to induce the 
secretion of fully active IL-1β a secondary detection event involving the activation of the caspase-1 
inflammasome is required 29,30. The requirement for confirmation prevents the unnecessary, energy-
wasting and potentially damaging effects of inappropriate cytokine secretion. The observed dual 
regulation mechanism for both IL-1β and TNF has not been identified for other cytokines. This could 
be due to the potential for IL-1β and TNF to cause significant damage to the host if uncontrolled 
secretion occurs. In contrast, other cytokines that do not have such a capacity to cause damage to 
the host do not require such complex regulation mechanisms. 
 
Upon invasion of a host, pathogens do not solely activate a single class or type of receptor. 
Pathogens contain multiple ligands that are able to bind to and stimulate multiple receptors. 
Therefore it is through integration of several signalling pathways that the immune response to a 
pathogen is generated. This had been demonstrated in studies using two intracellular bacterial 
pathogens, Klebsiella pneumoniae and Mycobacterium tuberculosis 193,451,473. One of the major TLR 
ligands associated with Gram-negative pathogens is LPS that is usually able to stimulate TLR4. 
However, the role for LPS in F. tularensis infection is not as clear cut as it does not appear to 
stimulate TLR4 in the usual manner but is still required in the generation of an antibody response to 
this pathogen 212,301,305. A previous study has shown that very low concentrations of E. coli LPS were 
able to enhance cytokine secretion in response to subsequent TLR9 stimulation by synthetic ODNs 
455,456. My work has extended this finding in the context of F. tularensis, and identified a potential 
function for TLR4, by demonstrating that sub-stimulation of TLR4 is able to prime and enhance 
subsequent TLR9 stimulation by F. tularensis genomic DNA. The importance of TLR4 sub-stimulation 
can be seen by the requirement for multiple TLR-stimulation events to induce the secretion of pro-
inflammatory cytokine such as IL-1β and TNF, as discussed earlier. TLR4 sub-stimulation alone does 
not have the capacity to induce optimal cytokine secretion and neither does TLR9 stimulation. 
However, when each individual signalling event is integrated the optimal secretion of inflammatory 
cytokines occurs. 
 
7.3 Future work 
This work has mainly focussed on infections using the less virulent F. tularensis LVS. However, some 
data was produced using the highly virulent SchuS4 strain and this enabled the identification of 
some characteristics that may contribute to enhanced virulence. Firstly, F. tularensis LVS infection of 
MH-S cells produced a rapid and transient p38 activation which is absent when the cells are infected 
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with F. tularensis SchuS4. Furthermore, although both strains induced sustained ERK activation 
during infection, this occurred sooner in infection with F. tularensis SchuS4 (Figure 3-8 and Figure 
3-20). It was also observed that F. tularensis SchuS4 induced a faster and greater degree of cell death 
and this might be associated with faster bacterial replication. Finally, the TLR9 stimulation assays 
identified that F. tularensis SchuS4 DNA demonstrated a higher stimulatory activity than F. tularensis 
LVS or F. tularensis U112 (Figure 6-1 and Figure 6-2). Due to the limited success in identifying secreted 
virulence factors that are associated with highly virulent strains, the potential for differences in 
genetic makeup to confer increased virulence is an interesting theory. Highly stimulatory DNA may 
enhance immune signalling via TLR9 that results in the overwhelming inflammation seen during the 
late stages of virulent F. tularensis infection. Although the identified ligands of TLR9 are CpG motifs 
present in DNA, the presence of these motifs alone does not relate to the stimulatory potency of 
DNA and, therefore, a genome with a high GC content does not necessarily equate to stimulatory 
DNA 458. The GC content of most of the F. tularensis strains, for which genomes have been 
sequenced, are very similar (~32%) 228,459. However, it is the GC dinucleotide content that is 
important to the stimulatory activity imposed on TLR9 458. It is possible that the more virulent F. 
tularensis strains, due to genomic rearrangement 228,236,464, contain a greater percentage of GC 
dinucleotides conferring greater TLR9 potency. The advantage for F. tularensis SchuS4 to stimulate 
TLR9 signalling can only be hypothesised at present but it may involve the recruitment of immune 
cells thereby increasing the replicative niche for bacterial replication and proliferation. Alternatively, 
stimulation of TLR9 could lead to the generation of the overwhelming inflammatory response that is 
characteristic of the late stages of F. tularensis infection. In this work, F. tularensis SchuS4 induced a 
faster sustained activation of ERK, associated with the induction of cell death, compared to the less 
virulent F. tularensis LVS. A greater ability to stimulate TLR9 may lead to the more rapid activation of 
signalling factors enabling the escape from immune cells and proliferation throughout the host. 
Further characterisation of the stimulatory activity of F. tularensis DNA could confirm the 
contribution of TLR9 stimulation to increased virulence. 
 
The use of the specific ERK inhibitor, PD0325901, has raised some interesting questions relating to 
the association between ERK activation and systemic spread of F. tularensis. When PD0325901 was 
administered to F. tularensis LVS infected mice, reduced bacterial colonisation of secondary organs 
(spleen and liver) was observed despite no reduction at the primary site of infection, the lungs. One 
mechanism that could account for this observation is that ERK inhibition reduces apoptosis of 
infected cells in the lungs, “trapping” F. tularensis in this organ and preventing systemic proliferation 
of bacteria. Blocking the adhesion of L. monocytogenes to the lung epithelium by intra-tracheal 
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administration of heparin prevented the systemic spread of bacteria to secondary sites such as the 
liver, spleen and kidneys 419. The containment of bacteria within the lung was associated with 
improved mouse survival 419. The effect of restricting bacterial dissemination has recently been 
shown in a murine model where the blockade of scavenger receptors reduced the damage to 
systemic organs after induction of sepsis by the cecal ligation puncture method 418. This hypothesis 
could be investigated further by using fluorescently labelled bacteria to allow the tracking of bacteria 
through the host. In this study, no improvement in survival was seen despite the reduction in 
systemic spread, possible due to the high bacterial numbers still present in the lungs. Previous 
studies investigating immune modulation as a therapeutic strategy have used a combination of 
therapeutics such as antibiotics 340. It is possible that using an ERK inhibitor combined with an 
antibiotic, to aid the killing of bacteria “trapped” within lung immune cells, might improve the rate 
of survival. 
 
An unexpected finding in this study was the observation that when PD0325901 was administered to 
F. tularensis-infected MH-S cells an increase in ERK activation occurred, although inhibition was 
expected. It seems that the combination of an ERK inhibitor with an ERK-suppressing bacterium 
induces activation of this signalling protein. The mechanism behind this surprising result definitely 
warrants further investigation as it is possible that it points towards the presence of a F. tularensis-
associated protein that, by interacting with PD0325901, prevents the modulatory action of both. 
First, it would be important to determine the critical binding interactions that occur between 
PD0325901 and its target protein MEK-1/2. The administration of other ERK inhibitors during F. 
tularensis infection, which use alternative binding sites to PD0325901, would establish whether the 
effect is inhibitor specific. Bioinformatic approaches could also be used to identify F. tularensis 
proteins that share homology to MEK-1/2 or contain similar binding sites to that targeted by 
PD0325901. At present there is limited knowledge of proteins that are secreted or expressed by F. 
tularensis that interact with immune signalling and it is thought that much of the ability of F. 
tularensis to evade immune responses and successfully colonise a host is related to indirect or 
passive strategies such as phagosomal escape and cytoplasmic replication. However, the observed 
suppression of inflammatory responses in the first 72 h after infection suggests a more direct 
interaction with immune signalling indicating the presence of secreted effector proteins. 
 
This is the first study to my knowledge that demonstrates the detection of F. tularensis genomic DNA 
by TLR9 being primed by non-stimulatory concentrations of LPS. Importantly, this might represent a 
mechanism by which the non-stimulatory LPS of F. tularensis can contribute to the generation of 
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inflammation. However, more work is required to provide evidence for this hypothesis. In this study 
E. coli LPS was used to demonstrate the “proof-of-principle” and, as such, the next logical step would 
be to use purified F. tularensis LPS as the priming ligand. Elucidation of the mechanism behind the 
priming of TLR9 also requires further investigation as it may be explained by the accumulation of 
activated signalling proteins or cytokine mRNA in the cytoplasm or due to an increase in TLR9 
expression both of which could be identified by using suitable cell staining techniques or 
transcriptional profiling. A recent study examining the priming of alveolar macrophages with LPS 
observed no up-regulation of TLR expression after priming but did identify an accumulation of 
activated p38 182. Similarly, a study investigating the sequential activation of TLR4 and TLR9 did not 
see any alteration in TLR9 expression after TLR4 stimulation by LPS and detect enhanced signalling 
factor activation particularly of ERK and p38 189. However, after priming of murine macrophages with 
IFN-γ an up-regulation of NOD-2 expression was seen associated with enhanced nitric oxide 
production indicating that receptor up-regulation can play a part in the priming of immune cells 426. 
 
Even with the massive advances in available technology, such as next-generation sequencers, 
attempting to elucidate and fully understand super-complex networks such as immune signalling 
pathways can seem to be a futile task if solely using molecular and immunological techniques. 
However, other scientific and non-scientific disciplines such as mathematics, electronics and physics, 
also work with complex networks and have developed tools and models, novel to the microbiology 
field, to analyse them. It could be that the incorporation of these tools with standard microbiological 
techniques could greatly enhance our ability to visualise and understand biological networks such as 
immune signalling pathways. Several groups have already begun using mathematical and electronic 
techniques to better describe biological functions ranging from cell invasion and replication to the 
regulation of ERK activation. Similar to cell signalling pathways, electronic circuits are used by 
engineers to coordinate multiple input signals and generate specific outputs. One example is a 
commonly used circuit called a negative feedback amplifier (NFA). In engineering, the NFA is used to 
regulate dynamic processes by removing fluctuations in the input signal and smoothing the output 
response 474. Experimental modelling showed that the ERK signalling pathway functions very 
similarly to a NFA, and converts an on/off response to a graded response 474. This finding closely 
matches the known characteristics of ERK activation where it is not just whether ERK is activated or 
not that is important but also the temporal dynamics of the activation. Mathematical modelling of 
macrophage invasion by S. typhimurium has also dramatically improved the knowledge of the 
pathogenesis of this organism 475. In combination with real-time video microscopy, it was found that 
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macrophages can be repeatedly infected by S. typhimurium but that re-infection events occur at a 
lower rate than the primary infection 475. 
 
The interaction of F. tularensis with immune cells, such as macrophages, would seem to be a perfect 
mechanism to study using a similar combination of experimental and mathematical modelling that 
has been used with Salmonella. Similarly, our understanding of the activation and progression of 
numerous signalling pathways through the stimulation of TLRs and NLRs by F. tularensis could be 
greatly enhanced through drawing comparisons with other disciplines such as electronic circuits.  
 
7.4 Final comment: Interaction of F. tularensis with immune 
signalling 
 
F. tularensis has been described as a stealth pathogen due to its ability to invade the host without 
inducing a detectable immune response at early time points 317. Moreover, for some time it 
appeared to orchestrate immune evasion without expressing immune-modulators or virulence 
factors such as toxins or cytolysins. However, as a greater understanding of immune signalling 
pathways has developed, elucidation of several mechanisms have recently begun to appear. One of 
the key advances was the characterisation of the FPI the genes of which were critical for phagosomal 
escape and intracellular replication 254,258,260,328. More recently a secretion system with similarities to 
the type-VI secretion system of V. cholerae was demonstrated to be essential for delivery or surface-
expression of VgrG and IglI 261. My work provides further evidence of the interaction between F. 
tularensis and the immune signalling network.  Clearly, it now appears that F. tularensis is a much 
more proactive immune-modulator than originally thought, interacting with immune processes and 
signalling pathways at multiple levels.  
 
The characteristic property of F. tularensis infection is the delay in the inflammatory response 
followed by overwhelming inflammation and the potential for multi-organ failure 200. The bacterium 
is able to modulate the immune response enabling bacterial replication unhindered by immune 
processes followed by systemic proliferation aided by the induction of inflammation and cell death. 
Previous studies have demonstrated how F. tularensis enters cells in a non-stimulatory manner and 
is able to prevent the activation of microbicidal complexes 240,319,321. These processes go some way to 
explain the lack of an immediate immune response. However, my work shows that F. tularensis may 
also be directly inhibiting the activation of ERK by MEK-1/2 preventing the efficient secretion of TNF, 
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a highly potent inflammatory cytokine. Furthermore, during the non-responsive phase of the 
immune response to F. tularensis, this stealth pathogen may be priming the host cells. Priming 
ensures that, once sufficient replication has taken place, the secondary induction of the immune 
response causes enhanced cytokine secretion and exacerbated inflammation which is both too 
strong and too late to protect the host. 
 
Significant work will be required to reveal and fully characterise all the interactions that F. tularensis 
exploits during infection. However, this research is crucial to identify mechanisms by which the 
immune response can be rebalanced in favour of the host. 
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